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ABSTRACT 
People of African ancestry (AA) are at greater risk of developing chronic kidney 
disease than those of non-AA.  Much of this risk has been linked to specific genetic 
haplotypes on chromosome 22, near the genes APOL1, encoding apolipoprotein L1, and 
MYH9, encoding non-muscle myosin heavy chain IIA (NMHCIIA).  The mechanisms by 
which the disease-associated chromosome 22 haplotypes promote kidney damage are 
unknown.  Apolipoprotein L1 is a circulating protein with no known role in kidney 
function. However, the kidney disease-associated chromosome 22 haplotypes are 
protective against trypanosome infection, resulting in positive selective pressure for these 
haplotypes in western Africa, where trypanosome infection is endemic.  In contrast, 
NMHCIIA may have an important role in glomerular function, and mutations in MYH9 
are associated with glomerular disease, yet the disease-associated chromosome 22 
haplotypes do not involve coding sequence variations in MYH9.  With no clear disease-
causing role for genes near the chromosome 22 risk locus, it is plausible that indirect 
mechanisms of gene regulation may be responsible for the increased disease risk.  This 
study examines several potential pathways for kidney injury, including altered glomerular 
  ix 
gene expression in carriers of chromosome 22 risk haplotypes, and the role of altered 
expression of MYH9 in podocyte cell biology and kidney disease. 
We found that carriers of chromosome 22 risk variants exhibited differential glomerular 
gene expression in pathways promoting kidney injury. We also found decreased 
glomerular NMHCIIA expression in human FSGS kidney biopsies, and altered cell 
structure and mechanical function when Myh9 is ablated in murine podocytes. Further, 
Myh9 podocyte deletion predisposed mice to glomerulopathy in response to injury by the 
DOCA-salt uninephrectomy model of hypertension. Taken together, these findings 
demonstrate direct and indirect effects of chromosome 22 risk variants on glomerular 
gene expression which promote kidney injury.   
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CHAPTER ONE 
1.0 Introduction 
Chronic kidney disease (CKD) is a major public health problem affecting nearly 200 
million people worldwide. Treatment of CKD and kidney failure cost the United States 
over 40 billion dollars in the fiscal year 2009 (NKUDIC, 2012). With an increase in the 
ageing population, the incidence of CKD is expected to rise thus corresponding to an 
increase in the global economic burden in the coming years. CKD is associated with a 
significant increase in death stemming from cardiovascular disease, cerebrovascular 
disease, or in extreme cases, kidney failure.  
With increasing incidence and prevalence of non-diabetic kidney disease, it has been 
found that CKD often aggregates in families (Conlon et al., 1999).  In the United States, 
African Americans (AA) have been identified to be at greatest risk, with CKD incidence 
between 4 and 50-fold higher than other racial groups (USRDS, 2008). Interestingly, this 
familial linkage is often not restricted to a specific disease entity within a particular 
family, in that relatives may be diagnosed with CKD but show disparities in underlying 
disease pathogenesis.  For instance, within a family, some family members may develop 
HIV associated nephropathy (HIVAN), while others may be diagnosed with 
“hypertension-driven” nephropathy, sickle cell nephropathy or diabetic kidney disease 
(Conlon et al., 1999).  Yet the prevelance of CKD in such a family may be unusually high 
relative to the population as a whole.  This observation has prompted the idea that there is 
an overarching “kidney failure gene” or set of genes in certain families that predisposes 
affected individuals to develop CKD, regardless of the initiating pathology or the 
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presence of particular modifying factors (Freedman et al., 1995).  Furthermore, it has 
been speculated that such a gene should be highly prevalent in the AA population 
(Freedman et al., 1995).  
Putting this together, when closed populations have undergone recent interbreeding 
with a distinct population, it is possible to utilize a technique called mapping by 
admixture linkage disequilibrium (MALD) to identify genes associated with population-
specific phenotypic features.  This technique takes advantage of the ability to use 
particular genetic markers that are able to represent the entire genome in parental 
populations of the interbred group under study to track disease-gene alleles.  The recent 
history of the African American population makes this group well-suited for use of this 
technique.  Using admixture mapping, a search for a kidney failure gene variant specific 
to the African American population was initiated.  This effort first resulted in the 
identification of genetic variants in the non-coding region of the MYH9 gene to be highly 
associated with non-diabetic kidney disease in the African population (Kao et al., 2008, 
Kopp et al., 2008). MYH9 encodes for the protein nonmuscle myosin IIA, which is 
important in cellular movement and actin cytoskeletal organization.  
More recently, a much stronger association has been observed between variants in the 
APOL1 gene prevalent in the African American population, and specific types of kidney 
damage including focal segmental glomerulosclerosis and “hypertension-driven” kidney 
disease (Genovese et al., 2010, Tzur et al., 2010).  The kidney risk genetic variant in 
APOL1 have been replicated in other forms of non-diabetic kidney disease (Ashley-Koch 
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et al., 2011; Larsen et al., 2013; Freedman et al., 2014) with the genetic risk initially 
identified in MYH9 seemingly residing in APOL1.  
The discovery of variants within the APOL1 gene has been one of the most important 
findings in kidney research thus far, solely present in some people of African descent and 
virtually absent in Caucasians or Asians. This has been explained by the trypanolytic 
activitiy of the APOL1 gene product, apolipoprotein L1, in human serum (Pays et al., 
2006; Grossman et al., 2010). Genovese et al., 2010, demonstrated that harboring 1 copy 
of the APOL1 risk variant protected an individual from African sleeping sickness, a 
disease associated with trypanosomal infection that is transmitted by a tsetse fly. On the 
other hand, carrying two copies of the risk variant results in a 10 fold increased risk to 
kidney disease, a finding similar to malaria and sickle cell disease whereby having one 
copy of the sickle cell gene is protective against malaria, whereas having 2 copies of the 
sickle gene results in development of sickle cell anemia. Based on the protective function 
of APOL1, the genetic variants seems to have spread mostly in people of African descent 
as a result of a selective sweep conferred by protection against trypanosomes. This 
explains the high frequency of the APOL1 allele in people of African descent compared 
to those without African descent. 
Despite these incredible associations between APOL1/MYH9 and kidney disease, a 
mechanistic view linked to these molecules has not been fully elucidated, warranting 
research in this area. My goal therefore is to increase our understanding of the roles these 
chromosome 22 haplotype genes play in kidney disease. Since the APOL1 risk variants 
seem to have arisen as a result of a selective pressure, and selective pressure influences 
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gene expression changes, I hypothesize that APOL1 risk variant alleles may be associated 
with gene expression changes present before kidney disease ensues, and these gene 
expression changes may be what is responsible for impacting kidney disease phenotypes 
in the presence of modifying factors such as hypertension, lupus and HIV. With the 
advent of gene expression tools, I seek to identity these gene expression changes which 
will go a long way to help understand disease pathogenesis and inform therapeutic 
measures. In addition, I will test the hypothesis that MYH9 is necessary for podocyte cell 
biology hence its loss is associated with loss of podocyte structure and function resulting 
in increased susceptibility to renal injury. I will use both in vitro and in vivo systems to 
test this hypothesis. 
A study of the role these chromosome 22 haplotype genes play in kidney disease 
pathogenesis will provide insights for non-diabetic kidney disease risk prevention, earlier 
kidney disease detection, and the generation of novel therapeutic targets and strategies to 
help slow and potentially reverse kidney disease which will go a long way to impact 
global health and economy. 
1.1 The Kidney 
The kidneys are a pair of fist-sized, highly specialized visceral organs, located 
posterior to the peritoneal cavity on each side of the spine, and insulated by adipose 
tissue. Together with the skin and respiratory system, they are the primary excretory 
organs of the body. The kidneys create urine, and in so doing they help maintain 
homeostasis of the body by selectively excreting and retaining substances such as water, 
metabolites, drugs, and toxins from the blood, based on the body’s specific needs. They 
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are also involved in the maintenance of electrolyte balance, and acid-base balance. In 
addition, kidneys have a hormonal secretory function. For example, they secrete 
erythropoietin, which is essential in stimulating bone marrow to make red blood cells. 
They also secrete calcitriol, a form of vitamin D, which helps the colon absorb calcium. 
Finally, kidneys secrete renin, which controls blood pressure. Kidney function is thus 
very essential, and complete loss of kidney function will result in death within a few 
days.  
The functional unit of the kidney is known as the nephron (Figure 1.1). There are 
about one million nephrons per human kidney.  Each microscopic nephron consists of a 
blood filtering structure known as the glomerulus, and a double hairpin-shaped tubule 
through which filtrate passes into the renal pelvis. The glomerulus is made up of the 
central mesangium, and many surrounding capillaries, which the mesangium supports.  
The glomerular capillaries consist of endothelial cells, the glomerular basement 
membrane, and visceral epithelial cells, called podocytes. These structures form the 
glomerular filter, which generally restricts filtration of molecules based on size and 
charge.  Molecules move across this barrier under the influence of hydrostatic and 
oncotic pressure.  The selective filtration of blood solutes is the fundamental function of 
the kidney, and normal glomerular structure is required for this function to be maintained. 
The podocyte layer is composed of highly specialized, terminally differentiated cells, 
with interdigitating foot processes interposed with specialized tight junctions called slit 
diaphragms. These slit diaphragms are critical to the formation of the filtration barrier 
and play a key role in modulating water flux and permselectivity.  
  
6 
The glomeruli are surrounded by the Bowman's capsule, which is lined by the parietal 
epithelial cells  The space between the podocytes and parietal epithelial cells, called 
Bowman’s space, is where the urinary ultrafiltrate initially collects. Bowman’s space is 
continuous with the proximal convoluted tubule, which continues successively as the 
loop of Henle and the distal convoluted tubule. The tubular system plays a critical role in 
the regulation of plasma osmolality by reabsorbing water, amino acids, electrolytes, and 
carbohydrates from the urinary ultrafiltrate.  Alterations in tubular structure and function 
may occur in association with glomerular damage.  
 
 
Figure 1.1. The functional unit of the kidney (Nephron)  
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1.2 Chronic kidney disease (CKD) 
Chronic kidney disease is a term used to describe a number of different disorders 
which result in nephron loss and loss of kidney function. These different disorders may 
vary with regard to pathogenesis, severity and rate of progression of the disease.  
Regardless of the cause, such kidney damage is typically accompanied by a 
compensatory process involving the remaining viable nephrons, called hyperfiltration. 
This compensatory process is ultimately maladaptive, and in the long term can lead to 
further glomerular injury, proteinuria and progression of chronic kidney disease.  Early 
CKD is usually not symptomatic and may not be obvious to the affected individual.   
CKD and associated kidney damage is identified clinically through detection of  
albuminuria, pathologic changes detected on biopsy, or decline in kidney function as 
indicated by a reduced glomerular filtration rate (GFR) over a period of at least three 
months.  In addition to the direct effects of impaired kidney function, CKD is associated 
with a wide spectrum of complications involving organ systems beyond the kidney, 
primary as a consequence of reduced GFR.  These complications include: increased risk 
of cardiovascular disease, increased incidence of infection, peripheral neuropathy, 
cognitive impairment, worsening hypertension, diabetes, anemia, mineral and bone 
disorders, dyslipidemia and premature death (Hsu et al., 2008; James et al., 2010; James 
et al., 2009; Hailpern et al., 2007; Wilhelm-Leen et al., 2009, Yang et al., 2011).   
1.2.1 Demographics of CKD/ESKD 
Kidney disease is the eighth leading cause of death in the USA (CDC, 2009) with 
9 out of 10 people who have CKD not knowing they do (CDC, 2011). Worldwide, CKD 
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is estimated to affect 10% of the population in many countries (James et al., 2010). This 
number is expected to increase, particularly in areas characterized by low economic 
development and limited availability of renal replacement therapy. In addition, the 
prevalence of ESKD also seems to be on the rise (>600% between 1980 and 2009) 
(NKUDIC, 2012) significantly beyond all predictions made (Eggers, 2011).  Data from 
the National Health and Nutrition Examination Survey (NHANES), involving a large 
sampling of the US general population, indicate that the prevalence of CKD was on the 
rise between the years 1988-2006 mostly in the aged population (Coresh et al., 2007) 
with no changes observed in people between ages 20-39 (below 0.5%). Data from the 
CDC also estimates that greater than 10% of adults within the United States (>20 million 
people) most probable have CKD with differences in severity (NCKDFS, 2014). Between 
the years 2000-2008 the incidence of CKD in people aged over 65 years was found to be 
more than doubled.   
Incidence of CKD has also been observed to exhibit racial disparity. CKD 
incidence is 3.8 times higher in African Americans compared to Whites (USRDS, 2012). 
In the African American population, ESKD was reached at a much younger age as 
compared to the Caucasian population (mean age of 57 versus 63 years) (Feehally, 2005).  
Studies have shown that populations with African ancestry are more likely to develop 
non-diabetic forms of kidney disease, and also exhibit poorer prognosis, than populations 
with European Ancestry (Naicker, 2009).  
In Africa, an estimated 200-300 per million people are known to be affected by 
CKD based on small population surveys (Naicker, 2010).  CKD in Africa is closely 
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associated with hypertension.  For example, in West Africa, 47% of hypertensive patients 
in Ghana have CKD, whereas in Nigeria, 60% of hypertensive patients show target organ 
damage which includes the kidney. Kidney disease in Africa and India exhibits a 
significantly lower age of incidence overall, as compared to the United States , primarily 
affecting people aged 20-50 years (Jha et al., 2013). In Africa, this lower age of incidence 
has been attributed to the high prevalence of hypertension and glomerulonephritis within 
the region (Arogundade and Barsoum, 2008). Studies have shown that the cumulative life 
time risk for African Americans compared to European American with ESKD is 7.5% 
versus 2.1%.  Socioeconomic differences do not seem to play a role in these differences 
(Kiberd and Clase, 2002). Mutations in a particular region of chromosome 22 involving 
the genes APOL1 and MYH9, which are prevalent in the African population, may play a 
role in the increased incidence of CKD in this population (Genovese et al., 2010; Tzur et 
al., 2010).   
It is also worth noting that despite the recorded numbers, there still remains a 
large number of ESKD patients who have not received diagnosis for kidney disease. For 
example, 90% of ESKD patients in India (Kher, 2002) as well as 43% of ESKD patients 
in the USA (USRDS 2011) had never seen a nephrologist upon starting dialysis. 
1.2.2 Diagnosis and Treatment of CKD 
CKD is defined by both a loss in kidney function or kidney damage. CKD 
diagnosis is important for effective treatment. Its diagnosis therefore involves assessing 
kidney damage and function, and requires evidence of kidney damage for at least 
3months. Kidney damage mostly a reflection of the status of glomerular structure and 
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function is determined by observing markers of damage or pathological changes such as 
alterations in urine or blood proteins (such as proteinuria, hematuria, serum electrolytes) 
and kidney biopsy imaging analysis. Together with the measurement of a kidney’s 
glomerular filtration rate, CKD is classified as shown in Table 1.1. Estimated glomerular 
filtration rate (eGFR) is the best choice for assessing a kidney’s functional status and 
prognosis. GFR is a reflection of the average filtration rate of each nephron multiplied by 
the total number of nephrons in both kidneys in an individual. It involves the 
measurement of serum creatinine, taking into account a patient’s body size, physical 
activity, diet, gender, age and race. A decline in GFR correlates with a reduction in a 
single nephron GFR or a total reduction in nephron number. One caveat to GFR is that, 
an initial decrease in nephron numbers could correspond to an immediate increase in 
GFR therefore not reflecting the true state of the kidney. In this case, kidney damage 
progresses to a severe state before GFR reduction can be observed. Increased blood 
pressure is also observed in most cases of CKD. 
CKD is a typical example of chronic diseases requiring long term treatment and 
management. Efficient diagnosis provides relevant information that is important for CKD 
treatment. Medical treatment of CKD involves three facets:  treating the underlying cause 
of the kidney damage, delaying progression of the existing kidney damage to maintain 
functional kidney mass, and treating and preventing complications.  Because CKD onset 
usually stems from an underlying cause, treatment of CKD mostly targets those 
underlying causes, in the process, delaying or potentially halting the progression of the 
disease and reducing complications. In most cases, treatments are also required for the 
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complications arising from CKD. Pharmeceutical approached treatments include 
angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers 
(ARBs), or diuretics among others for controlling high blood pressure. Mouse studies 
have demonstrated the onset of glomerular capillary hypertension (GCH) to be associated 
with CKD. GCH is reduced when treated with ARBs and ACE inhibitors by decreasing 
arterial perfusion pressures and relaxing the efferent arterioles, thereby preventing CKD 
progression (Hostetter, 2003; Zatz et al., 1987).  Pharmeceutical treatments aimed at 
preventing complications include: statins to lower cholesterol levels; erythropoietin 
hormone supplements for production of more red blood cells, thereby relieving fatigue 
and weakness associated with anemia; calcium and vitamin D supplements to protect 
bones; and a reduction in protein diet to minimize wastes in blood. 
There are side-effects associated with some medications. For example, non-
steroidal anti-inflammatory drugs (NSAIDs) could alter renal hemodynamics thereby 
exacerbating CKD (Haynes and Winearls, 2010).  
In severe cases of CKD, the following symptoms are observed; muscle cramps, 
anorexia, nausea, itching and cognitive impairment. In the presence of such symptoms 
potentially linked to ESKD, renal replacement therapy is required.  The two main 
approaches for renal replacement therapy are dialysis and kidney transplantation.  
Dialysis is the most commonly used approach. Dialysis is primarily an artificial way of 
removing waste and unwanted materials from the blood of individuals with ESRD, in the 
process helping to regulate the body’s homeostasis. It comes with several complications 
which include hypotension, muscle cramps, problems with both male and female fertility, 
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peritonitis and disequilibrium syndrome. In addition, the median life expectancy for 
kidney dialysis patients is relatively small (75% mortality by 5 years) (Gilbert and 
Weiner, 2014). Worldwide, an estimated 2 million ESKD patients are on dialysis which 
is expected to increase due to the growth in kidney dialysis patients especially in China 
(Gilbert and Weiner, 2014). The cost of treatment via dialysis in 2002 was projected to be 
over $1trillion dollars over the next decade (Lysaght, 2002). The ability to diagnose 
ESKD in addition to the time, cost, and prognosis associated with kidney disease 
treatment by dialysis is nerve cracking to individuals and has been linked to 
posttraumatic stress disorder (Gilbert and Weiner, 2014). Kidney transplantation has 
become the best choice of treatment for ESKD compared to dialysis (Wolfe et al., 1999).  
Kidney transplantation is a surgical procedure which involves transplant of a healthy 
kidney from a donor into an individual with failed kidney/s. People on a kidney 
transplant however, stand a chance of rejecting the new organ thus need to be on 
medications their entire life.  Other kidney transplantation challenges include cost, 
technical complications associated with surgeries, lack of individuals with surgical 
operation expertise, infectious diseases, lack of proper nutrition, and interestingly gender 
inequality mostly in developing countries (Verma et al., 2000; Ghods and 
Nasrollahzadeh, 2003; Sakhuja and Sud, 2003). The US experiences the largest number 
of kidney transplantation procedures in the world (Garcia et al., 2012), but there still 
remains a greater population on the kidney transplant waiting list (Gilbert and Weiner, 
2014).  In general, RRT is a costly treatment, especially in developing countries where 
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there is an economic struggle in providing even basic medical care. Therefore the focus 
should be to prevent CKD/ESKD or limit its progression. 
Table 1. 1 Stages of Chronic Kidney Disease 
Stage Description eGFR(ml/min/1.73m
2
) 
1 Kidney damage* with normal or increased 
eGFR 
≥90 
2 Kidney damage with a mild reduction in eGFR 60-89 
3A Moderate decrease in eGFR 45-59 
3B Moderate decrease in eGFR 30-44 
4 Severe decrease in eGFR 15-29 
5 Kidney Failure <15 (dialysis) 
*Kidney damage is assessed by pathological changes in kidney imaging studies or 
abnormalities in values of biological markers in blood and urine tests 
1.2.3 Cost and Burden of CKD 
CKD imposes an enormous economic burden, not only on affected individuals, 
but on their communities, nation and the world as a whole.  Further, the cost of CKD 
treatment and care is expected to increase with the increasing aging population. Since 
there is a strong association between CKD and hypertension, diabetes, cardiovascular 
disease, obesity and stroke, the cost of CKD extends beyond the direct expenses 
associated with CKD diagnosis and treatment. In developed countries, 2-3% of the 
health-care cost is spent on treatment of ESKD.  In the year 2009, the overall Medicare 
expenditure for people with CKD totaled 33.8 billion dollars. In that same year, 6.7% of 
Medicare’s total budget ($29 billion) was spent on kidney failure (USRDS, 2011). Japan 
spent 4.1% of its total healthcare budget on CKD in 1996, while in 2004; South Korea 
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spent 3.24% of its national health expenditure on CKD. Australia also spent an estimated 
AU$647 million in 2000-2001 on CKD, whereas in UK, the estimated cost of treating 
CKD in 2009-2010 was £1.44-1.45 billion (Jha et al., 2013).  Thus the economic burden 
of CKD is enormous throughout the Western world.  The total global cost for dialysis and 
transplantation was expected to exceed $1 trillion dollars in 2012 (Lysaght, 2002), which 
is a cost that is impossible for developing countries to meet, and that imposes a 
substantial burden on healthcare budgets throughout the world.  
1.2.4 Causes of CKD 
CKD results in irreversible kidney damage once it develops most especially in 
glomerular damage which is the filtering unit of the kidney. Treatment of CKD only aims 
at minimizing the rate of CKD progression and minimizing the complications associated 
with CKD. It is therefore important to understand the causes of CKD to provide ways in 
preventing it. The causes of CKD have mostly been identified from patients starting renal 
replacement therapy (RRT) for the first time. These include glomerulonephritis, diabetes 
mellitus, genetic diseases, drugs, hypertension, infections, obesity, with diabetic 
glomerulosclerosis and hypertensive nephrosclerosis being the top entities of 
pathogenesis especially in developed countries. Common causes of CKD within 
developing countries however are usually from infections and exposure to drugs or 
toxins. Recent studies have also shown that acute kidney injury (AKI) results in CKD and 
may even result in damage of non-renal organs (Basile 2004; Basile et al., 2001) 
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1.2.4.2 Diabetes Mellitus 
The most common cause of CKD in both developing and developed countries is 
diabetes mellitus. In the USA, about 40% of people with diabetes develop CKD (Evans 
and Taal, 2011). In general, patients with diabetes exhibit 12-fold increased risk of 
developing ESKD, in comparison to those without diabetes (Brancati et al., 1997). CKD 
caused by diabetes results in microalbminuria and an initial increase in GFR (Hostetter, 
2003) and if left untreated ultimately results in ESKD characterized by reduced GFR 
(Leon and Raij, 2005; Caramori et al, 2003).  
Various mechanisms play a role in the progression of CKD in the diabetic 
population primarily through an interaction of hemodynamic and metabolic factors. 
These include adaptive glomerular hypertension, advanced glycosylated end products, 
cytokines, and activation of the renin-angiotensin aldosterone system involving 
nonresident and resident kidney cells. These interactions through similar intracellular 
pathways increase the production of various growth factors and cytokines which are 
responsible for the increased permeability in the glomerulus and increased deposition of 
extracellular matrix in the kidney during disease pathogenesis.  
Kidney metabolic changes are induced by glucose influx through GLUT-1 
(glucose transporter 1), a kidney cell surface receptor. Increased production of GLUT-1 
mRNA and proteins has been identified in high glucose environments (Heilig et al., 
1997). GLUT-1 expression is driven by transforming growth factor (TGF) -beta 1 in 
response to high glucose levels (Inoki et al., 1999). TGF-beta 1 levels are regulated by an 
initial increase in another growth factor, platelet-derived growth factor (PDGF). This 
results in altered metabolic processes primarily in mesangial cells of the kidney (Schena 
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and Gesualdo, 2005). In vivo, antisense-GLUT1 protects diabetic mice from developing 
diabetic kidney disease, whereas overexpression of GLUT-1 in non-diabetic mice 
develop increased mesangial expansion and albuminuria (features of diabetic 
nephropathy). GLUT-1 levels can also be increased by hemodynamic changes. This has 
been demonstrated by Gnudi et al., 2003, where hypertensive Dahl salt-sensitive rats who 
have increased glomerular pressures and injury have an 80% increase in GLUT-1 
expression (Gnudi et al., 2003) supporting the potential role of GLUT-1 in driving 
diabetic nephropathy. 
Altered kidney hemodynamics primarily glomerular hypertension was observed 
more than 20 years ago in experimental diabetic nephropathy (Hostetter et al., 1982). The 
contribution of increased glomerular hypertension to diabetic nephropathy has been 
demonstrated in various animal models in which experimentally inducing glomerular 
capillary pressure enhanced severity of pathological features in diabetic rats (Mauer et al., 
1978; Steffes et al., 1978; Zatz et al., 1985). Additionally, use of angiotensin converting 
enzyme inhibitors decrease diabetic nephropathy progression potentially through a 
reduction in glomerular capillary pressure (Bernadet-Monrozies et al., 2002). Altered 
glomerular pressures are linked to cycles of stretch and relaxation in glomerular 
components (Cortes et al., 1996; Cortes et al., 1999, Endlich and Endlich, 2006). With 
this in mind, increased mesangial expansion has been observed when mesangial cells are 
exposed to repeated stretch and relaxation. This is due to increased mesangial 
proliferation (Harris et al, 1992), and extracellular matrix proteins such as fibronectin 
(Yasuda et al., 1996; Riser et al., 1992), collagen I (Harris et al., 1992; Yasuda et al., 
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1996; Riser et al., 1992), III (Harris et al., 1992; Yasuda et al., 1996) and IV (Yasuda et 
al., 1996; Riser et al., 1992), and laminin (Yasuda et al., 1996; Riser et al., 1992). The 
accumulation of extracellular matrix proteins corresponds to the degree of stretch 
(Yasuda et al., 1996; Riser et al., 1992) and is augmented in the presence of high glucose 
concentrations (Cortes et al., 1997). Increased TGF-beta 1 expression is also observed in 
stretched cells and may contribute tremendously to extracellular matrix accumulation in 
diabetic kidney disease (Ziyadeh et a., 1994; Hirakata et al., 1997; Gruden et al., 2000). 
As previously discussed, TGF-beta 1 expression therefore augments both GLUT-1 and 
extracellular matrix production both mediating disease progression.  
Kidney hemodynamics is dysrgulated by activation of the intrarenal renin-
angiotensin system (RAS) in addition to other vasoactive hormones such as urotensin and 
endothelin through continuous increase in blood glucose levels (Cooper and Boner, 
2004). The RAS pathway is stimulated primarily by angiontensin II which has been 
identified as a potent mediator or kidney damage in diabetes. Ang II demonstrates effects 
similar to mechanical stretch. Similarly they both can trigger pathways such as the TGF-
beta, VEGF, PDGF and NF-kappa B pathways. These pathways play a role in kidney 
disease development by mediating albuminuria, and fibrosis of the glomerulus and 
tubules (characteristic features of diabetic kidney disease) (Noh and King, 2007; Zhu et 
al., 2007).  Angiotensin II also acts as an inflammatory molecule in the kidney by 
triggering the proliferation and differentiation of macrophages and monocytes both 
driving the pathological findings seen in diabetic nephropathy (Ruiz-Ortega et al., 1998). 
Mechanical stretch may also contribute to the inflammatory process by induction of 
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monocyte chemoattractant protein-1 (MCP-1) (Gruden et al., 2005). MCP-1 plays a role 
in the induction of monocytes to sites of injury. Diabetic nephropathy patients indeed 
show increased glomerular MCP-1 and infiltration of macrophages (Furuta et al., 1993), a 
finding also observed in the glomeruli of diabetic rats (Sassy-Prigent et al., 2000). 
Knockout of MCP-1 prevents glomerular changes and proteinuria under diabetic 
conditions (Chow et al., 2006). 
As stated previously, glomerular pressures impact all the glomerular cellular 
components. Podocytes are essential in the synthesis of ECM proteins of the glomerular 
basement membrane and play a role in opposing distension of the capillary walls. Under 
continuous stress, podocytes exhibit a reduced cell body, and disorganized actin 
cytoskeleton (Endlich et al., 2001). Diabetic nephropathy is characterized by a reduction 
in podocyte numbers. This could be explained by a number of mechanical stretch studies 
in which stretching podocytes affects podocyte proliferation, apoptosis, and cell 
adhesion. Stretched podocytes express increased levels of cyclin-dependent kinase 
inhibitors with reduced expression of positive cell proliferation regulatory proteins, 
thereby experiencing reduced cell proliferation (Petermann et al., 2002). In addition, 
increased Ang II and TGF-beta1 production is observed in stretched podocytes which 
eventually mediates podocyte apoptosis (Durvasula et al., 2004). Ang II further exerts its 
effects on disease pathogenesis by altering ECM production through changes in the 
expression of alpha 3(IV) and collagen (Chen et al., 2005). Ang II also potentially alters 
the glomerular filtration barrier through the downregulation of nephrin expression 
(Doublier et al., 2003), a mechanism not fully elucidated. Nephrin is a slit diaphragm 
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protein essential for podocyte filtration function and has been implicated in proteinuria. 
Nephrin loss is abrogated by RAS blockade in both human (Langham et al., 2002) and 
animal diabetes (Bonnet et al., 2001; Davis et al., 2003).  
The role increased glomerular pressures and glucose levels play in podocyte 
adhesion loss could be explained by reduced expression of integrin alpha 3 beta 1. 
Integrin alpha 3 beta 1 is an adhesion molecule essential for podocyte adhesion to the 
glomerular basement membrane. Its glomerular expression is reduced in humans with 
diabetic nephropathy, diabetic rats and in podocytes treated with high glucose (Chen et 
al., 2000). In addition, integrin alpha 3 beta 1 expression is observed to be lost in 
mechanically stretched pododyctes with reduced adhesion to extracellular matrix 
substrate, albeit the mechanism of loss is not known (Dessapt et al., 2009).  
Despite the influx of glucose through GLUT-1, the precise mechanism by which 
glucose exerts its detrimental effect has not been fully unraveled. Current findings 
indicate contributions by advanced glycation end-products (AGEs) (Giunti et al., 2006) 
and mitochondrial superoxide production (Brownlee, 2001). AGEs are produced through 
interaction of glucose with lipids, proteins and nucleic acids. It is known that AGEs exert 
their detrimental effect through the RAS pathway. AGEs induce Ang II production in 
mesangial cells, in the process, triggering the TGF-beta1 pathway. Effects exhibited by 
either AGEs or the RAS pathway can be partly abolished by inhibiting either pathway 
using animal models (Thomas et al., 2005) demonstrating their potential use as 
therapeutic targets. 
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Racial factors also influence the progression of CKD in diabetic patients with 
African Americans with type II diabetes having a higher risk of developing irreversible 
kidney injury, compared to whites (Shlipak, 2010). 
The disease mechanisms discussed thus far seem to include pathways which may 
be present in other forms of kidney disease. All in all, despite the advancement in 
understanding disease mechanisms in diabetic driven nephropathy this has not been 
translated clinically, demonstrating the need for further research which could potentially 
impact therapeutic decisions  
1.2.4.3 Hypertension 
The relationship between elevated central arterial pressure (hypertension) and 
chronic kidney disease is controversial.  Some authorities propose that hypertension may 
cause kidney damage, whereas others suggest that CKD causes hypertension owing to the 
role of the kidney in blood pressure regulation, (Companion to Brenner & Rector's 
the kidney, 2010).  In modern society, the emergence of better therapeutic interventions 
to control blood pressure has tempered the impact of hypertension (Sarafidis et al., 2008). 
Nevertheless, in developed countries, hypertension remains a major problem that is 
linked with CKD.  Blood pressure regulation involves the kidney in several ways 
however its role in kidney disease still remains elusive. One idea is that, increased 
sympathetic nervous system activity which acts to increase central arterial pressure also 
results in increased vascular constriction of the efferent arterioles, and increased 
resistance to glomerular blood flow.  This increased resistance results in increased 
glomerular capillary pressure, which is a characteristic of both diabetic and hypertensive 
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kidney disease (Palatini, 2012). The increased glomerular pressure impacts production of 
proteins which promote cytokine and growth factor release mediating disease process. 
Another idea is that endothelial damage and a reduction in endogenous vasodilators play 
a role in disease pathogenesis. This results in the activation of the renin angiotensin 
aldosterone system, which modulates excretion of salt and water by the kidney, in turn 
modulates central blood pressure (Winternitz and Oparil, 1982; Hoobler et al., 1981; 
Companion to Brenner & Rector's the kidney, 2010). Activation of the RAS pathway also 
results in increased growth factor and cytokine release, signaling the recruitment of 
inflammatory cells which trigger apoptosis of kidney cells and increased ECM deposition 
(Morgado and Neves, 2011).  
Recent studies also point to the fact that hypertension linked kidney disease may 
be influenced by polymorphisms in genes such as MYH9 (Astor et al., 2010), APOL1 
(Genovese et al., 2010; Tzur et al., 2010) and CHGA (Chen, Rao et al., 2010) athough the 
mechanism in mediating disease pathogenesis is not known.  
 1.2.4.4 Glomerulonephritis 
Glomerulonephritis is the term describing damage to the glomerulus due to 
inflammation, and is the third major cause of ESKD.  There is a wide range of causes of 
glomerulonephritis, including derangements of the immune system, exposure to toxins, 
and infections (Companion to Brenner & Rector's the kidney, 2010).  These diseases 
cause damage to glomeruli in a variety of ways, including immune complex deposition, 
glomerular cell injury, inflammation-associated focal necrosis, and glomerular 
thrombosis.  The end result of these injury processes is glomerular scarring, called 
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glomerulosclerosis, which results in loss of glomerular function.   Glomerulonephritis is 
the principal cause of CKD in developing countries, a reflection of the high prevalence of 
bacterial, parasitic and viral infections affecting the kidneys (Arogundade and Barsoum, 
2008; Ayodele and Alebiosu, 2010). 
1.2.5 Risk factors of CKD 
Irrespective of the cause of kidney damage leading to CKD, there a number of 
factors, that increase the risk of developing CKD. It is important to identify these factors 
so that research could be directed to the high-risk groups.  These factors may play a role 
in CKD development (initiating factors) or they can drive CKD progression (perpetuating 
factors) (Evans and Taal, 2011). These factors include hereditary factors that stem from 
genetic defects, racial factors which are not associated with genetic defects per se, and 
socio-economic factors.   
  Genetic or racial factors clearly play an important role in CKD, in that African 
Americans are at 4 times greater risk to develop CKD than White Americans (USRDS, 
2012).  It is not clear if the newly discovered polymorphisms on chromosome 22 (Kao et 
al., 2008; Kopp et al., 2008; Cooke et al., 2012; Genovese et al., 2010; Tzur et al., 2010) 
are sufficient to explain this racial disparity. In addition, African Americans with diabetes 
are on average 2.5 times more at risk of progressing to ESKD compared to Whites (Xue 
et al., 2007). People coming from families where one or two first-degree relatives have 
ESKD are 1.3 or 10.4 times more at risk of ESKD respectively (Lei et al., 1998). Spray et 
al., 1995, also showed that the risk of developing ESKD in persons with second or third 
relatives having ESKD is 3.5 folds.  
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In addition, the incidence of CKD increases with age perhaps due to a 
corresponding loss in nephrons (Evans and Taal, 2011). Risk of CKD and ESRD is also 
higher in males than females (USRDS, 2010). 
Socio-economic factors such as lower income, environmental factors and 
education also affect CKD incidence. Studies in the USA show that Whites in the lowest 
income quintile are at 86% risk of having CKD compared to those in the highest quintile 
(White et al., 2008). Similarly, people in the highest quintile of social deprivation in the 
UK have a 40% risk of CKD incidence as compared to those in the lowest. 
Hypertension is an independent risk factor for ESKD (Klag et al., 1996; Tozawa 
et al., 2003) but it still remains to be understood whether hypertension causes kidney 
disease or kidney disease causes hypertension. 
1.3 Focal Segmental Glomerulosclerosis (FSGS) 
Focal Segmental Glomerulosclerosis (FSGS) is a pattern of glomerular damage 
characterized by glomerular epithelial cell (podocyte) injury and extracellular matrix 
(ECM) accumulation (Habib, 1973; Rich, 1957; D’Agati, 2003), resulting in permanent 
scarring of the glomerulus and loss of normal glomerular function.  In children and 
adults, it is the most common pattern of injury in idiopathic steroid-resistant nephrotic 
syndrome (Dingli, 2005). It was first described in 1925 by Fahr, based on findings in 
kidney biopsies of adults with nephrotic syndrome (cited in Habib, 1973; Rich, 1957). 
Later in 1957, Rich first described the finding in autopsies of children who had died of 
nephrotic syndrome (Habib, 1973; Rich, 1957; D’Agati, 2003).  The histologic finding of 
FSGS is associated with rapid progression to ESKD within 3 to 8 years (de Milk et al., 
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2013).  In the United States, it precedes 5-20% of all cases of ESKD (Kitiykara et al., 
2003; USRDS, 2007; Kitiyakara et al., 2004).   People of all ages can be affected with 
FSGS. The mean age for onset in adults is 40-50 with both genders affected equally. 
FSGS can be a primary (idiopathic) disorder present in 80% of FSGS patients or 
secondary (with an underlying cause) disorder present in the remaining 20%.  Primary 
forms of FSGS are characterized by severe podocyte injury, evident as diffuse foot 
process effacement on electron microscopy. A subset of primary FSGS appear as 
familial.  Recently, several mutations have been identified in familial forms of FSGS. 
These usually occur in genes associated with important podocyte functions, particularly 
maintenance of cytoskeletal structure. Alpha-actinin 4 (Kaplan et al., 2000), nephrin 
(Kestila et al., 1998), podocin (Boute et al., 2000) among others are examples of 
podocyte specific proteins in which mutations have been discovered in some familial 
forms of FSGS.  The pathogenesis of primary FSGS in some patients may be due to the 
presence of a circulating permeability factor known as serum soluble urokinase receptor 
(suPAR) (Wei et al., 2011).  Secondary forms of FSGS are thought to be associated with 
increased glomerular filtration or pressure due to loss of functioning nephrons (Korbet, 
1998).  
1.3.1 Clinical presentation and treatment of FSGS 
The essential clinical feature of FSGS is abnormal proteinuria (protein in the 
urine) due to dysfunction of the glomerular filtration barrier (Schnapper, 2003; Fogo, 
2003). The extent of proteinuria is classified as subnephrotic (<3.5 g/day) or nephrotic 
(>3.5 g/day). Microscopic hematuria and hypertension are also common features of 
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FSGS.  Kidney biopsies of FSGS patients show focal glomerular injury characterized by 
scarring and deposition of hyaline material, adherence of the glomerular basement 
membrane to the Bowman’s capsule, and collapse and wrinkling of some capillary loops 
under the light microscope.  Five main light microscopic variants have been defined, 
including FSGS (not otherwise specified [NOS]), perhilar variant, cellular variant, tip 
variant and collapsing variant (D’Agati, 2003).  Most importantly, electron microscopy 
shows podocyte foot process effacement (flattening and “fusion” of adjacent foot 
processes), indicative of severe podocyte injury.  These changes in the podocytes are 
likely to be responsible for the heavy proteinuria observed in these patients.  Treatment 
with corticosteroids may slow the progression of FSGS to ESKD. Sub-nephrotic 
proteinuria is associated with a better prognosis, with a renal survival greater than 80% 
after ten years (Deegens et al., 2008).  In secondary FSGS cases, patients often respond 
with resolution of proteinuria after successful treatment of the underlying secondary 
cause. Some drugs currently used to treat FSGS include steroids, ciclosporin, 
cyclophosphamide, angiotensin receptor blockers and angiotensin-converting-enzyme 
inhibitors. These drugs, however, do not target specific known disease mechanisms, and 
are only marginally effective.  Of note, familial forms of FSGS are typically steroid 
resistant. 
1.3.2 Pathophysiology of FSGS 
FSGS lesions are essentially glomerular although tubulointerstitial and vascular 
chronic damage is also common.  A normal glomerular structure and function is 
important for the ultrafiltration of plasma in the kidney.  This requires that the three 
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components of the glomerular filter, the glomerular endothelial cells (GECs), glomerular 
basement membrane (GBM) and podocytes, are intact and able to provide a 
permselective barrier. A compromised permselectivity results in proteinuria and 
nephrotic syndrome which are clinical hallmarks of FSGS.  The podocyte is pivotal in the 
permselective function of the glomerular capillary wall, thus FSGS mostly stems from 
directed damage to the podocytes and foot process effacement (D'Agati 2008; Shankland 
2006).  Several animal models have confirmed that foot process effacement is associated 
with disorganization of the cytoskeletal structure (Kerjaschki, 2001; Faul et al., 2007; 
Tryggvason et al., 2006)  
In secondary FSGS, the initial injury does not appear to affect the podocytes 
directly.  Rather, the podocytes appear to be injured secondarily due to changes in the 
mechanical environment in the glomerulus.  The podocytes may be thought to act as 
pericytes, with the foot processes controlling the distending forces of the high pressure 
perfusion experienced by the glomerular capillaries during blood flow.  The glomerular 
capillary pressures and associated distending forces present under normal hemodynamic 
conditions may be within the ability of the podocytes and capillary wall structures to 
control.  However, due to adaptive structural and functional responses of the glomerulus 
associated with high central arterial blood pressures, a congential low number of 
functional nephrons, or loss of a functional portion of the kidney through trauma or 
disease, the glomerular capillary pressures may be increased (Aggarwal and Appel, 2009; 
D’Agati, 2008). The mechanical forces stemming from increased glomerular pressures 
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may impact podocyte foot process structure and function through reorganization of the 
actin cytoskeletal structure.  
Several in vitro studies have demonstrated the possibility that podocytes respond 
to mechanical stress, in ways that affect the actin cytoskeleton and cell adhesion.  Endlich 
et al, 2001, demonstrated that mouse podocytes experiencing bi-axial cyclic stress exhibit 
reorganization of the actin cytoskeleton, forming actin rich centers (ACR), and show 
decreased cell body size with longer and thinner processes.  They also demonstrated that 
the formation of ARC was inhibited by Rho kinase inhibitor, suggesting a role for Rho 
kinase in podocyte response to mechanical stimuli.  In that same study, Ca
2+
 ion influx 
was also identified to be important for ARC and stress fiber formation in mechanically 
stressed podocytes (Endlich et al., 2001).  Subsequent studies focused on the effect of 
stress on adhesion showed that mechanical stress exposure is associated with decreased 
focal adhesion size, and this response is potentially mediated by overexpression of 
osteopontin and SPARC (Endlich et al., 2002; Endlich and Endlich, 2006; Schordan et 
al., 2011; Endlich et al., 2002; Durvasula and Shankland, 2005; Sussman et al., 2009).  
SPARC overexpression has been identified to be mediated by p38 activation, which in a 
number of studies has been shown to be essential to the response to stress (Martineau et 
al., 2004; Durvasula and Shankland, 2005; Faour et al., 2010; Petermann et al., 2005; 
Stitt-Cavanagh et al., 2010).  Other studies have shown alterations in the expression of 
several integrins in stretched podocytes, suggesting podocyte adhesion may be affected 
by mechanical stress (Schordan et al., 2011; Hafdi et al., 2000).  For example, Schordan 
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et al., 2011, show an upregulation of integrin alpha V, beta 1, and beta 3 in response to 
stress.  
Studies examining the direct mechanistic role of mechanical stress on glomerular 
pathophysiology in vivo are limited, in part due to the complexity of these studies and the 
limitations on mechanical force measurement in vivo on the scale of the glomerulus.  The 
seminal study in this area (Hostetter et al, 1983) employed a remnant kidney model, 
whereby 5/6 of normal kidney mass was removed surgically, in order to force the 
remaining kidney to process blood at an increased volume flow rate.  These studies were 
performed using the Munich-Wistar rat, which exhibits glomeruli at the capsular surface 
of the kidney, allowing access to these glomeruli for microcannulation and glomerular 
pressure measurement.  This study demonstrated a glomerular capillary pressure increase 
accompanied by prominent podocyte injury within days of the employment of the 
remnant kidney model.  This podocyte injury preceded more severe chronic changes 
(glomerulosclerosis) developing later on.  This study introduced the concept of 
hyperfiltration of remnant nephrons, and adaptive glomerulosclerosis occurring in 
response to nephron loss.  Further, this study showed that podocyte injury precedes 
glomerular chronic damage. 
An increase in glomerular pressure in vivo which results in mechanical stress on 
podocytes, could result in disorganization of podocyte actin cytoskeletal structure, 
alteration in slit diaphragm proteins and slit diaphragm structure, foot process effacement 
and altered podocyte adhesion. Loss of podocyte structure, podocyte hypertrophy and 
detachment from the GBM eventually results in podocyte apoptosis and depletion 
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(Asanuma and Mundel, 2003; Kwoh et al., 2006). The loss of podocytes is essential for 
the development of FSGS (Asanuma and Mundel, 2003; Kriz, 2003). The denuded GBM 
interacts with the glomerular parietal epithelial cells and also produces adhesion 
molecules which promote the formation of the sclerotic lesion and scaring of the 
glomerular tuft.  
The use of certain drugs such as sirolimus, pamidronate, and interferon may play 
a role in the induction of FSGS (Letavernier et al., 2007; Markowitz et al., 2001; 
Markowitz et al., 2010). For example, pamidronate, a drug used in the treatment of 
cancers through inhibition of the actin cytoskeleton, has been found to be associated with 
FSGS (Markowitz et al., 2001).  This drug may have a similar effect on podocytes, 
causing podocyte cytoskeletal dysfunction, foot process effacement, and glomerular 
injury.  Immunosuppressive drugs such as rapamycin influence FSGS development by 
causing a reduction in expression of slit diaphragm proteins such as nephrin, a protein 
essential for the filtration function of the glomerulus (Vollenbroker et al., 2009).  FSGS 
can also be induced by viral infections as has been observed with HIV infection. HIV-1 is 
able to directly infect podocytes resulting in disruption of podocyte cytoskeletal 
structures, and podocyte dedifferentiation and proliferation (D'Agati et al., 2011) 
FSGS often recurs in transplant kidneys.  Some patients with recurrent FSGS 
show proteinuria remission after plasmapheresis or kidney transplant (Daskalakis and 
Winn, 2006).  On the basis of this, it has been suggested that a circulating soluble factor 
may play a role in FSGS pathogenesis.  Recently, a candidate circulating factor has been 
identified as soluble urokinase–type plasminogen activator receptor (suPAR). Patients 
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with primary and recurrent FSGS show increased levels of suPAR concentrations.  
suPAR activates beta 3 integrin in podocytes.  Beta 3 integrin is essential for anchoring 
podocytes to the GBM and mature foot process development. Activation of beta 3 
integrin results in foot process effacement, proteinuria and FSGS development (Wei et 
al., 2011).  Cardiotrophin like cytokine 1 has also been identified as another circulating 
factor and is currently under study (D'Agati et al., 2011). 
Gene expression changes have been identified in biopsies from FSGS patients 
which may play a role in disease pathogenesis and progression.  For example, genes 
potentially associated with early stages of cell injury, including genes involved in  
dedifferentiation, proliferation, apoptosis and extracellular matrix remodeling, have been 
shown to be altered in FSGS (Barisoni et al., 1999).   Other studies have shown evidence 
of altered expression of genes involved in chronic changes (e.g., fibrosis), at both the 
gene and protein level, including the signaling pathway involving transforming growth 
factor (TGF) beta 1, TGF beta 2 receptors, thrombospondin 1 with their downstream 
modifiers, and phosphorylated Smad2/Smad3 (Kim et al., 2003). 
Recent studies have identified point mutations in several genes associated with 
the development of FSGS (Table 1.2).  Interestingly, most of the identified genes encode 
proteins important in the maintenance and regulation of the podocyte cytoskeleton, as 
indicated in Table 1.2.  Identification of these mutations has provided new mechanistic 
insights regarding the pathophysiology of FSGS, and highlighted the role of podocyte 
cytoskeletal derangement in this process. 
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Table 1. 2 Hereditary forms of Nephrotic Syndrome and FSGS 
Gene Protein Typical phenotype Function  
NPHS1 Nephrin Congenital 
Nephrotic 
Syndrome and 
infantile SRNS 
Transmembrane protein required 
for the maintenance of the slit 
diaphragm and regulation of actin 
cytoskeletal dynamics 
TRPC6 Transient receptor 
potential cation 
channel, subfamily 
C, member 6 
Juvenile and adult-
onset FSGS 
Transmembrane ion channel which 
may modulate actin cytoskeletal 
dynamics through calcium transport 
and RhoA pathway; also may act as 
mechanosensor 
ACTN4 Alpha-actinin-4 Juvenile and adult-
onset FSGS 
Actin-binding protein; regulates 
actin turnover for maintenance of 
podocyte cytoskeletal structure and 
function 
CD2AP C2 associated 
protein 
Suggested to be a 
predisposing factor 
for FSGS 
development 
Slit diaphragm protein; may 
participate in maintenance of actin 
cytoskeleton 
 
Recently, genetic defects have been identified that do not have an obvious direct 
effect on podocyte or glomerular function, but are nevertheless strongly linked to CKD 
and FSGS development.  These genetic defects include polymorphisms in the MYH9 
gene (Astor et al., 2010) and the APOL1 gene (Genovese et al., 2010; Tzur et al., 2010).  
Myh9 encodes for the non-muscle myosin IIA protein whereas APOL1 encodes for the 
apolipoprotein L1 protein. DNA sequence variations in both genes have been strongly 
associated with chronic forms of kidney disease.  These variants appear to be prevalent in 
the African American population, who are at 4 times greater risk of developing renal 
disease as compared with the non-African American population.  
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1.3.3 FSGS and African Americans 
People of African ancestry in the USA are at a greater risk of developing FSGS 
(USRDS, 2008).  A variant of FSGS commonly seen in people of AA is the collapsing 
variant.  It normally portends a worse prognosis as compared to the other variants and 
may play a role in the aggressive nature of FSGS in the African population (Detwiler et 
al., 1994).  The risk of developing HIV-1 associated FSGS, which is the prototype 
etiology of collapsing variant FSGS, is 18 fold greater for African Americans as 
compared to European Americans (USRDS, 2008; Kopp and Winkler, 2003; Kitiyakara 
et al., 2003).  Responses to treatment of FSGS in the African population have been 
variable. Crenshaw et al., 2000, did not find any beneficial effect of steroids in AA FSGS 
patients (Crenshaw et al., 2000). 
Many have proposed a genetic predisposition to be likely related to the high 
prevalence of kidney disease among people with AA, as compared to the European 
American population. Studies using mapping by admixture linkage disequilibrium 
(MALD) have identified a locus on chromosome 22 that is likely to be responsible for 
most of the increased risk for nondiabetic nephropathy in people with AA (Kao et al., 
2008; Kopp et al., 2008). The studies suggested that the MYH9 gene, located at this locus 
on chromosome 22, may harbor the disease causing variants(Kao et al., 2008; Kopp et al., 
2008), in view of the existence of other kidney disease-causing mutations in MYH9 
(Arrondel et al., 2002; Ghiggeri et al., 2003), and a potential physiological role for its 
protein product, non-muscle myosin IIA. Studies have shown a strong association 
between the disease haplotype termed E1 and albuminuria levels in hypertensive African 
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Americans (Freedman et al., 2009).  MYH9 SNPs rs4821480, rs4281481, rs2032487 and 
rs3752462 have also been found to be associated with increased ESRD susceptibility in 
Europeans Americans with type 2 diabetes mellitus-associated kidney disease (Cooke et 
al., 2012). This idea was exciting because of previous association between autosomal 
dominant mutations in MYH9 and giant platelet syndrome group of disorders which 
includes renal failure stemming from the glomerulus (Kopp, 2010). However, DNA 
sequencing revealed that all variants identified affected only intronic regions of the 
MYH9 gene, and gene variants with a clear functional effect on MYH9 protein product 
were not identified (Kao et al., 2008; Kopp et al., 2008). 
Because of the unclear role of the MYH9 gene in chronic kidney disease, and 
particularly the lack of identification of functional variants within coding regions of the 
MYH9 gene, data from the 1000 Genomes Project was used to re-analyze the 
chromosome 22 genomic region. This analysis revealed two coding sequence variants in 
the last coding exon of the APOL1 gene that are strongly linked and offer biologically 
plausibility for explaining the high incidence of kidney disease in AA populations 
(Genovese et al., 2010; Tzur et al., 2010).  These two variants are composed of a 
missense mutation termed G1 (rs73885319 (S342G) and rs609101145 (I384M)) and a 
combined deletion of two amino acid residues, termed G2 (rs71785313 (deldN388 and 
delY389).  Individuals with two risk variant alleles of any combination have a higher 
relative risk of developing FSGS as compared to those with one risk variant (Genovese et 
al., 2010).  The G1 and G2 risk variants both follow an autosomal-recessive pattern of 
inheritance.  About 50% of African Americans have either one or two risk alleles while 
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10%-15% have two risk alleles (Genovese et al., 2010).  AA with kidney disease carrying 
2 APOL1 risk alleles start dialysis about 10 years earlier than kidney disease patients 
with zero or one allele (Kanji et al., 2011; Tzur et al., 2012).   
Despite the strong association between the APOL1 gene variants and kidney 
disease susceptibility in AA, there is some data that contradicts a potential role for 
APOL1 in chronic kidney disease.  For instance, O’Seaghdha et al., 2011, have shown 
that these disease-associated SNPs in APOL1 do not explain disease susceptibility in 
European Americans (O’Seaghdha et al., 2011). 
1.3.3.1 MYH9 
Myosins are a superfamily of molecular motor proteins that are responsible for 
translocation or movement of cells or intracellular cargo.  Myosin proteins move along 
actin filaments in response to hydrolysis of ATP at the catalytic ATPase sites on the 
myosin amino-terminal (head) domain. The carboxyl domain of the myosins is 
responsible for attachment of cellular cargo to the myosin protein tail, thereby facilitating 
its movement.  Myosins also indirectly influence recruitment of adhesion molecules or 
signal transduction molecules through its interaction with actin filaments.  
There are about 24 isoform classes within the myosin superfamily. Of these, the 
large set of class II myosins are composed of those myosin heavy chains involved in 
whole-cell contraction.  Several isoforms are involved in generating contractility in 
cardiac, skeletal and smooth muscle cells.  The non-muscle myosin heavy chains are 
members of the class II myosins ubiquitously expressed in non-muscle eukaryotic cells. 
There are three members of the non-muscle myosins including: non-muscle myosin IIA 
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(NMIIA), NMIIB, and NMIIC, whose heavy chains are encoded by MYH9, MYH10 and 
MYH14 genes respectively. Similar to the muscle myosins, each NMII protein complex 
includes two catalytic ATPase globular head domains (230kDa), two regulatory light 
chain domains (20kDa), and two essential light chains for stabilizing the heavy chain 
structure (17kDa) (Figure 1.2). NMII has actin cross-linking and contractile properties 
similar to skeletal muscle myosin II, and contributes to cellular adhesion, cytokinesis, cell 
migration, cell shape maintenance, endocytosis and exocytosis. 
Myosins were first discovered in podocytes using immunoelectron microscopy in 
1988 (Drenckhahn and Franke, 1988). Within the podocytes, the myosins thus far 
identified include the class I myosins; Myo1b, Myo1c, Myo1d, Myo1e, and the class II 
myosins; NMIIA, NMIIB and NMIIC. 
As described above, recent studies implicate non-muscle myosin IIA (NMIIA) in 
glomerular pathophysiology, with a pattern of injury that suggests an important role for 
podocyte injury (Kao et al., 2008; Kopp et al., 2008).  Since NMIIA has actin cross-
linking and contractile properties, and plays a dynamic role in regulation of cell 
cytoskeletal organization and maintenance of membrane tension and cell shape, it is 
plausible that NMIIA alteration may influence podocyte structure and function. NMIIA 
contractile function might be essential not only for maintenance of podocyte structure 
required for normal filtration processes, but may also help bolster the capillary walls 
against the increase in glomerular capillary pressure associated with loss of nephrons, 
which is a cardinal feature of CKD (Kriz et al., 1994).  To date, the role of NMIIA in 
  
36 
podocyte function in vitro or in vivo using hypertensive models have not been 
extensively studied. 
Ablation of NMIIA by siRNA in mammalian cell lines in vitro has been shown to 
result in alteration of actin cytoskeletal organization, focal adhesion organization, and 
cellular contractility (reviewed in Conti and Adelstein, 2008).  NMIIA deficiency in cells 
is also associated with increased cell motility and exaggerated membrane ruflling, 
stemming from increased stabilization by microtubules (Even-Ram and Yamada, 2007).  
This latter finding is important because increased podocyte motility in vitro has been 
proposed to correlate with podocyte foot process effacement in vivo.  The increase in cell 
motility observed after myosin ablation in the above referenced study was found to be 
mediated by the small G-protein Rac1, its activator Tiam1, and a microtubule motor 
kinesin Eg5 (Even-Ram and Yamada, 2007).  Loss of NMIIA in embryonic stem cells 
results in disruption of cell-cell adhesion and altered cellular localization of major 
junction proteins such as beta-catenin and E-cadherin (Even-Ram et al., 2007).  This 
finding is also of importance in podocyte biology in that maintenance of podocyte 
intercellular junctions is necessary for podocyte filtration function. 
Homozygous Myh9 knockout mice are embryonically lethal due to the lack of 
formation of cell-cell adhesions and an inability to form a polarized visceral endoderm 
(Conti et al., 2004) whereas heterozygous knockout mice do not show any global 
phenotypic changes (Matsushita et al., 2004) Johnstone et al., 2011, have shown that 
podocyte-specific deletion of MYH9 in glomerulosclerosis-resistant C57BL/6 mice, 
predisposes them to glomerular injury after treatment with doxorubicin. Doxorubicin is a 
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drug which induces injury by direct toxicity to glomerular cells. It has been observed to 
result in altered slit diaphragm protein distribution although the mechanism is still not 
clear (Otaki et al., 2008).  In another study by Johnstone et al., 2013, they show that in 
podocyte-specific deletion of Myh9 in Tg26, a mouse HIVAN model, resulted in 
increased susceptibility to glomerulosclerosis. In that study, they also demonstrated that 
podocyte-specific deletion of Myh9 in C57BL/6 did not predispose them to other forms 
of kidney injury such as treatment with puromycin (podocyte toxin) and sheep 
nephrotoxic serum (coagulation mediated injury). However, in another mouse strain on a 
mixed background of C57BL/6, BALB/c and 129/SJ, Zhang et al., 2012, showed that 
mice with podocyte-specific knockout of Myh9 spontaneously develop glomerular 
lesions and albuminuria.  These results suggest that NMIIA in the podocyte may be 
important for protecting the glomerulus when conditions such as mouse strain of 
secondary stress favor the development of glomerulosclerosis. 
It is worth stating that mutations in Myh9 have been implicated in a number of 
autosomal dominant disorders currently classified as the Myh9 related disorders. These 
include May-Hegglin, Sebastian, Fechtner, and Epstein (Heath et al., 2001; Seri et al., 
2000) characterized by leukocyte inclusions, thrombocytopenia, with varying degrees of 
glomerular disease. Unlike the mutations associated with CKD, mutations associated with 
the Myh9 related disorders are missense or nonsense mutations which result in structural 
and functional changes in Myh9. Suzuki et al., 2013 and Zhang et al., 2012, demonstrate 
that mice harboring the different Myh9 mutations manifest similar phenotypes to humans 
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with Myh9-related disorders. It is interesting why these dominant mutations do not 
increase the risk of developing ESKD but the intronic variants confer a significant risk. 
The role of Myh9 and the impact the variations within the Myh9 gene play on 
podocyte function and on the kidney as a whole remains to be explained. 
 
 
Figure 1.2. Protein domains of non-muscle myosin II: The globular head domains of 
non-muscle myosin II (NM II) contain an enzymatic Mg2+ ATPase activity motor 
domain and an actin-binding domain. Through interactions between the NM II alpha 
coiled-coil rod domains, NMII dimers are formed. The head and rod domains are 
connected together by a neck (lever arms). The neck carries the essential light chains 
(ELC) and regulatory light chains (RLC). RLC phosphorylation is required for the 
formation of assembly-competent (dimer formation) NM II. The non-helical tail is 
involved in cargo binding and transport. 
1.3.3.2 APOL1 
Apolipoprotein L1 is a product of the APOL1 gene.  The gene is found in humans 
on chromosome 22, and is also present in other species, including non-human primates 
However, the gene is not found in all species; murine species in particular do not carry 
the gene (Seed et al., 1990; Lugli et al., 2004; Smith and Malik, 2009). APOL1 was first 
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identified as a secreted protein that interacts in the blood with high density lipoproteins 
(HDL), and in small amounts with very low-density lipoproteins.  The APOL1 protein 
includes a signal peptide domain which enables it to be expressed as a circulating protein 
(Figure 1.3).  In humans, apolipoprotein L1 is expressed in the pancreas, liver, kidney, 
and brain primarily (Duchateau et al., 1997; Dunham et al., 1999).  More recently, it has 
been found that apolipoprotein L1 may have a role in mitigating trypanosome infection 
and African sleeping sickness by promoting the lysis of circulating trypanosomes 
(Genovese et al., 2010).   
Derangements in APOL1 and apolipoprotein L1 have been implicated in a 
number of diseases.  For example, in a study by Duchateau et al., 2000, circulating 
APOL1 levels were found to be increased in hyperlipidemia patients compared to 
normolipidemia patients.  In the same study, type 2 diabetic patients showed increased 
APOL1 levels correlating with elevated triglyceride levels.  In humans, genetic variants 
within the APOL1 gene named G1 and G2 have been identified to be strongly associated 
with non-diabetic kidney disease, including hypertensive kidney disease and FSGS, with 
the disease phenotypes exhibiting an autosomal recessive model of inheritance (Genovese 
et al., 2010; Tzur et al., 2010).   These genetic risk variants within APOL1 have also been 
linked to severe and progressive sickle cell nephropathy and lupus nephritis (Ashley-
Koch et al., 2011; Larsen et al., 2013; Freedman et al., 2014). 
Although the biological role of APOL1 protein in kidney function has not been 
fully elucidated, the APOL1 variants associated with kidney disease have been found to 
impart a potentially beneficial biological effect.  Proteins expressed by these APOL1 
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gene variants contribute to human innate immunity against trypanosome brucei 
rhodesiense, one of the causative pathogens for African sleeping sickness.  Several 
features of the APOL1 protein account for this: 1) an anionic pore-forming domain which 
plays a role in lysosomal permeation and apoptosis; 2) a membrane-addressing domain 
which enhances HDL interaction at neutral pH and localization to intracellular organelles 
at acidic pH; and 3) a C-terminus amphipathic helix with a leucine zipper motif, which 
aids in protein-protein interaction.  The APOL1 S342G variant (G1) and the 6 bp deletion 
variant (G2), both of which have been strongly linked with renal dysfunction, modify the 
C terminal domain of the APOL1 protein. This modification especially in the G2 variant 
inhibits binding of a serum resistance associated protein (SRA) to the C-terminal domain 
of the APOL1 protein.  When SRA is unable to bind to the C-terminal domain of APOL1, 
the unbound APOL1 protein exhibits the ability to promote lysis of T. brucei rhodesiense.   
In a normal (non-variant) APOL1 protein, T. brucei rhodesiense trypanolysis is 
terminated due to the presence of SRA, which neutralizes their lytic capability of 
APOL1.  These findings suggest that selective evolutionary pressure is contributing to the 
high numbers of APOL1 risk variants in West Africa, in that inheritance of a single G1 or 
G2 allele can confer a selective advantage against Trypoanosoma brucei rhodesiense 
infection. This could explain the worldwide distribution of the APOL1 risk alleles which 
are most common in the population of West Africa, where Trypanosome infection is 
endemic.  Similarly, the APOL1 risk alleles are less prevalent in East Africa, where the 
trypanosome is uncommon.  In African Americans, 51% carry at least one risk allele 
whereas 13% carry two risk alleles (Genovese et al., 2010; Tzur et al., 2010; Freedman et 
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al., 2010).  Values are higher in people from West African regions, where renal disease 
and hypertension are highly prevalent (Ulasi et al., 2013).  
As mentioned earlier, people carrying 2 APOL1 kidney disease risk variants have 
been found to be at a higher risk of non-diabetic kidney disease such as HIVAN, FSGS, 
and hypertension-associated nephropathy, as compared to those carrying 0 or 1 APOL1 
risk variant (Genovese et al., 2010; Tzur et al., 2010; Freedman et al., 2010). Conversely, 
the relative infrequency of the G1 and G2 alleles in the Ethiopian population has been 
linked to the low incidence of HIVAN in the Ethiopian HIV patient population (Behar et 
al., 2006; Behar et al., 2011). The APOL1 risk variants have also been linked to younger 
age of onset of ESRD and hemodialysis initiation (Kanji et al., 2011), and have been 
identified to negatively correlate with allograft survival irrespective of the recipients 
APOL1 status (Reeves-Daniel et al., 2011; Lee et al., 2012).  This latter finding suggests 
that an intrinsic factor, present in donor kidneys harboring 2 APOL1 risk variants, may be 
responsible for the poor outcome of kidney allografts.  
It is noteworthy to mention that not all individuals harboring 2 of the genetic risk 
variants develop disease.  For example, the study by Kopp et al., 2011, showed that the 
lifetime risk of developing FSGS in all individuals harboring 2 risk gene variants is 4%, 
and 50% of HIV patients harboring 2 risk gene variants develop FSGS.  This finding 
raises the possibility that modifying factors play a role in disease pathogenesis.  This 
hypothesis has been supported by various studies.  For example, Divers et al., 2014, 
identified genetic variants in NPHS2, SDCCAG8 and near BMP4 that interact with 
APOL1 and modulate the risk for non-diabetic ESKD in people of African ancestry.   
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Studies showing linkage between the APOL1 risk haplotypes and sickle cell nephropathy 
and lupus nephritis also support this notion, since these distinct non-diabetic renal 
diseases show different kidney histopathological features at the glomerular, tubular and 
vascular levels (Ashley-Koch et al., 2011; Larsen et al., 2013; Freedman et al., 2014). 
Further studies targeted toward identifying similar modifying risk factors will go a long 
way toward understanding APOL1’s role in CKD pathogenesis. 
To identify possible functional roles for APOL1 in kidneys, the intracellular 
distribution of APOL1 in the kidney was first analyzed.  Madhavan et al., 2011, showed 
that apolipoprotein L1 is expressed in podocytes and proximal tubules in normal kidney, 
suggesting a potential role of the APOL1 gene product in these cells. They also showed 
APOL1 expression to be reduced in podocytes in HIV-associated nephropathy (HIVAN) 
and FSGS kidney biopsies.  Despite the reduction in APOL1 expression in podocytes, 
similar APOL1 levels were observed in proximal tubular epithelial cells of both normal 
and diseased (HIVAN and FSGS) kidneys (Madhavan et al., 2011).  These findings show 
an association between APOL1 expression in the podocyte specifically, and the 
development of glomerular lesions where the podocyte plays a key role in disease 
pathogenesis. 
Several suggestions have been made for the possible role of APOL1 in kidney 
disease pathogenesis.  Previous studies found apolipoprotein L1 to be involved in 
autophagy and apoptosis.   In an in vitro study, overexpression of APOL1 in cancer cells 
resulted in autophagic cell death (Wan et al., 2008).  Since autophagic pathways have 
been identified to play a role in normal kidney function (Hartleben et al., 2010; Huber et 
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al., 2012), it has been suggested that APOL1 may potentially have an effect on 
autophagic pathways in the kidney. This may be because apolipoprotein L1 includes a 
BCL2 homology domain 3 (BH3), which is necessary for autophagy.  In another study, 
Madhavan et al., 2011, showed that APOL1 protein levels in podocytes are increased 
when podocytes are treated with liposaccharides of tumor necrosis factor, a finding which 
has been demonstrated in our lab as well (data not published).  Lan et al., 2014, also 
showed that overexpression of both risk and non-risk APOL1 gene variants in podocytes 
resulted in podocyte injury, an effect that is augmented in the presence of hydrogen 
peroxide, hypoxia, tumor necrosis factor-alpha, and puromycin aminonucleoside. 
Despite the emerging evidence for a role for apolipoprotein L1 in the kidney, the 
strong linkage between the APOL1 G1 or G2 haplotypes and non-diabetic kidney disease 
has not yet yielded a mechanistic understanding of disease pathogenesis. The findings 
from my study certainly will impact kidney transplantation procedures, particularly in the 
population of donors carrying two risk variants. 
 
 
Figure 1.3. APOL1 functional domains: APOL1 contains a pore-forming domain, 
membrane-addressing domain and a serum-resistance associated (SRA) interacting 
domain at the C terminal end. It contains a signal peptide at the N terminus. 
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1.4 Rationale and Hypothesis 
Earlier work attributed the high incidence of ESKD in AA to the presence of a 
genetic variant termed E1 in the vicinity of the MYH9 gene, encoding non-muscle 
myosin IIA (NMIIA). Subsequently, analyses of the chromosome 22 genomic region 
using data from the 1000 Genomes Project identified two coding sequence variants in 
APOL1 which may explain the high incidence of kidney disease in AA populations. 
These two variants have been termed G1 and G2. E1 was found to be present in 89% of 
the G1 haplotypes and 76% of G2 haplotypes. 
The histologic pattern of kidney damage associated with the chromosome 22 
haplotypes falls under the morphologic category of focal segmental glomerulosclerosis 
(FSGS).  This pattern of injury affects the kidney glomeruli, which are the microscopic 
vascular filtration units of the kidney.  Injury of the glomerular visceral epithelial cells, or 
podocytes, is the initiating event that leads to the glomerular damage manifested as 
FSGS.  Glomerular hypertension, which develops to compensate for insufficient kidney 
function in a variety of circumstances, is thought to play a key role in this injury 
mechanism.  Currently, almost nothing is known about how the chromosome 22 genetic 
variants may alter cellular homeostasis in the glomeruli of people of AA, and thereby set 
the stage for the development of FSGS.  Given the role of NMIIA as a motor protein, it is 
conceivable that NMIIA contributes to glomerular stability and potentially resistance to 
hypertensive conditions, but this has not been demonstrated.  An important biological 
function for risk haplotype APOL1 has been identified outside of the kidney, in the form 
of increased resistance to trypanosome infection.  Natural selection pressure for the 
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kidney risk haplotypes of APOL1 exists in West African peoples who are at greatest risk 
of trypanosome infection, and these same populations exhibit a higher incidence of 
chronic kidney disease than the general population.  Yet it is not at all clear how APOL1 
may have a role in kidney function, specifically.. Thus it remains possible that either gene 
may have a role in AA kidney disease. 
Despite the strong association between APOL1/MYH9 variants and the high rate 
of non-diabetic kidney disease in Africans relative to Europeans, no obvious role for 
APOL1 or MYH9 in the kidney has been found.  Yet it is crucial to understand this 
process in detail as there has been an increase in the incidence of FSGS in the African 
population over the past decade, and it is presently the most common cause of ESKD in 
this population. FSGS is the most common cause of steroid resistant nephrotic syndrome 
in children, and also the second leading cause of kidney failure in children. An estimated 
half of FSGS patients not responding to steroids go into ESKD each year, either requiring 
dialysis or transplantation. With about a 1,000 FSGS patients who receive kidney 
transplants in a year, FSGS recurs in 30%-40% of these patients in a matter of weeks 
post- transplant. Thus there are compelling reasons to increase our understanding of how 
the chromosome 22 risk haplotypes confer increased risk for kidney disease. 
To this end, the studies presented here are intended to test the hypothesis that the 
chromosome 22 disease risk haplotypes are associated with altered expression levels of 
genes involved in glomerular function, and these in turn promote kidney disease. In the 
case of APOL1, an obvious role in glomerular function has not been found; thus the 
mechanism for APOL1’s role in disease is unknown. Possible mechanisms could include 
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altered sequences in promoter regions for other nearby genes, alterations in microRNA or 
lncRNA expression in the vicinity of APOL1, and or alterations in sequences of the 
RNAs themselves possibly influenced by natural selection. Any of these could have 
broader effects that can lead to an entire pattern of gene expression that as a whole, 
promotes development of glomerular damage over time. Hence, the need to examine the 
entire “transcriptome”, so that such a broad pattern can be identified. In this way APOL1 
may have an indirect effect on glomerular function. MYH9, on the other hand, is known 
to be expressed in glomerular cells including podocytes and does have a potential 
functional role in the glomerulus.  Therefore, I seek to test the hypothesis that glomerular 
damage with an FSGS pattern of injury is associated directly with altered expression 
(loss) of NMIIA in podocytes, which in turn, makes the glomerulus more vulnerable to 
hypertensive injury.  In order to model the loss of NMIIA function I am using Myh9 
siRNA “knock down” in cultured podocytes, and podocyte-conditional Myh9 knock out 
animals. 
Information obtained from these studies will help to clarify mechanisms of the 
pathogenesis of FSGS, identify biomarkers associated with kidney disease, and possibly 
find new treatment approaches for diseases that cause FSGS. In addition I expect to 
clarify the role of podocyte contractility and NMIIA in normal glomerular function and in 
the pathogenesis of glomerulosclerosis. Finally, these studies may reveal new genes with 
important functional roles in the podocyte and glomerulus. 
My goal is to determine if APOL1 or MYH9 have a role in AA kidney disease, by 
examining plausible mechanisms for each gene. Given the lack of a clear functional role 
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for APOL1 in glomerular function, it appears most likely that the effects of high risk 
APOL1 genetic variants are indirect, and manifest through altered expression of other 
functionally important genes. Therefore, I hypothesize that patients harboring the highest 
risk APOL1 genetic variant have altered gene expression in their kidney glomeruli 
milieu, existing before kidney damage develops and potentially associated with structural 
changes in cells and tissue. These gene expression changes are hypothesized to favor 
susceptibility to glomerular damage, particularly under conditions of glomerular 
hypertension. In contrast, MYH9 encodes NMIIA, a motor protein for which a potential 
functional role exists. Therefore, I hypothesize that changes in MYH9 expression in the 
podocyte directly alter the biomechanical behavior of the podocyte and glomerulus, 
thereby increasing susceptibility to glomerular damage, especially during hypertension-
driven nephropathy. Because each gene is hypothesized to have its affect through 
different mechanisms, the approaches taken to studying each of these genes are tailored 
toward examining the mechanisms in question. 
1.5 Aims 
1.5.1 Determine Glomerular Gene Expression Changes and Kidney Morphological 
Changes associated with APOL1 kidney risk variants 
Aim 1) This specific aim is to test the hypothesis that African American individuals 
carrying 2 APOL1 kidney risk variants in the APOL1 gene on chromomsome 22 (G1 and 
G2 haplotypes) exhibit distinct gene expression in their glomerular milieu and have 
altered kidney structure, existing before glomerular injury and chronic kidney disease 
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develops, which could set the stage for kidney disease development. To test this 
hypothesis; 
A) We will assemble a set of human nephrectomy samples (healthy kidney) and 
perform detailed analysis of kidney morphology in the nephrectomy samples and 
compare the results of these assessments based on the genotype of the sample.  
B) The site of initiation of injury within the kidney for FSGS has been suggested to 
be the glomeruli specifically the podocytes. I will therefore utilize a laser capture 
method to isolate glomeruli from these samples, extract RNA from the isolated 
glomeruli, and perform whole genome microarray analysis of gene expression in 
these samples.  
C) Finally, I will identify specific genes which exhibit consistent differences in 
glomerular gene expression in these samples comparing the disease risk haplotype 
population with the population without the risk haplotype, and that are the 
strongest candidates for being involved in development of kidney disease in AA 
individuals on the basis of ingenuity pathway analysis and what is known in 
literature.  
These studies will set the stage for future studies to investigate possible mechanistic roles 
of the identified genes and pathways mediating disease processes in the high risk kidney 
disease group. 
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1.5.2 Determine the effect of loss of Myh9, on podocyte behavior and kidney function in 
vitro and in vivo respectively 
Aim 2) The aim of these studies is to test the hypothesis that NMIIA plays an 
essential role in podocyte function and structure in vitro and in vivo, and altered podocyte 
NMIIA expression is associated with FSGS-like glomerular injury. To determine the 
effect of loss of MYH9 on podocyte behavior and kidney structure and function in vitro 
and in vivo respectively, 
A) I will first look at NMIIA expression in human kidney tissue to determine if 
NMIIA protein expression levels are altered under disease conditions.  Altered 
NMIIA levels in kidney disease would lend evidence for a role for NMIIA in 
kidney function and dysfunction. 
B) I will further assess the effect of loss of Myh9 on mouse podocyte cell 
morphology, traction, permeability and motility by knocking down Myh9 in 
podocytes. Podocytes express Myh9 and NMIIA, which contributes to cell 
structure and motility, and podocyte injury is considered a hallmark of 
glomerulopathies.  These studies will pin down the potential functional role of 
NMIIA in glomeruli and podocytes, and provide new insight into potential 
mechanisms of NMIIA-associated kidney disease.  
C) I will finally investigate the role of Myh9 loss in podocyte function in vivo in the 
presence of glomerular capillary hypertension using a deoxycorticosterone acetate 
(DOCA)-salt uninephrectomy mouse model.   These studies will investigate the 
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specific role of NMIIA in maintenance of glomerular structure under normal 
conditions and conditions of hemodynamic stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
51 
CHAPTER TWO 
Method 
2.1 Human Clinical Samples 
Fifty five formalin-fixed paraffin embedded nephrectomy specimens (normal 
kidney present in tumor or traumatic nephrectomies) were obtained from archived 
pathology material (year 2008-2012), available in the Boston University Medical Center 
(BUMC) Department of Pathology. The nephrectomies were obtained either from kidney 
cancer patients or patients with some form of injury to the kidney due to for example gun 
shots. These specimens were retrieved prospectively in a de-identified fashion with 
minimal demographic data retained; as such, this project has been deemed exempt from 
IRB approval by the BUMC Institutional Review Board. Donor race, gender and age 
were obtained where possible. Kidney tissues as reviewed by the renal pathologist, 
showing very obvious morphological changes (compression artifact of normal tissue due 
to the presence of tumor nearby) observed under the light microscope after periodic acid-
schiff (PAS) staining were not included in the study.  
2.2 Genetic Analyses 
DNA was extracted from five 5um sections cut from paraffin blocks by a simple 
proteinase K digestion and boiling method. DNA yield and purity was measured using 
the NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Thermoscientific, 
Wilmington, DE). Extracted DNA was stored at -20 degrees until subsequent analysis. 
DNA was amplified using the forward primer 5’- ACA AGC CCA AGC CCA CGA CC-
3’ and the reverse primer 5’-CCT GGC CCC TGC CAG GCA TA-3’  and sequenced 
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using capillary electrophoresis on the Genetic Analyzer 3130XL, to determine the 
APOL1 genotype and risk haplotype (Tzur et al., 2010). The sequencing results were 
analyzed using the ABI DNA Sequencing Analysis Software version 6. The accuracy of 
genotyping was validated by bidirectional sequencing. Some samples were replicated at 
different times and no DNA controls were included in the amplifications and sequencing 
reactions.  The characteristics of the set of specimens studied are summarized in Table 
3.1. Patients harboring no APOL1 risk variant or just one risk variant were classified into 
the control group (G0G0, G0G1, G0G2, whereas those carrying 2 risk variants either as 
homozygous (G1G1) or heterozygous (G1G2) were classified as the risk group. No 
G2G2 haplotypes were identified in our study sample. The APOL1 G1 allele is made up 
of single nucleotide polymorphisms (SNPs), rs73885319 and rs60910145, whereas the 
G2 allele is a 6bp deletion, rs71785313. 
2.3 Histopathological Review of Nephrectomy Materials 
Periodic acid-schiff stained and hematoxylin and eosin stained slides were 
available for the 55 genotyped samples and were reviewed by a renal pathologist masked 
to the genotype. Detailed assessment of glomerular, tubular, interstitial and vascular 
pathology was made. Glomerular features studied included, glomerular number, globally 
or segmentally sclerosed glomeruli, mesangial expansion, hypertrophied glomeruli. Other 
observations made included tubular atrophy and vascular pathology. The assessment was 
made as far from tumors as possible avoiding changes in our readout which may be as a 
result of tumor growth. Morphological observations were recorded as either percentages 
or severity scores (1: normal, 2: mild, 3: moderate, 4: severe).  
  
53 
2.4 Laser Capture, RNA Sample Preparation and Microarray Hybridization 
For each FFPE sample, five to ten sections (7 μm in thick) were used for laser 
capture of consecutive levels of the same glomerulus to reduce sampling effect within a 
glomerulus. Laser capture was performed using the PixCell
®
 IIe Laser Capture 
Microdisection System (Arcturus Bioscience; Mountain View, CA) with Olympus IX 50 
Microscope (Olympus America; Melville, NY) after deparaffinization, with an average of 
50 glomerular per cross sections obtained. Only well-preserved glomeruli were isolated 
from morphologically normal and undamaged tissue. Total RNA was isolated using the 
RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Austin, TX) yielding an average 
of 25ng/ul of RNA. RNA quality was analyzed using the RNA 6000 Pico Assay RNA 
chips run in Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). From this 
point, sample preparation and microarray procedures were carried out in the Boston 
University Microarray Resource Facility as described in GeneChip® Whole Transcript 
(WT) Sense Target Labeling Assay Manual (Affymetrix, Santa Clara, CA, current 
version available at www.affymetrix.com), and the  Nugen Ovation FFPE WTA System 
User Guide and Nugen Encore Biotin Module User Guide (Nugen, San Carlos, 
California, current versions available at http://www.nugeninc.com/nugen/). The Nugen 
Ovation FFPE WTA System kit has been generated for amplification of small degraded 
RNA especially found in formalin fixed paraffin embedded tissues for gene expression 
studies. The extracted RNA sample (50ng) was first reverse transcribed using a unique 
first strand DNA/RNA chimeric primer mix and reverse transcriptase (RT) (Ovation 
FFPE WTA System (NuGEN Technologies, Inc, San Carlos, CA). The resulting 
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cDNA/mRNA hybrid molecule contains a unique RNA sequence at the 5´end. The cDNA 
strand is fragmented creating priming sites for DNA polymerase to synthesize a second 
strand and amplified. The amplified double-stranded cDNA with DNA/RNA 
heteroduplex contains the Single Primer Isothermal Amplification (SPIA) tag. It was 
purified using Agencourt RNA clean XP Purification Beads and used as a template for 
SPIA amplification. The SPIA-amplified cDNA was further purified using Agencourt 
RNA clean XP Purification Beads, fragmented (5 ug) and labeled with biotin using 
Encore Biotin Module (Nugen, San Carlos, California). SPIA-amplified cDNA and 
fragmented cDNA quality controls were carried out by running an mRNA Pico assay in 
the Agilent 2100 Bioanalyzer.  The labeled fragmented DNA (final concentration in 
hybridization cocktail 23 ng/ul) was hybridized unto the Affymetrix Human Gene 1.0 ST 
array platform (Affymetrix, Santa Clara, CA) for 18 hours in GeneChip Hybridization 
oven 640 at 45
o
C with rotation (60 rpm).  The hybridized samples were washed and 
stained using Affymetrix fluidics station 450. The first stain with streptavidin-R-
phycoerythrin (SAPE) was followed by signal amplification using a biotinylated goat 
anti-streptavidin antibody and another SAPE staining (Hybridization, Washing and 
Staining Kit, Affymetrix, Santa Clara, CA). Microarrays were immediately scanned using 
Affymetrix GeneArray Scanner 3000 7G Plus (Affymetrix, Santa Clara, CA).  
2.5 Data Analysis 
Raw Affymetrix CEL files were normalized to produce gene-level expression 
values using the implementation of the Robust Multiarray Average (RMA) (Irizarry et al., 
2003) in the affy package (Gautier et al., 2004) included within in the Bioconductor 
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software suite (version 2.10.0) (Gentleman et al., 2004) and an Entrez Gene-specific 
probeset mapping from Brainarray (version 14.0.0) (Dai et al, 2003; 
http://brainarray.mbni.med.umich.edu/Brainarray/Database /CustomCDF). Differential 
gene expression was assessed using the implementation of Student’s two-sample t test 
with equal variance in the multtest package (Katherine et al., version 2.6.0)  Correction 
for multiple hypothesis testing was accomplished using the Benjamini-Hochberg false 
discovery rate (FDR) (Benjamini and Hochberg., 1995). The FDR value refers to the 
expected proportion of the null hypothesis that is falsely rejected relative to the total 
number of rejections. Linear modeling was performed using the limma package (Smyth, 
2005) and analyses of variance were performed using the sva package (Leek et al., 2012).  
Because the microarrays were processed in two separate batches, the strength of the batch 
effect was assessed using an analysis of variance (ANOVA) in a linear model of 
expression as a function of batch after correcting for APOL1 haplotype (as a four-level 
categorical variable: wildtype, G1 only, G2 only, G1+G2).  ComBat (Johnson et al., 
2007) was then used to adjust for the batch effect, taking the G1/G2 haplotype into 
account.  All of the above microarray analyses were performed using the R environment 
for statistical computing (version 2.12.0) (R Development Core, 2011; http://www.R-
project.org). We generated a hierarchial dendogram using median-centered average 
linkage unsupervised clustering of log2 transformed data with a p value ≤0.05. Supervised 
clustering comparing APOL1 disease risk variants (G1G2) with APOL1 control variants 
(G0G0, G0G1, and G0G2) was performed with a p value ≤0.05. Expression data were 
filtered eliminating genes with log intensity values less than the first quartile of the 
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maximum log intensity value.  The resulting gene lists (16379) were uploaded into 
ingenuity pathway analysis (IPA) software (Ingenuity Systems, Redwood City, CA) for 
literature mining. A probability value ≤0.05 with a fold change of 1.2 was chosen to 
indicate a statistically significant over-representation of molecules to be included in the 
analysis. 
2.6 Cell Culture 
Conditionally immortalized murine podocytes (glomerular epithelial cells) were 
cultured in a 5% CO2 environment with RPMI 1640 medium (Mediatech, Manassas, VA) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, HyClone, Thermo 
Scientific, Rockford, IL), and 1% Antibiotic-Antimycotic (Life Technologies, Grand 
Island, NY). The cells were plated on type I collagen coated culture dishes. The cells 
express the temperature sensitive SV40T-antigen, a proto-oncogene whose expression is 
driven by the presence of interferon gamma resulting in cell proliferation. The cells were 
propagated under permissive conditions at 33 °C in the presence of interferon-γ (IFN-γ, 
100 U/ml, Sigma-Aldrich, St. Louis, MO) to promote cell propagation. The cells are 
switched to 37 °C (non-permissive temperature), where the SV40T-antigen is degraded, 
thereby inducing cell cycle arrest and differentiation. At 37
0
C, IFN-γ-free culture 
medium is used. Absence of IFN-γ-free results in the loss of induction of the T antigen, 
(Jat et al., 1991; Mundel et al, 1997; Shankland et al., 2007).  For some studies, 
blebbistatin (Sigma-Aldrich, St. Louis, MO) dissolved in chloroform/methanol/acetic 
acid (95:5:5) as vehicle at 100uM or lysophosphatidic acid (LPA; Sigma-Aldrich, St. 
Louis, MO) dissolved in (chloroform/methanol/acetic acid (95:5:5) as vehicle at 1uM 
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were added directly to media to interfere with activity of all non-muscle myosin II 
isoforms, or to stimulate non-muscle myosin II activity, respectively. 
 
2.7 Lentiviral RNA Interference System 
Lentiviral vectors conferring expression of short-interfering RNA (siRNA) 
designed to interfere with Myh9 and Myh10 gene expression, as well as vectors 
conferring expression of non-targeting control siRNA with identical GC content, were 
generated following a previously described protocol (Battini et al., 2006; Battini et al., 
2008; Zufferey et al., 1997; Fedorova et al., 2006). Briefly, the plasmid, VIRHD/E which 
includes a green fluorescent protein (GFP) expression cassette, was cloned with custom 
designed siRNA-encoding oligonucleotide constructs (Appendix A).  The 
oligonucleotides of the siRNA were annealed and ligated between the BamHI and EcorI 
sites of the VIRHD/E lentiviral vector. Lentiviral supernatants were produced by 
transient transfection of 293T cells using Fugene6 reagent (Roche Diagnostics, 
Indianapolis, IN) with the individual siRNA-encoding plasmids, simultaneously with the 
plasmids pCMVdelR8.91 and pVSV-Env, which encode for lentiviral packaging proteins. 
After 24 hours, transfection media was replaced with cDMEM (DMEM, 10%FBS, 1% 
Antibiotic-Antimycotic). After 48hours, cDMEM media was harvested from transfected 
293T cells, filtered, aliquoted and stored at -80 degrees for subsequent podocyte 
transfections. Podocytes cultured under non-permissive conditions for 24hours were 
transduced with lentivirus supernatants specific for the different siRNAs in cell culture 
medium supplemented with polybrene (5 µg/ml, American Bioanalytical, Natick, MA). 
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Transduction was confirmed by observation of green fluorescent protein epifluorescence 
48 hours after transduction.  Eleven days after lentiviral tranduction, cell lysates were 
analyzed by western blot and real time PCR to assess knockdown efficiency. 
2.8 Standard and Real-Time (Quantitative) Polymerase Chain Reaction 
Total RNA was extracted from cultured podocytes using TRIzol reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.  From each sample, 
cDNA was generated from 1 μg total RNA using Transcriptor First Strand cDNA 
Synthesis kit (Roche Diagnostics, Indianapolis, IN).  Real time PCR was carried out 
using gene-specific primer sets amplifying exon-spanning sequences of each gene 
examined. Myh9, Myh10, and GAPDH were measured in each sample; the GAPDH gene 
was used as an internal reference gene. Reactions were performed in 25 μl reaction 
volumes containing 1 μl of cDNA, 0.25 μM each of forward and reverse primer, and 12.5 
μl of SYBR Green PCR Master Mix (Applied Biosystems, Bedford, MA). PCR reaction 
conditions included a 10 min pre-denaturing step at 95℃, followed by 40 cycles of 30 
seconds at 95℃, 30 seconds at 55℃, and 1 min at 72℃.  Ct values for each reaction were 
calculated from the amplification and melting curves, and the mRNA amount of Myh9 
and Myh10 in each sample relative to GAPDH was determined using the equation 2
-∆∆Ct
. 
 
2.9 Protein Electrophoresis and Immunoblotting  
Cultured podocytes or isolated glomeruli were lysed in radioimmunoprecipitation 
assay (RIPA) buffer (Cell Signaling Technology, Danvers, MA) containing protease and 
phosphatase inhibitors (Thermo Scientific, Rockford, IL), and centrifuged at 10,000g at 
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4°C for 10 min. Protein samples were loaded at equal concentration and separated on 
7.5% polyacrylamide gels, and transferred to PVDF membranes.  Membranes were 
blocked for 1 hour in a Tris-buffered saline/0.1%TWEEN-20 (TBST) solution containing 
5% nonfat dry milk, and incubated with primary antibodies against non-muscle myosin 
heavy chain IIA (NMHC IIA), non-muscle myosin heavy chain IIB (NMHC IIB), or 
mouse anti-tubulin (all at 1:5,000, Sigma-Aldrich, St. Louis, MO) overnight at 4
o
C. After 
primary incubation, the membranes were rinsed three times in TBST for 5 mins each, 
incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (Thermo 
Scientific, Rockford, IL) at room temperature for 1 hour, and rinsed in TBST three times 
for 5 minutes each.  Immunostained membranes were treated with chemiluminescence 
substrate (Thermo Scientific, Rockford, IL) and exposed to radiographic film for 
appropriate duration to obtain a signal in the linear range of the film.  Radiographs were 
digitized and relative protein levels were quantified by densitometric image analysis of 
radiographic bands using Image J version 1.45 software (available for free download 
from http://rsb.info.nih.gov/ij/).  
 
2.10 Immunocytochemistry 
For immunocytochemistry, after 7 days of podocyte differentiation, podocytes 
were cultured on collagen I-coated glass coverslips for 4 days under non-permissive 
conditions with gradual serum concentration transitions. At the end of this period, cells 
were fixed with 4% paraformaldehyde and permeablilized with 0.3% Triton X-100 in 
PBS. After washing with PBS, the cells were immunostained to reveal NMHC isoforms 
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and vinculin. Podocytes were incubated overnight at 4°C with primary antibodies against 
NMHC IIA and IIB (Sigma-Aldrich, St. Louis, MO) or vinculin (Invitrogen, Carlsbad, 
CA), followed by PBS washes and incubation with Cy3 conjugated IgG secondary 
antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) at a dilution of 
1:1,000 for 1 h at room temperature.  Cells were also stained with fluorescein phalloidin 
(Life Technologies, Grand Island, NY) to visualize filamentous actin and 4',6-diamidino-
2-phenylindole (DAPI) (Invitrogen, Carlsbad, CA) to visualize nuclei.  Coverslips were 
mounted to glass slides with fluorescence mounting medium (Dako, Carpinteria, CA) and 
digital photomicrographs of representative cells were collected under an epifluorescence 
microscope (Olympus BX60, Center Valley, PA) using identical exposure settings for all 
samples examined.  
2.11 Actin stress fiber and focal adhesion quantification 
Focal adhesion densities were quantified using NIH ImageJ software. Images of 
cells stained for vinculin, a marker of focal adhesions, were obtained at 20× 
magnification at similar exposure settings using an epifluorescence microscope (Olympus 
BX60, Olympus Corporation of the Americas, Center Valley, PA) and the Retiga 2000R 
camera (Q Imaging, Surrey, BC Canada). The TIFF images obtained were converted to 8-
bit grayscale. Membrane extension of cells of interest was individually outlined utilizing 
the freehand selection tool of the NIH ImageJ software. Measurements of cell area (AC), 
integrated density (DC) and mean gray value of vinculin staining were obtained. To 
obtain a background density, 3 images of random regions surrounding the cell were also 
obtained and analyzed for their mean gray value to obtain the final average of the three 
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mean gray values (BF). To obtain the vinculin density in each cell, the following formula 
was used. Corrected total cell fluorescence (CTCF) = DC - (AC)(BF). The individual 
CTCF for each cell was averaged for at least 20 cells per group to obtain the vinculin 
average intensity for each group. The average intensity of all treated cells, that is control 
lentivirus and Myh9/Myh10 lentiviral treated cells were normalized to the average of 
untreated WT cells. The normalized intensities were plotted for each group. All 
parameters were the same during image acquisition. 
Stress fiber quantification was also processed similarly to focal adhesion 
quantification using NIH Image J software. Stress fibers were identified by staining with 
fluorescein phalloidin. Images were obtained at 20× magnification using the Olympus 
BX60 (Olympus Corporation of the Americas, Center Valley, PA) and the Retiga 2000R 
camera (Q Imaging, Surrey, BC Canada). A region was drawn around each cell to be 
measured after TIFF images were converted to 8-bit grayscale. Similar sized regions 
were drawn in an area without fluorescence to be used for background correction. The 
stress fiber density was measured as described for focal adhesion density above. The 
intensities obtained were plotted for each group. 
 
2.12 Traction Force Microscopy (TFM)   
TFM utilizes polyacrylamide gels cast as thin, flat sheets, which serve as 
translucent, elastic cell culture substrates with known mechanical properties (Wang and 
Pelham, 1998; Butler et al., 2002). The substrates are embedded with microscopic latex 
fluorescent spheres that serve as “fiduciary markers”, and provide a means to observe the 
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movement of the elastic substrate under the influence of cell-generated traction forces.  
For these studies, polyacrylamide elastic substrates with Young’s modulus of 
approximately 15,600 N/m2 were used for these experiments. Preliminary studies 
revealed that substrate stiffness in this range favors the adherence and spreading of 
murine podocytes, while also allowing for sufficient resolution of substrate deflection 
using our microscope system (data not shown).  In brief, thin polyacrylamide gels (7.5% 
acrylamide and 0.2% bis-acrylamide) containing 0.5 m diameter red fluorescent latex 
spheres (FluoSpheres, Invitrogen, Carlsbad, CA) at 0.001% concentration were 
polymerized between a glutaraldehyde-treated 22 mm square coverslip and an untreated 
12 mm round coverslip after addition of tetramethylethylenediamine (TEMED). The 
round coverslips were gently removed after 30 min polymerization, and the substrate 
surface was chemically activated by immersing the substrate in pure hydrazine hydrate 
(Sigma-Aldrich, St. Louis, MO) overnight.  Activated substrate assemblies were washed 
with 5% acetic acid and water for 1 hour each, immersed in poly-D-lysine (BD 
Biosciences, San Jose, CA), and washed extensively with PBS.  Poly-D-lysine coated 
substrates were plated with cells, and incubated at 37°C in 5% CO2 for 4 days (Figure 
5.2), to allow for cell attachment and spreading, and to accommodate a gradual transition 
to serum-free media. Immediately prior to imaging, the cell-seeded substrate assemblies 
were mounted individually in 6 cm cell culture plates under standard media, and treated 
with lysophoshatidic acid (LPA) (Sigma-Aldrich, St. Louis, MO) or vehicle.   
For these studies, TFM was performed using an automated upright 
epifluorescence microscope (Nikon Labophot 2, Melville, New York) equipped with 
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immersion objectives and an environmental chamber.  The microscope was interfaced 
with a Diagnostic Instruments SPOT RT Monochrome digital camera (Diagnostic 
Instruments, Sterling Heights, Michigan, USA) and Dell Optiplex GX280 computer 
running SimplePCI software (Hamamatsu Corporation, Sewickley, PA), which was used 
to collect the required digital images.  The substrate surface was initially scanned at low 
power using brightfield illumination to identify and record x,y coordinate locations of 
fields containing candidate cells.  Cells that appeared well-spread and isolated from 
contact with other cells were considered acceptable for imaging; typically 10 to 25 cells 
would be identified on a single substrate assembly.  The initial imaging sequence was 
performed at a specified time interval after treatment with LPA or vehicle, and consisted 
of collection, at each field location, of z-stacks of both brightfield (Hoffman modulation 
contrast) images of the cell bodies, and epifluorescence images of the fluorescent spheres 
near the substrate surface.  The cells were then lysed by addition of 1% SDS to the 
media, cell lysis was confirmed by examining each field location in brightfield, and 
another z-stack of epifluorescence images was collected to record the baseline position of 
the fluorescent spheres. The image stacks were pre-processed using ImageJ (National 
Institutes of Health, Bethesda, MD) and Adobe Photoshop, to obtain well-aligned, high 
contrast images showing fluorescent spheres near the substrate surface before and after 
cell lysis.  Cell areas were also measured from brightfield images using ImageJ.  Fourier 
Transform Traction Cytometry (FTTC) was performed to extract substrate displacement 
and traction fields, and root mean square (RMS) traction generated by each cell, using 
software kindly provided by Dr. Donald Ingber (Butler et al., 2002).  
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2.13 Wound Healing Assay   
For wound healing assay, podocytes were cultured on collagen I-coated six well 
plates on Day 7 after transduction. Cells were plated to ensure a confluent layer for 4 
days under non-permissive conditions with gradual serum concentration transitions. 
Wounds were created in confluent cells by using a 200-μl sterile pipette tip with two 
strokes at a 90° angle. Floating cells were removed by 3 vigorous washes with PBS. 
Fresh medium containing 10% fetal bovine serum was added. Marks were made under 
the plate to help align photographic images that were taken at different time points. 
Images were taken under phase-contrast inverted microscope (OLYMPUS, Center 
Valley, PA) at time 0 (T=initial) and 24 (T=final) hrs after wounds were generated. The 
area of the wound for each image was measured and processed using Image J. The 
relative change in area from T=initial was obtained using the equation [Ai-Af]/Ai=∆A, 
where Ai=area at T=initial and At=area at T=final and ΔA is the relative change in area. 
Statistically significant differences between the groups were found using Student's t-test 
(Chen, Wassenhove-McCarthy et al., 2010). 
2.14 Cell Attachment Assay 
To assess podocyte adhesive properties twenty four-well plates were coated with 
collagen I for 1hour at room temperature. The 24 well plates were washed twice with 
PBS and blocked with 1% bovine serum albumin in PBS. Differentiated podocytes (7 
days post-transduction) were harvested with trypsin/EDTA and resuspended in RPMI 
1640 medium (Mediatech, Manassas, VA) medium. The harvested cells were counted 
and 500 cells seeded into the 24 well plate. The cells were allowed to attach at 37°C for 2 
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h. Unbound cells were removed by washing the wells twice with PBS. Attached cells 
were fixed in 4% paraformaldehyde for 20mins and stained with 0.1% crystal violet for 
20mins at room temperature. The wells were washed extensively with water and the cells 
were counted blindly. Cell counts were obtained by averaging the cell numbers from at 
least three wells. 
2.15 Animal Breeding 
Mice with podocyte-specific disruption of Myh9 gene was generated as 
previously described by Johnstone et al., 2011, using Myh9 flox mice and Pod::Cre mice 
(gifts from Weining Lu, Boston University School of Medicine). All mice were on a 
C57BL/6 background. Myh9-floxed and Cre positive double heterozygous 
(Cre/wt;Myh9flox/wt) mice were generated by crossing Myh9-floxed homozygous mice 
with NPHS2-CRE mice. Podocyte specific knockout mice (Cre
+
/wt;Myh9flox/flox) was 
then generated by  crossing a double heterozygous mice with a Cre
-
;Myh9flox/wt mice to 
ensure that our knockout and control mice contained only one copy of the NPHS2-CRE 
transgene. The following mice generated from the cross served as control; 
Cre+;Myh9wt/wt, Cre-;Myh9wt/wt, and  Cre-;Myh9flox/flox. Genomic DNA from tails 
was prepared in DirectPCR lysis reagent (mouse tail) (Viagen Biotech Inc. Los Angeles, 
CA) plus proteinase K (0.3mg/ml, Sigma-Aldrich, St. Louis, MO). After DNA extraction, 
genotyping was performed using the following Myh9 PCR primers; forward primer 5’- 
AAG ACA TGT CAT TAG TGT CCT GAG AGC AGT G -3’ and reverse primer 5’- 
TAT GGC AGA TTC AGG CAT GGA GTT TGT GAT G -3’. PCR was performed 
using the HotStarTaq Plus Master Mix Kit (Qiagen). To genotype for Cre, we used the 
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following PCR primers; forward primer 5’- TTA GTC TCT CTG CCA CCT AC -3’ and 
reverse primer 5’- CTG AGC ACT TGT TCT CAG TC -3’.Product sizes from PCR 
reactions were observed on a 1.5% agarose gel stained with ethidium bromide. 
Hypertension was induced in 10-12 week old genotyped mice. Mice were first 
anesthetized by isoflurane inhalation and anesthesia confirmed via the toe-pinch reflex, 
after which right uninephrectomy was performed followed by implantation of a 60-day 
release DOCA salt pellet (Innovative research of America). After recovery from 
anesthesia, animals were housed singly in cages and fed on standard chow and given 1% 
saline as source of drinking water. Sham control animals were generated by just 
performing a right uninephrectomy and maintained on standard chow and tap water. Pre-
operatively animals received (1) Buprenorphine: 0.1 to 0.5 mg/kg SC x 1 immediately 
pre-operatively; and (2) Carprofen: 5mg/kg PO daily for the duration of the recovery 
period, typically 7 days.  
Systolic blood pressure (SBP) was measured indirectly using the tailcuff 
technique (BP-2000, Visitech Systems) each week post treatment. For each measurement 
time point, a minimum of six recordings was performed 3 days successive days each 
week, and all valid recordings over the three days were averaged to present the SBP per 
week for each animal. Prior to surgical procedures, mice were acclimated to the device 
for at least a week. 
Urines were obtained from each mouse weekly post-operatively in customized 
containers after 3 to 4 hours ensuring there is no contamination with feces. Urinary 
albumin/creatinine ratios and nephrin levels were obtained by an enzyme-linked 
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immunosorbent assay (ELISA) plate reader () using a mouse Albuwell kit (Exocell), 
creatinine companion (Exocell), and a nephrin kit (Exocell) respectively. 
All mice experiments were conducted according to the IACUC guidelines at the 
Boston University School of Medicine. 
2.16 Histopathology and Immunohistochemistry 
Kidneys were perfused with phosphate-buffered saline (PBS) and harvested post 
treatment, and sections from the middle portion of the mice kidneys were cut and fixed in 
10% buffered neutral formalin (NBF). The cut sections were 2-3 mm in thickness and left 
to be fixed overnight for proper penetration. After tissue was fixed, tissues were 
submitted to the Boston University Medical Centre Pathology Core for dehydration using 
a series of increasing concentrations of alcohol followed by cleaning using xylene. The 
tissue was embedded in paraffin after which tissue sections (5um in thickness) were 
obtained on slides for histological and immunohistochemistry analysis. 
Sections were stained with Periodic-acid Schiff (PAS) stain for histopathological 
assessment. All glomeruli were evaluated for pathological differences and plotted as 
percentage of number showing pathological changes to total number of glomeruli 
assessed per sample by two examiners who were blinded to the experimental conditions. 
Tubular pathological observations were also made and recorded as percentage of area 
tubular injury to entire tubular area. Masson trichrome staining was also performed using 
a trichrome staining kit (Masson’s 2000 Trichrome Stain KitTM, American Mastertech 
Scientific Inc) 
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2.17 Electron Microscopy 
Small pieces of harvested kidney cortex were fixed in 3% glutaraldehyde-based 
fixative (Karnovsky’s) overnight at 4 °C in a scintillation vial and post fixed in 1% 
osmium tetroxide with cacodylate buffer (applied under a chemical hood). Osmium 
tetroxide is a lipid stain that embeds a heavy metal into cell membranes, providing 
contrast to the images. The tissues were then dehydrated using a graded series of acetone 
(50%, 90%, and 100%) after which they were embedded in an epoxy resin/acetone 
mixture (1:1) on a rotator for 45-90 minutes. Finally, the tissues were embedded in 100% 
epoxy resin mixture. Ultrathin sections were obtained using a microtome (Leica UC7 
microtome) unto grids and counterstained with 4% aqueous uranyl acetate and 0.4% 
aqueous lead citrate. The grids were examined using a transmission electron microscope 
(Jeol JEM-1011, Japan), and detailed images of the glomeruli were taken with a digital 
camera system (Gatan Erlangshen ES1000W). The examination focused on capillary 
loops, especially podocytes and surrounding structures. 
For immunohistochemistry studies, the following primary antibodies were used; 
rabbit anti-Myh9 (1:1000 gift from Holzmann), guinea pig anti-nephrin (1:400, Fitzgerald 
Industries International, Acton, MA), rabbit anti-podocin (1:400, Sigma-Aldrich, St. 
Louis, MO), rabbit anti-alpha actinin 4 (1:400, Sigma-Aldrich, St. Louis, MO), and rabbit 
anti-ILK (1:100, Cell Signaling Technology, Boston, MA). All stainings were done 
manually with DAB chromogen stainings performed following the EXPOSE Mouse and 
Rabbit Speicific HRP/DAB detection IHC kit (ab80436, Abcam, Cambridge, MA) with 
slight modifications. Secondary antibodies used for immunofluorescence staining 
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included alexa fluor 594-conjugated donkey anti-rabbbit IgG (H+L) preadsorbed and 
alexa fluor 594-conjugated goat anti-guinea pig IgG (H+L) preadsorbed (Life 
Technologies, Beverly, MA). Briefly,5 micron kidney sections were deparaffinized using 
xylene (5 mins twice), 100% ethanol (3mins twice), 95% ethanol (1min), and 75% 
ethanol (1 min), and transferred into tap water for 5mins. Antigen retrieval was 
performed for 95
o
C (20mins) in 0.05M TBS, 0.05% Tween 20, ph9.0. After antigen 
retrieval, sections were encircled with a Pap pen, blocked with the protein block from the 
kit, incubated with the primary antibody of interest, washed 3 times, incubated with 
secondary antibody, washed 3 times, and mounted with (Life Technologies, Beverly, 
MA). In the case of detection with DAB chromogen, after primary antibody incubation 
and washing 3 times, sections were treated with 1% hydrogen peroxide to quench 
endogenous peroxidases, washed twice, incubated with secondary HRP conjugate for 30 
mins, washed 4 times, developed with DAB chromogen at various times depending on 
the primary antibody and counterstained with hemotoxylin. Negative controls for 
stainings were performed by omitting primary antibodies. Images were obtained with an 
Olympus BX60 microscope (Olympus USA) using a Q imaging Retiga 200R camera 
using fixed settings and exposure time for each immunofluorescence images. For each 
sample section, all glomerular per section were assessed for primary antibody staining 
due to the focal nature of the disease in a blinded fashion. Stainings were graded semi 
quantitatively on a scale of 0 to 4 (0=non antibody staining; 1=25% or less staining; 
2=>25%-50%; 3=>50%-75% 4=>75%). Number of glomeruli for each score was 
presented as a percentage of the total number of glomeruli per sample section/s. 
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2.18 Isolation of Glomerular and Podocyte Cultures 
Mice kidneys were prepared by perfusion with phosphate buffered saline (PBS) 
after mice were euthanized with isofluorane. Mouse kidneys were then harvested through 
a ventral incision and placed in 25 ml of sterile ice-cold PBS in a conical tube. Kidneys 
were then decapsulated and renal cortex separated, minced and digested by collagenase I 
(1mg/ml) in PBS for 30mins at 37
o
C. Tissues were then passed through a 100um cell 
strainer and a 70um cell strainer (BD falcon) in PBS. The tissue remaining on the 70-μm 
cell strainer was washed with 25 ml PBS and collected and a sample examined on a glass 
slide under the light microscope to confirm the presence of glomeruli. Isolated glomeruli 
for protein extraction were collected in radioimmunoprecipitation assay buffer (RIPA) 
(Cell Signaling Technology, Danvers, MA) containing protease and phosphatase 
inhibitors (Thermo Scientific, Rockford, IL). For podocyte primary cell culture, freshly 
isolated glomeruli were plated in a six well plate in RPMI 1640 in the presence of 10% 
FBS and 1%APS (Life Technologies) and incubated at 37
o
C. After three days, podocytes 
were observed to grow on the dish. Subculture of podocytes was performed by detaching 
with trypsin-EDTA and passing through 40um cell strainer (BD Biosciences) and plated 
on collagen I coated six well plates for wound healing assay. 
2.19 Primary cells wound healing migration assay 
For primary podocyte wound healing migration assay, confluent layer of primary 
podocytes were scraped with a 200-μl sterile pipette tip at a 900 angle. Floating cells were 
removed by 3 vigorous washes with PBS. Fresh medium containing 10% fetal bovine 
serum was added. Marks were made under the plate to help align photographic images 
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that were taken at different time points. Images were taken under phase-contrast inverted 
microscope (OLYMPUS, Center Valley, PA) at time 0 (T0=initial), 6 and 12 (Tf=T6 and 
T12) hrs after wounds were generated. The area of the wound for each image was 
measured and processed using Image J. The relative change in area from T=initial was 
obtained using the equation [Ai-Af]/Ai=∆A, where Ai=area at T0 and At=area at Tf and 
ΔA is the relative change in area. Statistically significant differences between the groups 
were found using Student's t-test (Chen et al., 2010). 
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CHAPTER THREE 
 Glomerular Gene Expression Profiling and Kidney Morphology in Carriers 
of APOL1 Kidney Risk Alleles 
3.1 Introduction 
In the United States, people of African ancestry (AA) are 3.5 times more at risk of 
developing end stage kidney disease (ESKD) (incidence rate of 1010 per million)  
compared to European Americans (279 per million population) (National Chronic Kidney 
Disease Fact Sheet, 2014), and the rate since 2000 has increased by 7% (USRDS 2010).  
This has been attributed to genetics rather than socioeconomic status or access to 
healthcare within the African American Population. 
Several population-based studies have identified linkage between certain genetic 
haplotypes occurring on chromosome 22 and the high prevalence of hypertensive and 
HIV-driven kidney disease among people with AA and European ancestry (EA) (Kopp et 
al., 2008; Kao et al., 2008). Earlier work identified genetic variation in the MYH9 gene 
(termed E1) located on chromosome 22 to be associated with the high incidence of ESKD 
in individuals of AA (Kopp et al 2008; Kao et al., 2008; Freedman et al., 2009). 
Subsequently, analyses of the chromosome 22 genomic region using data from the 1000 
Genomes Project has identified two coding sequence variants in the nearby APOL1 gene 
which may explain much of the risk disparity (Genovese et al., 2010). These two variants, 
present in the last exon of the APOL1 gene, have been termed G1 and G2.  
Both homo (G1G1, G2G2) - and heterozygosity (G1G2) for these genetic variants 
have been strongly linked with a number of etiologies of chronic kidney disease which 
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primarily involve glomerular or microvascular dysfunction (Genovese et al., 2010; Tzur 
et al., 2010; Kopp et al., 2011; Lipkowitz et al., 2013). Based on the different etiologies, 
the pattern of kidney damage which develops in individuals carrying the APOL1 risk 
haplotypes seems to begin in the glomeruli (Genovese et al., 2010; Tzur et al., 2010; 
Kopp et al., 2011; Lipkowitz et al., 2013; Freedman et al., 2014). 
Despite the remarkably strong linkage between the APOL1 risk haplotypes and 
chronic kidney disease, no clear functional role for Apolipoprotein L1 has currently been 
identified in glomerular cells. Carrying one risk variant allele offers a protective selection 
against African sleeping sickness due to a trypanolytic activity exhibited by the APOL1 
risk variant proteins against Trypanosoma brucei rhodesiense, whereas carrying two of 
the risk variant alleles puts an individual at risk of CKD (Genovese et al, 2010). The 
locus harboring the APOL1 risk variants have been identified to have undergone natural 
selection in West Africans (Grossman et al, 2010).  
 A number of studies assessing global gene expression changes in the glomeruli 
have shown that diseased kidneys (diabetic nephrosclerosis, FSGS, etc.) exhibit distinct 
patterns of glomerular gene expression compared to glomeruli from normal kidneys 
(usually, normal tissue obtained from nephrectomy samples) (Baelde et al., 2004; Hodgin 
et al., 2010).  Various mutations have also been identified in glomerular cells which alter 
gene function or expression in ways that favor renal dysfunction (Natoli et al., 2002; 
Akilesh et al., 2007).  Thus, it is conceivable that mutations in APOL1 may not directly 
impair filtration function of the kidney, but due to natural selection, may be associated 
with genes or non-coding DNA outside of the APOL1 coding region that affects 
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expression of other genes relevant to glomerular function. Morphological or phenotypic 
differences in any given cell can be impacted by gene expression changes resulting from 
natural selection (Ackermann et al., 2013). The glomerular gene expression changes 
associated with the APOL1 risk variants could lead to direct kidney lesion development, 
or may prime the glomerulus for a “second hit” as may occur in kidney diseases 
associated with hypertension, HIV, or systemic lupus erythemathosus. 
In this study, we investigated the hypothesis that carriers of 2APOL1 kidney risk 
alleles may exhibit altered glomerular gene expression profiles and/or kidney 
morphology, which are present before overt kidney injury is apparent. We observed a 
differential glomerular gene expression profile in non-kidney disease individuals 
harboring 2 APOL1 kidney risk variants compared to non-kidney disease individuals 
carrying 0/1 APOL1 kidney risk variant. Data analysis of the differentially expressed 
genes provided potential biological pathways that may impact kidney disease progression 
in the risk population. The presence/absence of 2APOL1 risk variants did not alter kidney 
morphology in non-kidney disease patients. 
3.2 Results 
3.2.1 Characteristics of samples 
To determine if there is a correlation between disease-associated APOL1 variants 
and patterns of glomerular gene expression which could promote glomerular disease, we 
obtained formalin-fixed paraffin embedded (FFPE) nephrectomy specimens (normal 
kidney present in tumor or traumatic nephrectomies) from archived pathology material 
available in the Boston University Medical Center Department of Pathology and 
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Laboratory Medicine. Archived kidneys included those between the years 2008-2012. 
Samples showing obvious morphological changes (e.g., compression artifact of normal 
tissue due to the presence of tumor nearby, pre-existing disease, etc.) were not used.  
Samples were obtained from 34 African Americans, 5 Caucasians and 11 
Hispanic/Latinos, and APOL1 genotypes were determined for all samples. Table 3.1 
shows characteristics of the samples studied, in addition to the haplotype distribution in 
this sample population as obtained using capillary electrophoresis sequencing (Figure 
3.1).  Of the number of samples procured, 52.9%, 31.37% and 15.69% of genotyped 
specimens possessed 0, 1, and 2 APOL1 risk variant alleles, respectively. In all analyses, 
patients harboring no APOL1 risk alleles or one risk allele were assigned to the “control 
group” whereas those carrying 2 APOL1 risk alleles (either homozygous or heterozygous 
G1G2) were assigned to the “risk group”, consistent with previous studies (Reeves-
Daniel et al., 2011; Lee et al., 2012). 
3.2.2 APOL1 risk haplotype does not alter normal kidney histology  
After stratifying samples based on genotype, we examined the samples 
histologically, to determine if there were histological differences between samples which 
might be associated with later development of chronic kidney disease, and which might 
point to alterations in kidney and glomerular function.  Specifically, we sought to find out 
if there were any morphological differences in kidneys in normal patients harboring the 2 
risk APOL1 gene variants in comparison to those harboring either 1 or 0 APOL1 risk 
variant. As shown in figure 3.2, the histologic characteristics examined, including 
glomerular, tubular, and vascular features, were not significantly different between the 
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risk group or the control group.  Thus, the presence of APOL1 risk variants did not seem 
to be associated with morphologic differences in kidney tissues using light microscopy. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 3.1. Identification of APOL1 Mutations: Panels A, B, and C show sequencing 
eletropherograms. Top panel (A) shows heterozygous G1 rs60910145 A/C , rs73885319 
T/C, middle panel (B) shows homozygous homozygous G1 rs60910145 A/C, rs73885319 
T/C , panel below (C) shows heterozygous G2 Rs71785313 -/TTATAA, panel below 
(arrows show location of base pair substitution) (D) shows RFLP reaction for APOL1 G2 
variant. The TTATAA deletion eliminates a recognition site of endonuclease PsiI. 
Samples heterozygous for the G2 variant show two bands (arrow head) whereas samples 
which do not carry the G2 variant show one band (arrow)  
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Table 3. 1 Characteristics of samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Characteristics Percentage (n) or Mean  ±SD 
Gender  
Male 49.02% (25) 
Female 37.25% (19) 
Unknown 13.73% (7) 
Race  
African American 66.67% (34) 
Caucasian 9.80% (5) 
Hispanic Latino 21.57% (11) 
Unknown 1.96% (1) 
Genotype  
Control Group  
WT+WT 52.94% (27) 
WT+G1 21.57% (11) 
WT+G2 9.8% (5) 
Risk Group  
G1+G2 13.73% (7) 
G1+G1 1.96% (1) 
  
Age 45.48 ±18.83 
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Figure 3.2. APOL1 1 risk gene variant carriers do not exhibit kidney morphological 
differences compared to APOL1 control gene carriers: Blinded scoring of glomerular 
injuries or tubular injuries either by percentage (percentage of number of glomerular 
lesions per total number of glomerular counted on section, percentage of tubular injury 
per kidney section being observed) or severity score (1=normal, 2=mild, 3=moderate, 4=) 
of Periodic acid-Schiff (PAS) sections were recorded. (A) Carriers of APOL1 risk 
variants do not show a significant change in glomerulosclerosis and glomerular 
hypertrophy (graph) (B) No significant differences were observed in tubular atrophy and 
interstitial fibrosis (graph) (C), and in arterial sclerosis and arteriolar sclerosis (graph). 
PAS stain of (a) normal looking glomerulus (b) hypertrophied glomerulus (c) normal 
renal tubules (d) tubular atrophy (arrow head) and tubular interstitial fibrosis (arrow) (e) 
normal artery (f) arteriosclerosis showing thickening of the wall of the artery (*) 
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3.2.3 Laser capture and microarray gene expression 
As indicated previously, we hypothesized that gene expression changes associated 
with APOL1 disease-associated haplotypes are most likely to affect glomerular function, 
since the observed patterns of kidney injury in affected populations primarily involve the 
glomerulus.  Therefore, in order to focus on glomerular gene expression specifically, and 
minimize contributions from kidney tissue outside of the glomerulus, we utilized laser 
capture microdissection (LCM) to isolate glomeruli (Figure 3.3A, 3.3B, 3.3C) for gene 
expression analysis.  Previous studies have demonstrated the feasibility of isolating RNA 
from laser-captured glomeruli, and using these extracted RNA samples for gene 
expression studies (Bennett et al., 2007; Hodgin et al., 2010).  In our study, the quality of 
RNA extracted from laser captured glomeruli was similar (Figure 3.3D) to that reported 
in methodologically similar studies by Hodgin et al., 2010.  We performed genome wide 
gene expression analysis on each sample by hybridization with the Affymetrix Human 
Gene 1.0 St array platform.  
3.2.4 Validation protocol 
Once the gene expression data had been obtained, we performed several analyses 
in order to validate the fidelity of the data.  First, we assessed the expression of two Y 
linked genes (DDX3Y and RPS4Y1) in each of our samples, to serve as a measure for 
signal-noise ratio of the microarray experiment, as the expression of these two genes are 
specific to (and higher in) the male population. As observed in figure 3.4, expression 
levels of these genes in the samples revealed that the 2 Y-linked genes are highly 
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expressed in the male population exclusively with minimal expression in the female 
population, which is consistent with the expected results.  
We also confirmed that our RNA extract was specific to the glomerular region.  
To do this, we examined expression levels for several podocyte, endothelial, tubular and 
non-renal cell specific transcripts. The results (Table 3.2) demonstrate the enrichment in 
these samples of markers present in the glomerular compartment, relative to those for 
tubulointerstitium or non-renal cell compartment. These results lend additional 
confidence in the validity of the microarray data. Examination of the absolute detection 
signals of podocyte and tubular cell specific transcripts from captured glomeruli 
demonstrates the enrichment of glomerular RNA relative to tubulointerstitial RNA in our 
samples.  
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Figure 3.3. Isolation of glomerulus by laser capture microdissection from a 5um 
kidney section on a microscopic slide. (A) A glomerulus surrounded by tubules can be 
easily identified  (*) (B) successful isolation of glomerulus using laser capture leaving 
behind surrounding tissue (∆) (C) capture of glomerulus unto laser capture cap (D) RNA 
quality of extracted RNA was measured using >50ng extracted RNA with the Agilent 
2100 Bioanalyzer. The RNA integrity is determined by the RNA integrity number (RIN) 
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Figure 3.4. Expression of two Y linked genes (DDX3Y and RPS4Y1) within sample is 
specific to annotated male samples: The top panel shows the annotated sex of samples as 
obtained from patient demographics and its corresponding genetic sex as obtained from 
microarray analysis. The bar graph shows expression of the two Y linked genes assessed 
though microarray normalized to minimum value per gene/batch and reveals that the 2 Y-
linked genes are highly expressed in the male population exclusively. Gene expression 
was normalized to minimum expression of gene expressed among samples. 
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Table 3. 2 Tissue-specific mRNA enrichment in laser captured glomerular  FFPE samples 
Gene Absolute signal 
Glomerular  
Podocalyxin 3029.48 
Podocin 1715.44 
PECAM1 925 
Tubular  
PKD2L2 2.34 
SPP2 3.37 
Non renal  
TITF1 6.45 
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3.2.5 Clustering analysis reveals a gene expression pattern specific to carriers 
of the APOL1 risk haplotype 
After validating the gene expression data, we performed cluster analysis with the 
goal of identifying groups of samples which are similar based on gene expression values 
without a priori group assignment. Clustering analysis of our microarray data 
successfully distinguishes samples in the risk group from those in the control group. 
Specifically, samples included in the risk group distinctly clustered together (cluster 1) 
whereas samples genotyped as carrying either 1 or no APOL1 risk alleles seemed to fall 
into 2 clusters (cluster 2 and 3) with samples carrying different genotypes distributed 
throughout these clusters (figure 3.5A).  Closer examination of the control samples 
revealed that all samples carrying the G0G0 APOL1 genotype did not segregate from 
samples carrying either G1G0 or G2G0, in terms of gene expression profile. The wide 
distribution of gene expression profiles in samples containing either 1 or 0 APOL1 risk 
alleles suggests that a single distinct gene expression profile cannot be used to describe 
these samples (Pérez-Rivas et al., 2014). On the other hand, gene expression pattern or 
profile could be used to classify individuals carrying 2APOL1 risk alleles. 
Supervised clustering analysis, an analysis that takes into account the 
experimental groups, was also performed, and reflected findings from unsupervised 
clustering in which two distinct clusters were observed between samples in the risk group 
and the control group (figure 3.5B). Taken together, these findings suggest that 
homozygous/heterozygous carriers of 2APOL1 kidney risk alleles may exhibit distinct 
biological behavior in the glomeruli stemming from a unique gene expression profile.  
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Figure 3.5. Heatmap (unsupervised/left, supervised/right) of top 100 differentially 
expressed genes by student p test risk vs control group: Colors have been scaled with 
red signifying intensity above average, white signifying intensity at average and blue 
signifying intensity below average. APOL1 haplotype is indicated by bar on top grey- 
G0G0, gold- G1G0, blue- G2G0 and green- G1G2.  
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3.2.6 Carriers of APOL1 risk haplotype show a differential glomerular gene 
expression pattern 
To investigate gene expression changes associated with the APOL1 risk gene 
variant, patients were stratified into the control group (G0G0, G0G1, G0G2) and the risk 
group (G1G2). We utilized the nominal p values, ≤0.05 generated from analyzing the 
data since no differentially expressed genes were identified using the adjusted p value 
(Magbanua et al., 2011). We then chose a fold change of 1.2 as a way to rank the genes 
and to select differentially expressed genes which helped to provide biological 
information relevant to kidney disease processes during the exploratory analysis. A total 
of 558 genes (308 downregulated, 250 upregulated) were identified to be differentially 
expressed in APOL1 risk haplotype carriers relative to controls (see Appendix B and C 
respectively).  
We sought to determine if glomerular gene expression changes described in 
similar studies of various forms of kidney disease could overlap with the changes seen in 
our study, and  point to common disease mechanisms worthy of further investigation.  To 
do this we used the Molecular Signatures Database 
(http:www.broad.mit.edu/gsea/msigdb), a software that enables one to compare a gene set 
to a database of uploaded gene sets from previous experiments. This resulted in the 
identification of a number of datasets with significant molecular overlap. Among the 
collections with significant overlap was findings by Baelde et al., 2004, a study which 
compared the transcriptional profile of glomeruli from diabetic patients with glomeruli 
from control subjects. Twenty three genes were identified (Table 3.3) with varied 
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functions which included protein dephosphorylation and regulation of actin cytoskeleton 
that are relevant to cell and podocyte function. 
Many known driver genes harboring mutations associated with CKD progression 
such as NPHS1 (Kestilä et al., 1998; Hinkes et al., 2007), NPHS2 (Boute et al., 2000; 
Hinkes et al., 2007; Tsukaguchi et al, 2002; Hinkes et al., 2008; Weber et al., 2004), 
CD2AP (Gigante et al., 2009), ACTN4 (Kaplan et al.,  2000), MYO1E (Mele et al., 
2011), TRPC6 (Winn et al., 2005), APOL1 (Genovese et al., 2010; Tzur et al., 2010; 
Kopp et al., 2011), and MYH9 (Kopp et al., 2008; Kao et al., 2008) did not exhibit a 
change in gene expression in this study except TRPC6 (fold change: 1.3 p value: 1.01E-
02). This suggests that disease associated mutations in these genes if present in the 
APOL1 kidney risk variant group may exert their deleterious effects without a change in 
expression level.  
In addition, genes encoding proteins such as podocin, nephrin, and synaptopodin 
that have been identified to be essential in podocyte structure and function did not exhibit 
a change in gene expression. This contrasts with studies that have demonstrated a 
reduction in these genes under disease conditions associated with glomerulopathy 
(Hodgin et al., 2010) 
Ingenuity Pathway Analysis (IPA) software may be used to examine a set of 
differentially expressed genes, and identify molecular pathways associated with specific 
cellular functions or disease states.  Analysis of our gene expression data with IPA 
showed associations of differentially expressed genes with genetic pathways that are 
linked to developmental disorders, hereditary disorders, metabolic disease, and 
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organismal injury and abnormalities. Several networks corresponding to the differentially 
expressed genes identified in our study are shown in Table 6. Among these are networks 
involved in kidney failure, organismal injury and disorders, and renal and urologic 
disease. The table also shows the specific differentially expressed genes associated with 
these networks. Table 3.5 shows several interesting canonical pathways associated with 
the set of differentially expressed genes that may be associated with kidney disease 
processes in the risk population. Some of these pathways, as will be discussed, are known 
to play a role, or have the potential to contribute to kidney disease progression. Finally, 
disease processes predicted to be associated with our differential gene expression data 
based on significant p values and potential roles in renal dysfunction were those related to 
inflammation and immune responses, infectious diseases, infection of mamalia, lupus 
erythematosus, cell to cell adhesion and the hematological system. These might explain 
the gene-environment or gene-gene linkage surrounding CKD in patients harboring the 
APOL1 risk variant.  
To gain a more comprehensive insight of the biological relevance of 
overexpressed or underexpressed genes we utilized GoMiner. GoMiner is a software tool 
which uses gene expression changes (upregulation or downregulation) in a microarrary 
data set to cluster sets of genes into biologically relevant categories in the context of 
Gene Ontology (GO). Using an adjusted p value ≤0.02 generated from Gominer, in our 
data set, 6 functional categories were identified for down regulated genes.  The two most 
significant GO terms identified among down-regulated genes in our data set included 
“protein binding” and “protein folding”.  On the other hand, no significant functional 
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categories were identified among up-regulated genes in our data set.  This suggests that 
down-regulated genes may be more important biologically than up-regulated genes in 
setting the stage for the development of kidney disease in patients who are dual-allelic for 
APOL1 risk variants.  
3.2.7 HMOX1 gene mapping to chromosome 22 q13 locus exhibited 
differential expression.  
As discussed previously, genome-wide admixture studies have identified a strong 
association of SNPs on chromosome 22 q13 locus with non-diabetic kidney disease 
within the African-American population. Therefore, we sought to find out if genes in the 
vicinity of this locus exhibited differential expression between the risk and control 
population.  As shown in figure 3.6., gene expression analysis showed no significant 
difference among APOL1 haplotypes in glomerular expression levels of APOL1, MYH9, 
and several other genes in the chromosome 22 risk region.  However, there was one 
important exception:  HMOX1 (fold change -1.4, p value 6.92E-03), the gene encoding 
heme oxygenase 1, was differentially expressed between the two groups (Figure 3.6).  
Heme oxygenase 1 is a stress responsive protein and is known to be cytoprotective 
against oxidative agents (Otterbein et al., 2000). Thus heme oxygenase 1 could play a 
role in protecting glomerular function under stress conditions, and its down regulation in 
patients carrying APOL1 risk haplotypes could leave the glomerulus more vulnerable to 
oxidative damage. 
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Table 3. 3 Differentially expressed genes present in  gene list from Baelde et. al., human diabetic FSGS 
Gene 
Symbol 
Description 
HIRA HIR histone cell cycle regulation defective homolog A (S. cerevisiae) 
B3GNT1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 
AP3B1 adaptor-related protein complex 3, beta 1 subunit 
RHEB Ras homolog enriched in brain 
SDC2 syndecan 2 (heparan sulfate proteoglycan 1, cell surface-associated, 
fibroglycan) 
DST# Dystonin 
PTGER4 prostaglandin E receptor 4 (subtype EP4) 
GSTA4 glutathione S-transferase A4 
CAPN2 calpain 2, (m/II) large subunit 
PRKCI# protein kinase C, iota 
ARF6# ADP-ribosylation factor 6 
RBMS1 RNA binding motif, single stranded interacting protein 1 
PTPN14* protein tyrosine phosphatase, non-receptor type 14 
ACSL3 acyl-CoA synthetase long-chain family member 3 
PTPRO* protein tyrosine phosphatase, receptor type, O 
CDC14A* CDC14 cell division cycle 14 homolog A (S. cerevisiae) 
SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 
FAM98A family with sequence similarity 98, member A 
LOX lysyl oxidase 
FRY furry homolog (Drosophila) 
AKAP10 A kinase (PRKA) anchor protein 10 
MEGF9 multiple EGF-like-domains 9 
GPRC5A G protein-coupled receptor, family C, group 5, member A 
*Protein dephosphortylation enrichment gene 
#actin cytoskeleton organization enrichment gene 
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Table 3. 4 Functional networks involving differentially expressed genes in APOL1 risk variant group glomeruli 
identified using IPA 
Top Diseases and Functions Number of 
molecules 
Kidney Failure, Organismal Injury and Abnormalities, 
Renal and Urological Disease 
27 
Cellular Assembly and Organization, Embryonic 
Development, Organismal Development 
26 
Humoral Immune Response, Protein Synthesis, Cellular 
Assembly and Organization 
25 
Hematological Disease, Hereditary Disorder, Tissue 
Development 
24 
Post-Translational Modification, Protein Degradation, 
Protein Synthesis 
23 
Cell Death and Survival, Organismal Injury and 
Abnormalities, Cancer 
21 
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Table 3. 5 Top canonical pathways involving differentially expressed genes in APOL1 risk variant group 
glomeruli identified using IPA 
Canonical Pathway p-value Molecules 
IL-15 Production 3.47E-04 JAK1, MST1R, PRKCI, PRKCZ, PTK2 
Aldosterone 
Signaling in 
Epithelial Cells 
8.52E-04 AHCY, CRYAB, DNAJB5, DNAJC8, 
DNAJC10, DNAJC18, HSPB11, HSPE1, 
PRKCI, PRKCZ, SLC9A1 
PI3K/AKT Signaling 2.29E-03 BCL2L1, INPP5B, JAK1, MAP3K5, 
PRKCZ, RHEB, SFN, THEM4, TSC1 
NRF2-mediated 
Oxidative Stress 
Response 
3.27E-03 DNAJB5, DNAJC8, DNAJC10, 
DNAJC18, GSTA4, GSTP1, HMOX1, 
MAP3K5, PRKCI, PRKCZ, SCARB1 
NAD Salvage 
Pathway III 
5.13-03 NMNAT3, NMRK1 
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Figure 3.6 HMOX1 gene transcript on chromosome 22q13 locus is downregulated: 
HMOX1 gene mapping to chromosome 22 q13 locus unlike other genes within the same 
locus exhibited significant differential expression of fold change less than 1.2  
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3.3 Discussion 
Genome-wide association studies have shown a strong correlation between the 
presence of either of 2 alleles termed G1 and G2 in the APOL1 gene encoding 
apolipoprotein L1, and chronic kidney disease in people of African ancestry (Genovese et 
al., 2010; Tzur et al., 2010; Kopp et al., 2011). In the absence of an obvious functional 
role in the glomerulus, the way in which the APOL1 risk alleles confer increased kidney 
disease risk remains obscure.  Since there is a positive selective pressure to inherit the G1 
and G2 risk alleles due to their protective effect against trypanosome infection (Genovese 
et al., 2010), it is possible that other genetic information which have a role in glomerular 
function are also being inherited associated with the protective G1 and G2 alleles.  This 
could take the form of mutations in other genes, or alterations in non-coding DNA 
(promoter regions, microRNA, etc.) that can alter expression of other genes and in the 
process impact kidney phenotype. We therefore tested the hypothesis that 
homozygosity/heterozygosity for the APOL1 G1 and G2 alleles is associated with 
glomerular gene expression patterns and kidney morphological changes in non-kidney 
diseased patients. 
Gene expression profiles from formalin fixed paraffin embedded (FFPE) samples 
has in recent years proven to be a powerful tool for understanding disease pathogenesis in 
renal disease (Peterson et al., 2004; Baelde et al., 2004; Wu et al., 2006; Bennett et al., 
2007; Hodgin et al., 2010). In our analysis, we examined the APOL1 genoptypes which 
have been associated with kidney disease in nephrectomy samples (non-kidney disease 
samples) and their association with gene expression patterns in laser captured glomeruli 
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from FFPE samples. We demonstrated successful genotyping and gene expression 
profiling of samples using DNA or RNA extracted from FFPE samples respectively.  
In assessing differentially expressed genes between the risk and control groups, 
no genes were differentially expressed after adjustment for multiple comparisons, a 
standard statistical tool used during microarray analysis. This may be because of the 
limited sample size, large number of genes assessed, or subtle changes in gene expression 
which are difficult to pick up as a result of technical noise (Mootha et al., 2003). On the 
other hand, given the fact that the samples from both groups were from normal patients, 
there may simply be no differences in gene expression between the two groups based on 
an adjusted p value. We however utilized the nominal p value to assess gene expression 
changes and to perform exploratory analysis for obtaining biologically relevant 
information.  
Of particular interest is the cell population analyzed in this study. Most studies 
examining glomerular gene expressions compare normal kidney tissues to diseased 
kidney tissues (Peterson etal., 2004; Baelde et al., 2004; Wu et al., 2006; Bennett et al., 
2007; Hodgin 2010). These studies identified a significant reduction in transcripts of 
proteins involved in maintenance of podocyte structure and function such as nephrin, 
podocin and synaptopodin. A loss of these transcripts may be associated with diseased 
podocytes or podocyte loss, especially since podocyte loss has been associated with 
glomerulopathy (LeHir et al., 2007; D’Agati, 2008; Wiggins et al., 2007; Barisoni et al., 
2007; Mundel et al., 2002). One may therefore argue that the cell populations being 
assessed in these studies may include different cell populations (glomeruli with healthy 
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podocytes present from normal kidneys vs glomeruli with sick or no podocytes from 
diseased kidneys), thereby impacting glomerular gene expression changes. In our study 
however, we do not observe a differential gene expression in these podocyte specific 
genes, suggesting that we have well preserved podocytes and thus gene expression 
changes being observed may directly stem from comparing the same cell populations.  
Interestingly,  we show that samples harboring 2 risk APOL1 variants cluster 
together compared to those harboring 0/1 risk APOL1 risk variant under unsupervised 
clustering analysis based on their gene expression profile. It is therefore possible to 
determine to some degree African American patients at risk of kidney disease progression 
based on their gene expression pattern (V’ant Veer et al., 2002). In our opinion, this is an 
interesting finding, as natural selection due to the APOL1 risk variants may be 
manifesting itself at the gene expression level potentially revealing the molecular 
mechanisms associated with disease associated APOL1 gene variant. 
Canonical pathway analyses (in IPA) on supervised clustered differential 
expressed genes revealed genes highly enriched in the APOL1 carrier risk variant group 
which are strongly associated with lupus erythematous, an association which may explain 
why African Americans harboring the APOL1 risk variant  may be more susceptible to 
lupus nephritis. In general, African Americans are at a higher risk of Lupus nephritis and 
more often progress to end stage renal disease (Freedman et al., 1997; USRDS 2012; 
Richman et al., 2012). Recent studies by Freedman et al., 2014, showed that APOL1 
G1/G2 alleles strongly impact the risk of LN-ESRD in African Americans. This gene 
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expression profile strongly linked to SLE development in the APOL1 risk variant group 
may explain why this population presents with severe forms of renal dysfunction.  
IPA identified the aldosterone signaling pathway to be highly dysregulated 
between the two groups. The renin-angiotensin aldosterone system (RAAS) has been 
identified as a key player in the pathogenesis of renal and cardiac diseases (Volpe et al., 
2002). There is strong evidence supporting the contribution of the mineralocorticoid 
receptor and aldosterone signaling system to renal disease (Greene et al., 1996; Dworkin 
et al., 1984; Brown et al., 2000; Fujisawa et al., 2004; Rosenthal 1976; Rocha et al., 
2000; Wenzel et al., 2008) especially mediated by renal sodium regulation. The RAAS 
pathway exacerbates hypertension through effects of angiotensin II on AT1 receptors, 
resulting in aldosterone release, vasoconstriction and baroflex dysfunction. Increased 
plasma renin activity (PRA) and angiotensin converting enzymes (ACE) are essential in 
RAAS activity mediating hypertension (Jamerson, 2000) in the general population 
(Richardson et al., 2013). On the other hand, low PRA and ACE has been associated with 
hypertension in African Americans (Lee et al., 1990; Falkner 1990; Somova and 
Mufunda 1996; Rayner et al., 2001; Pratt et al., 1999). This suggests a different RAAS 
role in hypertension and thus in hypertensive associated kidney disease in the percentage 
of African Americans exhibiting low PRA and low ACE. In this study, renin and 
angiotensin gene transcript levels were also identified to be downregulated in the risk 
population. Herein, we show that alteration of genes associated with the aldosterone 
signaling pathway may explain the increased risk in hypertensive driven nephropathy in 
the APOL1 risk group population (Papeta et al., 2011; Kopp et al., 2011; Genovese et al., 
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2010; Genovese et al., 2010). This could also explain why African Americans are more 
resistant to anti-hypertensives that target RAAS molecules compared to treatments by 
diuretics and calcium channel blockers (Richardson et al., 2013).  
The Nrf2-mediated oxidative stress response pathway was also observed to be 
modulated in the APOL1 risk variant group. The Nrf2 system regulates a number of 
essential cytoprotective genes utilized by vertebrates over the course of evolution. In 
effect, it helps protect many cells and organ systems in which it is expressed (Kobayashi 
and Yamamoto 2006; Kensler et al., 2007). Studies in Nrf2-deficient mice have shown 
increased susceptibility to a number of kidney diseases such as autoimmune nephritis 
(Yoh et al., 2001), ischemia reperfusion injury (Liu et al., 2009) and diabetes mediated 
renal injury (Yoh et al., 2008). In addition, studies in CKD rat models revealed a link 
between impaired Nrf2 activity, increased oxidative and inflammatory response and 
increased kidney disease progression (Kim and Vaziri, 2010). Lack of Nrf2 activity may 
augment the oxidative and inflammatory response in the diseased kidney favoring disease 
progression (Kim and Vaziri, 2010). On the brighter side, protective roles of Nfr2 have 
been identified using dietary Nrf2 activators such as sulforaphane (Zheng et al., 2011) or 
synthetic triterpenoid such as bardoxolone methyl (Liby et al., 2005; Yates et al., 2007; 
Sporn et al., 2011). Induction of the Nrf2 pathway involves an increase in protein activity 
such as the protein heme oxygenase 1 (Wu et al., 2011). Heme oxygenase activity is 
essential in complementing the anti-inflammatory response exerted by Nrf2 (Zoja et al., 
2014). In our study, we identified the heme oxygenase 1 gene to be downregulated. The 
regulation of the Nrf2 signaling pathway may therefore be contributing to the molecular 
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mechanism by which patients harboring the Apol1 risk variant are at a higher risk of 
CKD progression. Certainly if these populations have an impaired antioxidant and anti-
inflammatory response, interventions targeting the Nrf2 signaling pathway may prove 
beneficial in ameliorating CKD. 
In addition, the IL15 pathway was identified to be associated with the APOL1 risk 
group. IL-15 production in FSGS pattern of kidney disease has not being explored much, 
however it has been identified to play a protective role in T-cell dependent nephritis, by 
preventing the induction of chemokine driven recruitment of leukocytes into the kidney 
(Shinozki et al,. 2002). Kidney leukocyte recruitment contributes to progression of 
chronic kidney disease through production of proinflammatory, proapoptotic, and 
profibrotic factors (Eddy, 2000; Anders et al., 2006).  Further studies exploring the role 
of IL-15 in renal diseases specifically in the risk group could provide pathogenic 
mechanistic insights. 
APOL1 risk variants have also been strongly associated with increased 
susceptibility to HIV driven nephropathy among African Americans. Interestingly, 
APOL1 control variant HIV infected persons do not develop HIVAN. HIVAN stems 
from infection of renal epithelial cells with HIV-1 and expression of viral genes in the 
host. The immune system, both systemic and within the kidney are altered during HIV-1 
infection and may contribute in exacerbating HIV-driven nephropathy. In this study, 
using IPA, genes involved in viral infection and immunity were identified to be 
dysregulated, suggesting that at the glomerular gene expression level we may be able to 
explain why carriers of APOL1 risk variant have increased susceptibility HIVAN. 
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As stated earlier, the two most significant GO terms identified using Gominer for 
the down-regulated genes in our data set included protein binding and folding.  Protein 
folding is essential to protein. It is therefore possible that downregulation of proteins 
involved in folding may be relevant to pathological conditions in the kidney (Dobson, 
2003).  
Further, we identified an upregulation of transient receptor potential channel 
TRPC6 and protein tyrosine kinase 2 (PTK2) also called focal adhesion kinase (FAK). A 
gain of function mutation in TRPC6 has been identified to be associated with an 
autosomal dominant form of human kidney disease. TRPC6 expression levels have also 
been identified to increase in human glomerular diseases leading to increased calcium 
flux (Möller et al., 2007). Thorough TRPC6 examination in this group could also provide 
some pathogenic insight and therapeutic directions.  
Using mouse models, PTK2 has been identified to be activated by 
phosphorylation during injury within the glomerulus. Pharmacological inhibition of FAK 
or podocyte specific loss of FAK abrogated glomerular injury (Ma et al., 2010). FAK 
plays a critical role in cell migration, a process thought to correlate with podocyte foot 
process effacement during injury. Further studies of PTK2 could prove beneficial to 
curbing renal disease particularly in this population. 
Few studies have looked at the role of APOL1 risk haplotypes in the morphologic 
appearance of kidney disease (Fine et al., 2012; Atta et al., 2012).  Histopathological 
examination of kidney biopsies is the diagnostic gold standard for different renal 
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diseases, and can be useful for assessing the type and severity of disease. We found no 
significant difference in any of the morphologic features that we examined between 
kidneys from patients carrying APOL1 risk variants and controls. This suggests that 
APOL1 variants do not influence baseline kidney structure, at least before disease 
detection at the light microscopy level. The absence of detailed clinical information 
pertaining to the patient population was a limitation in this study. Subjects were selected 
for this study based on their clinical pathology report which does not include their clinical 
history. We were therefore unable to examine other risk factors for FSGS pattern of 
kidney disease such as hypertension, HIV infection, diabetes among others which may 
have been present in these patients. However, a morphological assessment of tissues 
obtained from this population indicated no significant differences.  
APOL1 still remains the gene of interest when looking at the development and 
progression of nondiabetic kidney disease in individuals with African Ancestry. The 
mechanisms underlying how the APOL1 risk genotypes contribute to kidney disease 
however remains unclear.  
This is the first study looking at gene expression profiles of morphologically 
normal glomeruli classified into those harboring the APOL1 risk variant or control 
variant. Although we did not identify significantly differentially expressed genes in our 
study in the presence of 2 APOL1 risk variants, that is, based on an adjusted ‘p’ value, 
exploratory analysis of gene expression changes obtained using unadjusted ‘p’ values 
revealed potential pathways or intriguing genes that could be of interest in mediating 
kidney disease progression.  
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In conclusion, we propose that persons harboring 2 APOL1 kidney risk gene 
variants have a differential glomerular gene expression milieu which sets the platform for 
increased risk to renal dysfunction particularly in the presence of other modifying factors 
because not all individuals harboring the risk genes develop kidney disease. Most 
importantly a study of the RAAS pathway and related genes in kidney disease APOL1 
risk patients could provide pathogenic mechanistic insights and inform therapeutic 
choices in the risk population.  
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CHAPTER FOUR 
Non-Muscle Myosin IIA is Critical for Podocyte F-actin Organization, Contractility 
and Motility 
4.1 INTRODUCTION 
Recent studies have implicated non-muscle myosin IIA (NMIIA) in glomerular 
pathophysiology. Certain autosomal dominant MYH9 mutations have been associated 
with focal segmental glomerulosclerosis (FSGS) (Ghiggeri et al., 2003).  More recently, 
genome wide association studies have revealed a strong association between genetic 
variation in the MYH9 region on chromosome 22 and the risk of CKD in individuals of 
African descent (Kao et al., 2008; Kopp et al., 2008).  Several glomerular pathologies, 
including FSGS, collapsing glomerulopathy, and diabetic glomerulosclerosis have 
subsequently been linked to genetic variation in the region of MYH9 (Kao et al., 2008; 
Kopp et al., 2008; Cooke et al., 2012).  Importantly, in all of these examples, the pattern 
of injury implicates the podocyte, as these glomerular lesions develop as a result of 
podocyte injury. 
There are three non-muscle myosin IIs in mammals, (NMIIA, NMIIB, and 
NMIIC) with varying expression across cell types (Vicente-Manzanares et al., 2008). The 
non-muscle myosin heavy chains IIA and IIB (NMHC IIA and IIB) are important motor 
proteins that modulate cell movement and tone with distinct kinetics (Golomb et al., 
2004; Kim et al., 2005; Kovacs et al., 2003; Nagy et al., 2013; Wang et al., 2003; 
Rosenfeld et al., 2003). They have actin cross-linking and contractile properties similar to 
skeletal muscle myosin II, and are found in many somatic cell types. NMHC IIA and IIB 
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are the protein products of the genes MYH9 and MYH10 respectively. In the human 
renal glomerulus, mRNA of both genes are expressed in podocytes (Nabet et al., 2009). 
In a number of functional studies, the two heavy chains have been identified to play 
either redundant roles or different biological roles and have also been identified to be 
present in the same cells or different cells (reviewed in Vicente-Manzanares et al., 2009). 
Given the importance of MYH9 in human kidney disease, our hypothesis is that 
NMHCIIA plays a critical role in podocyte cytoskeletal/contractile function.   
In this study, we demonstrate that podocytes have contractile properties and this is 
non-muscle myosin heavy chain (NMHC) II isoform specific. We used a pharmacologic 
agent (blebbistatin) to interfere with function of all NMHC II isoforms, and a lentiviral 
RNA interference system to ablate specific NMHC II isoforms in murine podocytes in 
vitro.  In the resulting cells with ablated NMHC expression and in corresponding control 
cells, we studied cytoskeletal structure, cell morphology, traction generation, and cell 
migration. We show that blebbistatin results in decreased podocyte traction which seems 
to be dependent on NMIIA, as NMIIA downregulation but not NMIIB downregulation 
results in decreased podocyte contractile properties. Moreover, NMIIA ablation resulted 
in altered cytoskeletal structure and increased cell migration, features not observed in the 
absence of NMIIB.    
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4.2 RESULTS 
4.2.1 Podocyte actin cytoskeletal stability and contractility in vitro is non-
muscle myosin II heavy chain dependent.  
We initially investigated the role of NMHCII isoforms in the structure and 
function of the cytoskeletal contractile apparatus in podocytes using pharmacologic 
inhibition of all NMHCII isoforms with blebbistatin.  In pilot studies, we found that a 
concentration of 100 µM blebbistatin and exposure period of 30 minutes resulted in a 
maximal functional effect without widespread toxic effects (data not shown).  Using this 
concentration and exposure period, we investigated cell morphology, actin filament 
length and localization, presence of NMHCIIA and IIB isoforms, vinculin distribution 
and single cell contractility in cultured differentiated murine podocytes (Figure 4.1). We 
found that vehicle-treated cells exhibited morphologic and cytoskeletal features typical of 
these cells in culture, including an epithelioid morphology, prominent trans-cytoplasmic 
stress fibers associated with co-localization of NMHCIIA and IIB along the length of the 
stress fibers, and vinculin co-localization at the ends of stress fibers (Figure 4.1A-C).  In 
addition, NMHCIIA appeared somewhat more prominently along the stress fibers than 
IIB, and NMHCIIB was restricted to the central part of the stress fibers.  In the 
blebbistatin-treated cells, cell morphology was generally unaffected, but we observed a 
widespread loss of actin stress fibers accompanied by redistribution and greatly 
diminished intensity of NMHCIIA, NMHCIIB, and vinculin (Figure 4.1A-C).  
NMHCIIA was redistributed to the cell periphery of some cells treated with blebbistatin 
(Figure 4.1A). Traction force microscopy revealed that vehicle-treated cells exhibited a 
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wide range of root mean square (RMS) traction magnitudes, with a mean value of 355 Pa, 
consistent with our experience with untreated wild type murine podocytes (Figure 4.1D-
E).  In contrast, blebbistatin-treated cells exhibited almost complete abolishment of 
traction force generation (Figure 4.1D-E).  These data show that the integrity and 
function of the actin-based contractile apparatus in podocytes requires NMHC II activity. 
4.2.2 Experimental ablation of specific myosin II heavy chain isoforms in 
cultured murine podocytes does not significantly affect expression of other 
myosin II heavy chain isoforms. 
Initial studies revealed that mRNA of both NMHC IIA and IIB isoforms are 
present in cultured murine podocytes. We therefore sought to find out if the blebbistatin 
effect on podocytes was dependent on either NMHIIA or NMHIIB. We used RNA 
interference techniques to elucidate the distinct function of each isoform.  Small 
interfering RNA (siRNA) targeting each NMHC isoform, or non-targeting siRNA, was 
transiently introduced into wild type murine podocytes via a lentiviral transduction 
system, as described in Methods (Battini et al., 2006).  Using this system with siRNA 
targeting NMHC IIA and IIB, we found maximal reduction in expression of the target 
gene product ten days after lentiviral transduction into cells cultured under non-
permissive conditions.  Therefore, all experiments utilizing RNA interference followed a 
specific time line in order to study fully differentiated podocytes at maximal protein 
ablation (Figure 4.2).  
To evaluate transduction and protein ablation efficiency of this system, and to 
look for off-target effects, we used real-time PCR and immunoblot densitometry to 
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quantify Myh9 and Myh10 mRNA, and NMHC IIA and IIB, respectively, in lentivirus-
treated and control podocytes (Figure 4.3). At 10 days post-transduction, Myh9 mRNA 
and NMHC IIA protein expression were both significantly reduced (69%±4.2% and 
85±9.8%, respectively; p<0.05) in Myh9 siRNA-treated cells (“Myh9 KD”) in 
comparison to corresponding control siRNA-treated cells (“Myh9 CTRL”), while Myh10 
mRNA and NMHC IIB protein expression levels were not significantly affected (Figure 
4.3A and B).  Similarly, Myh10 mRNA and NMHC IIB protein expression were both 
significantly reduced at 10 days post-transduction (63%±9.8% and 80±6.9%, 
respectively; p<0.05), in Myh10 siRNA-treated cells (“Myh10 KD”) as compared to 
control siRNA-treated cells (“Myh10 CTRL”), but Myh9 mRNA and protein expression 
levels were not significantly affected by Myh10 siRNA-treatment (Figure 4.3C andD). 
This data indicates that ablation of both NMHC IIA and IIB protein expression using the 
previously described lentiviral transduction system was specific and efficient.  This data 
also suggests that in murine podocytes, NMHC IIA and IIB do not compensate 
significantly for loss of the complementary isoform through upregulation of their 
expression. 
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Figure 4.1. Podocyte actin cytoskeletal stability and contractility in vitro is non-muscle 
myosin II heavy chain-dependent: (A-C) Differentiated murine podocytes, cultured on 
glass with equal plating density, and treated for 30 minutes with 100 uM blebbistatin 
(BLEBBISTATIN), a non-muscle myosin II heavy chain inhibitor, or vehicle alone 
(VEHICLE), followed by immediate fixation. (A) Podocytes stained for F-actin and non-
muscle myosin heavy chain IIA (NMHCIIA). In cells treated with vehicle alone (left 
column), prominent parallel, transcellular actin stress fibers are apparent, and NMHCIIA 
is co-localized with actin along the entire length of these stress fibers.  In cells treated 
with blebbistatin (right column), the number and density of actin stress fibers in the 
cytoplasm is greatly diminished, and the intensity of background actin filament staining 
in the cytoplasm (presumably representing staining of small actin filaments) is increased 
in the periphery of the cells.  NMHCIIA is apparent at the interface between the central 
and peripheral regions of the cells, and co-localized with residual stress fibers, but its 
intensity appears diminished. Vehicle-treated and blebbistatin-treated cells exhibit similar 
morphology, with most cells exhibiting an epithelioid morphology and the remainder 
exhibiting a fusiform morphology.  (B) Podocytes stained for F-actin and non-muscle 
myosin heavy chain IIB (NMHCIIB). In cells treated with vehicle alone (left column), 
NMHCIIB is co-localized with actin in the central region of the stress fibers, sparing the 
periphery of these structures.  Nuclear staining for NMHCIIB is also apparent. Cells 
treated with blebbistatin (right column) show a similar pattern of NMHCIIB co-
localization with actin stress fibers as seen in the vehicle-treated cells, but the intensity of 
staining is greatly diminished in association with the overall loss of stress fibers.  Nuclear 
staining for NMHCIIB is retained. (C) Podocytes stained for F-actin and vinculin, a 
marker of focal adhesions.  Cells treated with vehicle alone (left column) show prominent 
focal adhesions at the ends of actin stress fibers, whereas blebbistatin-treated cells (right 
column) reveal a dramatic reduction in the number density and staining intensity of focal 
adhesions. (D and E)  Results of traction force microscopy experiments performed to 
examine the effect of blebbistatin on podocyte contractility.  Differentiated murine 
podocytes, cultured on polyacrylamide substrates, were treated for 30 minutes with 100 
uM blebbistatin (BLEBBISTATIN), or vehicle alone (VEHICLE), followed by traction 
force microscopy.  (D and E)  Results of traction force microscopy (TFM) experiments, 
performed to determine the effect of blebbistatin on podocyte static contractility.  (D) 
Brightfield microscopic images (top) and corresponding calculated traction vector maps 
(bottom) for representative cells from each treatment group.  Root mean square (RMS) 
traction calculated for each cell is indicated at upper right of each traction vector map.  
White outlines in lower panels indicate region containing traction vectors used to 
calculate RMS traction for each cell.  The cell treated with vehicle alone (VEHICLE) 
exhibits epithelioid morphology and inward directed traction vectors throughout the cell.  
The cell treated with blebbistatin (BLEBBISTATIN) also exhibits epithelioid 
morphology, but almost no traction vectors attributable to the cell are observed.  (E) TFM 
results for the entire experiment show that RMS traction is significantly decreased after 
blebbistatin treatment.  Also apparent is the wide range of traction values observed in 
vehicle-treated cells, in contrast to blebbistatin-treated cells.  Long horizontal cross bars 
represent the mean of the data, and the interval bars represent 95% confidence intervals. 
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Figure 4.2. Time line for all Myh9 and Myh10 ablation experiments:  On Day 0, 
immortalized murine podocytes, cultured under permissive conditions, are subcultured 
and thermoshifted to non-permissive conditions to inhibit proliferation and promote 
differentiation.  On Day 1, subcultured cells are transduced with lentivirus expressing 
siRNA targeting Myh9 (“Myh9 KD”) or Myh10 (“Myh10 KD”), or corresponding 
control lentivirus expressing non-targeting scrambled siRNA (“Myh9 CTRL”, “Myh10 
CTRL”).  Control cells not transduced with lentivirus (“UNTREATED”) were also 
prepared for all experiments.  Virus is removed 24 hours later on Day 2.  On Day 7, cells 
are re-plated onto polyacrylamide substrates for traction experiments, or onto new 
polystyrene culture plates for other experiments.  Beginning on Day 8, cells were 
gradually transitioned to serum-free media over the succeeding 3 days, and experiments 
were performed on Day 11. 
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Figure 4.3. Experimental ablation of specific myosin II heavy chain isoforms in 
cultured murine podocytes does not significantly affect expression of other myosin II 
heavy chain isoform: (A) Myh9 mRNA transcription as quantified by real-time PCR:  
Treatment of cells with Myh9 shRNA (Myh9 KD) resulted in reduction in Myh9 mRNA 
levels by 70±4.2% (p=0.0327) relative to Myh9 CTRL cells. This extent of reduction in 
Myh9 expression was not observed in other control cells (UNTREATED, Myh10 CTRL) 
A B 
C D 
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or in Myh10 KD cells. (B) NMHCIIA expression:  Western blot analysis shows 85%±9.8 
reduction in NMHCIIA protein levels in Myh9 KD cells when compared to Myh9 CTRL 
cells (p=0.0112).  This reduction in NMHCIIA expression was not observed in other 
control cells (UNTREATED, Myh10 CTRL) or in Myh10 KD cells.  Representative 
images of western blots are shown.  (C) Myh10 mRNA transcription:  Myh10 mRNA 
level was reduced in Myh10 KD cells by 70%±9.8 (p=0.0072) as compared to Myh10 
CTRL cells; Myh10 mRNA expression level in the other control cells (UNTREATED, 
Myh9 CTRL) and in Myh9 KD cells was somewhat less than in Myh10 KD cells, but 
these differences were not found to be statistically significant.  (D) NMHCIIB expression: 
NMHCIIB protein expression was markedly reduced in Myh10 KD cells (~80% ±6.9) as 
compared to Myh10 CTRL cells (p=0.0100), as quantified by Western blot. 
Representative images of western blots are shown. Values in these figures are mean ± 
SEM, n=3 
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4.2.3 Cell morphology, actin cytoskeletal organization and stress fiber 
density, and non-muscle myosin heavy chain density are altered in Myh9 and 
Myh10-ablated podocytes.   
Once efficient ablation of individual non-muscle myosin heavy chain isoforms 
was established in differentiated, cultured podocytes, we first investigated the effect of 
loss of specific myosin isoforms on cell structure, including cell morphology, actin stress 
fiber organization, and NMHC isoform localization. We found that while untreated and 
control lentivirus-transduced cells exhibited uniform epithelioid morphology and cell 
size, Myh9-ablated cells maintained a similar epithelioid morphology but exhibited 
greater variation in cell size, with both small fusiform cells and large epitheloid cells 
appearing more frequently (Figure 4.4A and B).  Myh10-ablated cells were sparsely 
populated and exhibited a smaller, simplified epithelioid or fusiform morphology (Figure 
4.4A and B).  Actin stress fibers were present throughout the cytoplasm of untreated and 
control lentivirus-transduced cells, exhibiting a parallel transcellular or peripheral 
circumferential arrangement (Figure 4.4A and B).  However, stress fibers were markedly 
simplified in Myh9-ablated cells, with many of these cells, particularly larger cells, 
exhibiting a sparse, disorganized collection of short stress fibers (Figure 4.4A and B). 
Myh10-ablated cells exhibited networks of parallel transcellular or circumferentially-
oriented stress fibers, although shorter than in untreated and control cells due to the 
smaller size of these cells.  Stress fiber quantification revealed a significant reduction in 
stress fiber length density in Myh9-ablated cells relative to control cells (Figure 4.5). A 
slight decrease in stress fiber length density was observed in Myh10-ablated cells relative 
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to control cells, but this change was not statistically significant.  NMHC IIA was present 
in untreated and control lentivirus-transduced cells along the entire length of stress fibers, 
most prominently in the central cell body (Figure 4.4A). NMHC IIA was also seen along 
stress fibers in Myh10 KD cells (Figure 4.4A).  In contrast, NMHC IIA is almost entirely 
absent from the cytoplasm of Myh9 KD cells, with only a minimal amount seen in 
association with rudimentary stress fibers, and focally in nuclei (Figure 4.4A).  NMHC 
IIB was present in untreated and control lentivirus-transduced cells, but found to be 
confined to the central portion of stress fibers (Figure 4.4B).  NMHC IIB was also seen 
along the central portion of the rudimentary stress fibers of Myh9 KD cells, but little 
NMHC IIB was observed along stress fibers in Myh10 KD cells (Figure 4.4B).  
However, immunoreactivity for NMHC IIB was seen diffusely in the nuclei in all 
treatment groups, including Myh10 KD cells (Figure 4.4B).  These data indicate that in 
murine podocytes, NMHC IIA has a critical role in maintenance of actin cytoskeletal 
structure and stress fiber formation, while NMHC IIB is less important for preservation 
of actin cytoskeletal architecture. 
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Figure 4.4.  Cell morphology, actin cytoskeletal organization, and non-muscle myosin 
heavy chain density are altered in Myh9 and Myh10 ablated podocyte:  Differentiated 
murine podocytes, cultured on glass with equal plating density, and stained for 
localization of filamentous actin (“F-ACTIN” A and B), and non-muscle myosin heavy 
chains IIA (“NMHCIIA”, A) and IIB (“NMHCIIB”, B).  Cells were transduced with 
lentivirus expressing shRNA targeting Myh9 (“Myh9 KD”) or Myh10 (“Myh10 KD”), or 
corresponding control lentivirus expressing non-targeting scrambled shRNA (“Myh9 
CTRL”, “Myh10 CTRL”), as described in Figure 4.2.  Cells not transduced with 
lentivirus (“UNTREATED”) are also shown.  Images are epifluorescence micrographs at 
500x magnification, taken 10 days after lentiviral transduction.  Cell morphology and 
actin stress fiber organization (A and B):  Untreated and control lentivirus-transduced 
cells exhibit uniform epithelioid morphology with mild variation in cell size, and parallel 
transcellular or peripheral circumferential actin stress fibers throughout the cell body. (A) 
In contrast, Myh9 KD cells show retention of typical epithelioid morphology, but with 
mildly decreased cell population density, greater variation in cell size, and simplification 
of actin stress fibers, including shortening, disorganization, and decreased stress fiber 
density.  
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(B) Myh10 KD cells are sparse and exhibit simplified morphology, including unspread, 
fusiform, and small epithelioid cells.  Myh10 KD cells show a simplified pattern of 
parallel, transcellular stress fibers, best seen in cells with fusiform and epithelioid 
morphology.  NMHCIIA localization  (A) Untreated and control lentivirus-transduced 
cells exhibit strong immunoreactivity for NMHCIIA along the entire length of stress 
fibers, most prominently in the central cell body.  NMHCIIA is almost entirely absent 
from the cytoplasm of Myh9 KD cells; only diffuse, weak nuclear NMHCIIA 
immunoreactivity and minimal NMHCIIA immunoreactivity associated with rudimentary 
stress fibers is noted.  Strong stress fiber-associated NMHCIIA immunoreactivity is 
observed in Myh10 KD cells. NMHCIIB localization (B)Untreated and control lentivirus-
transduced cells exhibit moderate immunoreactivity for NMHCIIB that is generally 
confined to the central portion of stress fibers, as well as diffuse moderate nuclear 
immunoreactivity.  Similar immunoreactivity for NMHCIIB is seen along rudimentary 
stress fibers and in nuclei of Myh9 KD cells.  Myh10 KD cells show diminished 
immunoreactivity for NMHCIIB along stress fibers, while nuclear immunoreactivity is 
retained. 
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Figure 4.5. Actin stress fiber length density is decreased in Myh9-ablated podocytes: 
Results of actin stress fiber quantification for each of the five treatment groups described 
in Figure 4.3 (“UNTREATED”, “Myh9 CTRL”, “Myh9 KD”, “Myh10 CTRL”, “Myh10 
KD”).  Cells were prepared as described in Figure 4.4, and actin stress fiber length 
density for each treatment group was determined from calibrated epifluorescence 
micrographs of filamentous actin staining as the total actin stress fiber length per unit cell 
area (µm-1).  Results are presented as mean +/- SEM, normalized to the untreated 
sample.  Stress fiber length density is significantly reduced in Myh9 KD cells relative to 
Myh9 CTRL cells by 29.2% (p=0.0269).   A slight decrease in stress fiber length density 
observed in Myh10 KD cells relative to Myh10 CTRL cells is not statistically significant. 
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4.2.4 Traction force microscopy reveals that NMHC IIA is the primary 
contributor to podocyte contractile behavior in vitro.    
Since non-muscle myosin II heavy chains are actin-based motor proteins and are 
known to be major contributors to cell contractility and motility, we investigated the role 
of non-muscle myosins IIA and IIB in generating static contractile forces, manifested as 
substrate surface traction, in individual podocytes.  To do this, we used the lentiviral 
siRNA system described above in combination with traction force microscopy, following 
the experimental sequence illustrated in Figure 4.2, to measure contractile forces 
generated by individual cells after gene ablation.  We also examined the effect of Rho 
GTPase pathway stimulation on actomyosin contractile response by exposing a subset of 
cells from each treatment group to lysophosphatidic acid (LPA) 30 minutes prior to 
commencing TFM imaging; the remaining cells received vehicle alone.  The results of 
these studies are presented in Figure 4.6.   
Traction force microscopy revealed that unstimulated (vehicle-treated) control 
cells (UNTREATED, Myh9 CTRL and Myh10 CTRL) and Myh10 KD cells exhibit a 
wide range of RMS traction magnitudes, with minimum values ranging from 30 to 132 
Pa, maximum values ranging from 922 to 1094 Pa, and mean values ranging from 426 to 
495 Pa (Figure 4.6A).  These results are strikingly consistent across all four of these data 
sets, and are also consistent with results for vehicle-treated cells in blebbistatin 
experiments (Figure 4.1E). In contrast, Myh9 KD cells exhibited a narrower range of 
RMS traction values, ranging from 113 to 390 Pa, with a mean RMS traction of about 
238 Pa that is significantly less than Myh9 CTRL cells (p<0.05; Figure 4.6A).  LPA 
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stimulation had a variable effect on RMS traction of WT, Myh9 CTRL, Myh10 CTRL 
and Myh10 KD cells.  Although occasional cells within each of these groups displayed 
very strong contractile responses (maximum RMS traction values ranging from 1247 to 
3417 Pa), mean RMS traction of each of these groups was only mildly increased relative 
to unstimulated cells, ranging from 508 to 732 Pa, and these increases were not 
statistically significant in any case (Figure 4.6A and B).  Myh9 KD cells also showed a 
modest response to LPA stimulation, with RMS traction values ranging from 118 to 715 
Pa, with a mean of 274 Pa. 
Brightfield microscopic images and corresponding traction force vector maps 
revealed that UNTREATED, Myh9 CTRL, and Myh10 CTRL cells exhibited inward 
directed traction vectors distributed across a large portion of the cell area (Figure 4.6C).  
Although smaller, Myh10 KD cells also showed widely-distributed, inward directed 
traction vectors, similar to control cells (Figure 4.6C).  In contrast, traction force vector 
distribution in Myh9 KD cells tended to be less organized and limited to the central peri-
nuclear region of the cell, corresponding to the less organized and sparse stress fiber 
distribution noted in Myh9 KD cells in immunostaining studies (Figure 4.6C).  These 
traction force vector distribution patterns were conserved in LPA stimulated cells (Figure 
4.6C).  Taken together, these data show that NMHC IIA is critical for podocyte traction 
force generation, and NMHC IIB does not appear to contribute significantly to this cell 
function. 
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Figure 4.6. Traction Force Microscopy reveals greatly diminished static contractility in 
Myh9-ablated podocytes; contractility of Myh10-ablated podocytes is not reduced:  (A 
and B) Results of two groups of experiments performed to examine the effect of Myh9 
and Myh10 ablation on podocyte contractility.  Cells were prepared for traction force 
microscopy (TFM) as described in Figure 4.2, and treated 30 min prior to TFM imaging 
with 10 uM lysophosphatidic acid (LPA), a Rho GTPase activator and contractile 
stimulator, or vehicle alone. Individual cells were selected and imaged as described in 
Methods, and root mean square (RMS) traction values were calculated for each cell.  (A)  
TFM of unstimulated (vehicle-treated) cells.  Individual RMS traction values of 
UNTREATED, Myh9 CTRL, Myh10 CTRL, and Myh10 KD cells are spread over a wide 
range.  Mean values for these groups are comparable to that of vehicle-treated cells in 
blebbistatin experiments (see Figure 4.1E).  In contrast, RMS traction values of Myh9 
KD cells are tightly clustered around a mean value that is much less than that of the other 
treatment groups (p=0.0008 vs. LV CTRL cells), and that approaches the noise level for 
this type of measurement.  This indicates that NMHC IIA is critical for podocyte 
contractility.  Note that mean RMS traction of Myh10 KD cells is comparable to that of 
the control groups, suggesting that loss of NMHC IIB is not detrimental to podocyte 
contractility.  (B) TFM of LPA-stimulated cells.  LPA stimulation is associated with a 
wider range of RMS traction values and a slight increase in mean RMS traction values in 
UNTREATED, Myh9 CTRL, Myh10 CTRL, and Myh10 KD treatment groups, as 
compared to unstimulated cells (compare to Figure 4.6A).  Several cells in these 
treatment groups exhibited remarkably high RMS traction values.  In contrast, Myh9 KD 
cells show minimal response to LPA stimulation. 
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(C) Brightfield microscopic images (1
st
 and 3
rd
 rows) and corresponding calculated 
traction vector maps (2
nd
 and 4
th
 rows) for representative cells from each treatment group, 
for both unstimulated (vehicle-treated; top two rows) and LPA-stimulated (bottom two 
rows) podocyte traction experiments.  Root mean square (RMS) traction calculated for 
each cell is indicated at upper right of each traction vector map.  Traction vector maps 
show individual calculated traction vectors at each point of the computational grid that 
indicate direction and magnitude (indicated by vector length), as well as a color-coded 
“heat map” corresponding to traction magnitude (dark blue = 0 Pa, dark red = 500 Pa).   
White outlines in traction vector maps indicate region used to calculate RMS traction for 
each cell.  UNTREATED and Myh9 and Myh10 CTRL cells exhibit epithelioid 
morphology and inward directed traction vectors throughout the cell.  Myh9 KD cells 
also exhibit epithelioid morphology but show diminished traction vectors focused near 
the cell nucleus.  Myh10 KD cells are smaller but retain an epithelioid morphology and 
show inward directed traction vectors similar to control cells. Data in A and B are 
presented for each of the five treatment groups described in Figure 4.2 (“UNTREATED”, 
“Myh9 CTRL”, “Myh9 KD”, “Myh10 CTRL”, “Myh10 KD”), as RMS traction of 
individual cells (circles); long horizontal cross bars represent the mean of each treatment 
group, and the interval bars represent 95% confidence intervals.   
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4.2.5 Myh9-ablated podocytes exhibit increased cell motility.  
We further examined the biophysical role of NMHC IIA and IIB in the podocyte 
by performing a “wound healing” assay with cells prepared using the lentiviral siRNA 
system described above.  The experimental sequence illustrated in Figure 4.2 again 
served as the template for these experiments, except cells were re-plated onto polystyrene 
cell culture plates on day 7 at appropriate density to achieve confluence on day 11 post-
thermoshift.  For this assay, a uniform linear defect (“scratch”) was created in the 
confluent cell monolayer, and digital images of the defect at the time of placement and 24 
hours later were processed to determine the proportion of the scratched area covered by 
cells 24 hours after scratch placement.  We found that Myh9 KD cells exhibited 
significantly greater wound area coverage at 24 hours post-scratch compared to 
UNTREATED and Myh9 CTRL treatment groups (Figure 4.7).  In contrast, Myh10 KD 
cells exhibited no significant difference in wound area coverage compared to 
UNTREATED and Myh10 CTRL treatment groups (Figure 4.7).  This suggests that 
NMHC IIA plays a role in restraining podocyte migration in vitro, while NMHC IIB 
(Myh10) appears to have no significant role in cell migration. 
4.2.6 Cell adhesion is altered in Myh9 and Myh10 ablated podocytes.  
Podocyte adhesion to the glomerular basement membrane is crucial for podocyte 
function, and non-muscle myosin II is suggested to participate in cell adhesion (Vicente-
Manzanares et al., 2009) Therefore, we quantified focal adhesions and performed cell 
attachment assays to investigate the effect of loss of NMHC IIA and IIB on podocyte 
adhesion.  First, cells were stained for localization of filamentous actin and vinculin to 
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localize and quantify focal adhesions (Figure 4.8A).  In control cells (UNTREATED, 
Myh9 CTRL and Myh10 CTRL), vinculin-stained focal adhesions were present 
throughout the cell and most prominently at the periphery (Figure 4.8A).  In contrast, 
focal adhesions in Myh9 KD cells appeared smaller, sparse, and were limited to the 
central region of the cell (Figure 4.8A). Myh10 KD cells exhibited strongly 
immunoreactive focal adhesions comparable to those seen in control cells, that were 
prominent at the periphery, but largely absent in the central region of the cell (Figure 
4.8A). Quantification of focal adhesions revealed significantly reduced vinculin 
immunostaining intensity in Myh9 KD cells relative to Myh9 CTRL cells, while vinculin 
intensity was significantly increased in Myh10 KD cells relative to Myh10 CTRL cells 
(Figure 4.8B).  A cell attachment assay revealed a significant reduction in cell attachment 
efficiency in both Myh9 KD and Myh10 KD cells, relative to control cells (Figure 4.8C). 
These data imply that NMHC IIA and IIB have differential but significant roles in the 
maintenance of focal adhesions and cell adhesion. 
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Figure 4.7. Myh9-ablated podocytes exhibit increased cell motility:  Results of “wound-
healing” assay performed to examine the effect of Myh9 and Myh10 ablation on 
podocyte motility.  Cells were prepared as described in Figure 4.2, except cells were re-
plated onto polystyrene cell culture plates on day 7 at appropriate density to achieve 
confluence on day 11 post-thermoshift.  For this assay, a uniform linear defect (“scratch”) 
was created in the cell monolayer on each plate on day 11.  Images of the scratched 
surface were obtained immediately after scratch placement, and 24 hours later.  Digital 
image processing was used to determine the proportion of the original defect covered by 
cells at 24 hr.  A)  Percentage of scratched area covered by cells at 24 hr for each of the 
five treatment groups described in Figure 4.2 (“UNTREATED”, “Myh9 CTRL”, “Myh9 
KD”, “Myh10 CTRL”, “Myh10 KD”).  Results presented as mean and standard deviation 
of two replicates (UNTREATED group composed of four replicates).  Myh9 KD cells 
exhibit significantly greater wound area coverage at 24 hours post-scratch, as compared 
to UNTREATED and Myh9 CTRL treatment groups.  Myh10 KD cells reveal no 
significant difference in wound area coverage compared to UNTREATED and Myh10 
CTRL treatment groups.   (B) Representative images of scratched surface for each of the 
five treatment groups, immediately after scratch placement (T=0) and 24 hours post-
scratch (T=24 hr).  Myh9 KD cells show the greatest wound area coverage at 24 hr. 
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p<0.0001 
p=0.003 
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Figure 4.8. Focal adhesion density and cell attachment are altered in Myh9 and 
Myh10 ablated podocytes:  (A) Epifluorescence micrographs (500x) of differentiated 
murine podocytes, cultured and treated with lentivirus as described in Figure 4.2.  Cells 
were stained for localization of filamentous actin (“F-ACTIN”), and vinculin 
(“VINCULIN”) to localize focal adhesions.  Untreated and control lentivirus-transduced 
cells reveal vinculin-associated focal adhesions at the ends of stress fibers and scattered 
throughout the cell, out to and most prominently at the cell periphery.  Focal adhesions in 
Myh9 KD cells also appear at the ends of stress fibers, but are generally smaller and less 
densely distributed in the cells, with very few adhesions apparent at the cell periphery.   
Focal adhesions in Myh10 KD cells appear comparable in size, distribution and density to 
control cells. (B) Quantification of focal adhesions.  Results of focal adhesion 
quantification determined from the average pixel intensity for each cell obtained from 
calibrated epifluorescence micrographs of vinculin staining.  Values are normalized to the 
mean of the untreated sample and represent the mean ± SEM of at least 26 cells.  
Vinculin intensity is significantly reduced in Myh9 KD cells relative to Myh9 CTRL 
cells.  In contrast, vinculin intensity in Myh10 KD cells is significantly increased relative 
to Myh10 CTRL cells.  (C) Cell attachment assay.  Results of cell attachment assay 
performed to investigate the effect of Myh9 and Myh10 ablation on podocyte adhesion.  
Cells were prepared as in Figure 4.2, except 500 cells from each treatment group were 
replated on day 11 into 24 well plates.  Three hours after plating, unattached cells were 
washed away with PBS, and remaining attached cells were fixed, stained with crystal 
violet, and counted. Values represent the mean ± SEM of the resulting cell counts for 
three replicates (seven replicates for UNTREATED group).  Ablation of both Myh9 and 
Myh10 resulted in a significant reduction in attached cells.   
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4.3 DISCUSSION 
Podocytes are uniquely characterized epithelial cells which aid in the filtration 
process in the kidney glomerulus. Much has been known about their function aided 
largely through the identification of genes associated with renal diseases. Various in vitro 
studies indicate the need for coordinated re-organization of cytoskeletal proteins for 
podocyte function. Genetic studies have identified SNPs in Myh9 the gene encoding non-
muscle myosin IIa to be associated with kidney disease 
As demonstrated in our studies, podocytes exhibit contractile forces and this is 
dependent on the coordinated arrangement of the actin cytoskeleton mediated by NMHC 
IIA. Knockdown of Myh9 significantly altered actin bundling or cytoskeletal structures, 
resulting in decreased traction of podocytes. We also observed fewer stress fiber and 
focal adhesion formation which may have contributed to the loss of traction. These 
findings are similar to previous studies in mouse embryonic fibroblasts in which traction 
force was decreased when NM IIA was knocked down (Cai et al., 2006). Initial studies 
have shown that force is proportional to the size of focal adhesions (Tan et al., 2003; 
Balaban et al., 2001). Through a myosin II driven mode, focal adhesions mature into 
elongated focal adhesions which interact with the actin-cytoskeleton needed for traction, 
explaining why loss of NM IIA results in decreased traction force in NM IIA KD 
podocyte cells. Myh10 expression levels did not change to compensate for the loss of 
Myh9 in podocytes. Myh10 KD in podocyte cells showed minimal loss of traction, 
suggesting NM IIB may also be involved in cell contractility to some degree. Myh10 KD 
in podocytes did not however influence focal adhesions and stress fiber formation, 
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consistent with earlier studies (Bridgman et al., 2001; Cai et al., 2006; Lo et al., 2004). In 
podocytes, NM IIA may be the main player in generating force through the formation of 
focal adhesions and stress fibers. Thus the absence of NM IIA due to NM IIA knockdown 
in podocyte cells, or treatment of cells with blebbistatin may prevent the maturation and 
growth of focal adhesions which are necessary for contractility. 
Treatment of cells with blebbistatin which results in loss of function of NM II 
isoforms resulted in almost a total loss in podocyte traction. This suggests that the 
difference in traction between blebbistatin treated cells and NM IIA KD cells may be as a 
result of residual NM IIA in KD cells or other myosins in KD cells involved in podocyte 
cell traction. Blebbistatin is known as a non-muscle myosin II specific inhibitor (Straight 
et al., 2003) and its influence on cell division, cell motility and cell contraction has been 
studied extensively in various cells (Liu et al., 2010; Guha et al., 2005; Zhang et al., 
2005; Calaminus et al., 2007; Salhia et al., 2008; Wang et al., 2008). The loss of 
contraction in blebbistatin treated cells emphasizes the importance of NMHC IIA activity 
for traction in podoctye cells. This is consistent with studies using blebbistatin on 
different cells as mentioned above. Reduced number of focal adhesions was observed 
after blebbistatin treatment by immunostaning for vinculin, a focal adhesion marker. In 
addition, the contractile apparatus was disorganized in blebbistatin treated podocyte cells 
with NMHC IIA immunostaining observed in the periphery of cells. These findings are 
potential contributors to the reduced podocyte contractility observed in the presence of 
blebbistatin.  
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The formation of actin filament and maturation of focal adhesions is mediated by 
RHOA signaling resulting in increased contractility and decreased motility. RHOA 
signaling results in further activation of non-muscle myosins thus increased formation of 
actomyosin bundles and reduction in Rac signaling which mediates cell motility. 
Lysophosphatic acid, an agonist for RHOA was used to assess podocyte traction in the 
absence of Myh9. As observed, treatment of podocytes with LPA in the absence of Myh9 
did not rescue podocyte contractility. This may because RHOA activation is 
compromised in the absence of Myh9 or RHOA signaling for traction generation requires 
NMHCIIA. Treatment of podocyte cells harboring Myh9 with LPA resulted in a slight 
increase in cell traction although not significant. This suggests that podocyte contraction 
primarily depends on the presence of the non-muscle myosin IIa and may be independent 
of RHOA activation although this will need to be confirmed either by knocking down 
RHOA or using RHOA inhibitors.  
The morphological changes observed in Myh9 KD cells included cells spreading 
more widely on the substrate as compared to controls and Myh10 KD cells. This is 
consistent with finding by Cai et al, 2006, in fibroblasts. This suggests that NM IIA may 
be necessary for intracellular tension by pulling in the actin cytoskeleton, thus, restraining 
the cell from spreading. With loss of Myh9 in podocytes, cells lose their ability to 
contract and spread more widely on the substrate.  
Previous studies have shown that for cells to contract effectively, they need to 
attach to the extracellular matrix (ECM) through the integrin-mediated cell focal 
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adhesions (Lauffenberg and Horwitz, 1996) which connect the actin cytoskeleton and the 
ECM.   
Although podocyte cell spreading may be distinct from podocyte effacement in 
vivo, studies by Ma et al., 2010, showed that podocytes foot process effacement 
correlated with spreading of podocytes isolated from focal adhesion kinase knockout 
mice. This suggests that podocyte spreading in vitro might correspond to foot process 
effacement in vivo. In the same study, podocyte migration correlated with foot process 
effacement. Increased podocyte migration is likely to imply increased foot process 
effacement. In our studies, Myh9 knockdown in podocyte cells resulted in increased cell 
migration as compared to control cells. This finding of increased migration is similar to 
studies in NM IIA KO embryonic stem cells and NM IIA knockdown human fibroblast 
cells (Even-Ram et al., 2007). In podocytes, NM IIA may be necessary for opposing 
cellular migration and contributing to cellular contractility. As observed in this study, 
NM IIA loss resulted in less stress fibers and focal adhesions which may contribute to 
cell migration due to weakened attachment of cells to extracellular matrix. NMIIA 
expression has been identified to be decreased in glomeruli of human FSGS and HIVAN 
patients, disesases in which podocyte foot process effacement is a distinct feature. It 
could be suggested that the loss of NMIIA may contribute to increased podocyte 
migration observed as foot process effacement in these disease processes. 
The glomerular experiences an amount of pressure (60mmHg) while performing 
its function of blood filtration. Increase in urinary protein is a reflection of altered 
glomerular filtration due to perhaps altered glomerular structure stemming from increased 
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glomerular pressure. The function of podocytes has been uncovered through the 
observation of disrupted podocyte slit diaphragm, a characteristic feature in patients with 
focal segmental glomerulosclerosis (FSGS) who also exhibit heavy proteinuria. It is 
therefore imperative that for podocytes to function well, ensuring efficient filtration and 
bolstering glomerular capillary walls during normal and increased pressured, there is the 
need for a well-structured cytoskeleton (Faul et al., 2007) of which NM IIA Is potentially 
required. NM IIA is expressed in most cells and tissues. The kidney is not an exception 
with expression observed in the endothelial cells of interlobular arteries and arterioles and 
peritubular capillaries, mesangial cells, glomerular endothelial cells, podocytes, and 
tubular cells. In our studies we show that NM IIA interacts with F-actin to result in 
contraction of the cytoskeleton to help in the maintenance of cell membrane tension and 
shape similar to other studies. In a study by Miura et al. 2013, reduction in NMHCII A 
expression has been observed in glomeruli of idiopathic nephrotic syndrome patients. In 
the same study, glomerular NMHC IIA expression was observed to be decreased in PAN 
treated rat kidneys. Hays et al., 2012, also showed that glomerular expression of Myh9 is 
reduced in HIVAN cases. Animal studies using podocyte specific knockout mice showed 
spontaneous development of histopathology similar to FSGS in mouse strains of a mixed 
background (Zhang et al., 2012) while mice on a C57BL/6 background were only 
susceptible to injury in the absence of podocyte Myh9 and presence of Adriamycin 
treatment. Together these findings show that podocyte Myh9 is important for maintaining 
glomerular function, by maintaining the integrity of actin cytoskeleton to help in 
generating the contractility necessary for either regulating the permeability of the 
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filtration barrier via foot process cellular changes, or resisting the high intraluminal 
hydrostatic pressure present in glomerular capillaries to prevent capillary expansion 
(Mundel and Kriz, 1995). These findings suggest that a loss of NMHC IIA may be 
involved in the pathogenesis of glomerular injury observed in FSGS cases. Intact actin 
cytoskeleton is also needed for signaling events stemming from the slit diaphragm as 
signals received in the slit diaphragm are transmitted through various adaptor proteins to 
the actin cytoskeleton (Noris and Remuzzi, 2012). 
Findings from our studies point to the fact that loss of podocyte Myh9 may 
correlate to increase podocyte effacement in the disesased models described above 
correlating with the increased podocyte migration in vitro in Myh9KD cells. As 
mentioned earlier, podocyte motility in vitro is associated with proteinuria in vivo. 
Arhgap24 knockdown or hyperactivation of alpha-v-beta-3 have been found to result in 
increased podocyte motility associating with FSGS in humans or proteinuria in mice 
respectively (Akilesh et al., 2011; Wei et al., 2008; Wei et al., 2011).  
Although the role of NMII A in the formation of actomyosin bundles required for 
cell cytoskeleton contraction has been studied in other cells, this is the first time we 
demonstate that loss of podocyte Myh9 influences podocyte contractility, shape and 
motility. Questions on how Myh9 expression is regulated during disease processes is still 
unknown. Although Rho and Rac pathway are well characterized mediators of cell 
contraction and motility respectively, podocyte contractility seems to be more dependent 
on NMHC IIA and thus the loss of NMHC IIA was not rescued by treatment of cells with 
LPA. We also show that Myh9 and Myh10 do not play redundant roles in podocytes at 
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least in relation to podocyte contractility and motility. Further molecular and functional 
understanding of Myh9 owing to its linkage to renal disease will provide more insight 
into podocyte biology and thus possibilities of developing therapeutics.  
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CHAPTER FIVE 
 Podocyte Specific MYH9 Deletion in C57BL/6 Mice Results in Increased 
Susceptibility to Glomerulopathy in Hypertensive DOCA-Salt Uninephrectomy 
Model 
5.1 Introduction 
Chronic kidney disease (CKD) affects about 11% of the adult population in the 
United States and has been linked to several complications including end stage kidney 
disease (ESKD), cardiovascular disease and often results in death (Coresh et al., 2003). 
With an increasing aging population correlating to an increase in the growing numbers of 
people at risk of developing CKD, the cost and burden of CKD on the economy will 
continue to increase. In 2010, the treatment cost for CKD and ESKD was over 40 billion 
dollars (NKUDIC, 2012). Current understanding of the mechanism of CKD pathogenesis 
and progression is limited, resulting in very little advance in therapeutic interventions.  
The most serious outcome of CKD is kidney failure (end stage kidney disease, 
ESKD) which is characterized by a dramatic reduction in kidney function, thus requiring 
dialysis or kidney transplantation. Loss in kidney function is accompanied by a 
compensatory response in the remaining functional glomeruli leading to elevated blood 
pressure in the renal glomeruli or glomerular capillary hypertension (GCH). Continuous 
GCH can eventually lead to irreversible glomerular damage contributing to CKD 
progression (Cortes et al., 1996). Podocytes, visceral epithelial cells surrounding the 
capillaries, form an integral part of the glomerulus and are required to bolster the 
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glomerular capillary walls against normal hemodynamic pressure (Kriz et al., 1994) and 
most likely under GCH conditions.  
Mutations in several podocyte proteins have been linked to glomerulopathy due to 
disruption in the podocyte slit diaphragm proteins (filtration barrier) and reorganization 
of the podocyte cytoskeletal structure (Faul et al., 2007). Previously, polymorphisms 
within MYH9, a gene encoding non-muscle myosin IIA (NMIIA) protein,  which is a 
mechano-enzyme with actin cross-linking and contractile properties, were associated with 
an increased risk of non-diabetic kidney disease mostly in the African-American 
population (Kop et al., 2008; Kao et al; Nelson et al., 2010). This association was later 
attributed to SNPs within APOL1, a neighboring gene known to have a stronger 
association with non-diabetic kidney disease. Nevertheless, SNPs within Myh9 have 
continued to be identified in association with other forms of renal disease such as type 2 
diabetic ESKD in European Americans (Cooke et al., 2012), and IgA nephropathy in a 
large Chinese cohort (Cheng et al., 2011). In addition, altered NMIIA distribution and 
expression have been observed in podocytes exposed to plasma from FSGS patients 
(Babayeva et al., 2011) and podocytes transduced with HIV-1 respectively (Hays et al., 
2012).  
Given the strong association between MYH9 and kidney disease, the defined role 
of MYH9 in a number of cells, and its expression in podocytes, we hypothesize that loss 
of podocyte NMIIA may result in increased susceptibility to glomerulopathy under GCH 
conditions. We examined glomerular NMIIA expression in FSGS kidney biopsies and 
observed a reduction in expression compared to normal kidney tissues. Next, we 
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determined the effect of the loss of podocyte MYH9 on the pathogenesis of renal disease 
in C57BL/6 mice experiencing GCH caused by reduced renal mass (uninephrectomy) and 
increased blood pressure (stimulated by Deoxycorticosterone acetate and 1% salt 
treatment). This strain has been found to be resistant to renal injury. We show that 
podocyte MYH9 is lost during FSGS and that lack of podocyte MYH9 results in 
increased susceptibility to glomerulopathy C57BL/6 mice under GCH conditions.  
5.2 Results 
5.2.1 Glomerular Myh9 expression is reduced in human FSGS  
To show a pathogenic role of Myh9 in renal disease and specifically in the pattern 
of kidney disease observed in hypertensive driven nephropathy (focal segmental 
glomerulosclerosis (FSGS)), we examined non-muscle myosin IIA expression by 
immunohistochemistry in normal human kidney tissues from nephrectomy samples 
(n=23) and in kidney biopsies from subjects with FSGS (n=11). Consistent with previous 
studies (Miura et al., 2013), intensity scores of non-muscle myosin staining in glomeruli 
of FSGS samples was significantly reduced (p<0.0001) compared to glomeruli in normal 
kidney sections (Figure 5.1), suggesting a potential role of NMIIA in renal disease 
pathogenesis. 
5.2.2 Systemic blood pressure increases in normal C57BL/6 mice and podocyte 
specific Myh9 knockout mice 
The C57BL/6 mouse strain is resistant to chronic kidney disease. Initial studies 
have indicated that podocyte specific deletion of Myh9 in C57BL/6 mice does not result 
in the development of kidney disease either spontaneously or in models of kidney disease 
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such as treatment of mice with sheep nephrotoxic serum or puromycin (Johnstone et al., 
2011; Johnstone et al., 2013). However, podocyte-specific deletion of Myh9 C57BL/6 
mice are hypersensitive to kidney injury in response to Adriamycin (Johnstone et al., 
2011) and to the Tg26 model of HIVAN (Johnstone et al., 2013). We generated 
podocyte-conditional Myh9 knockout mice using the Cre-lox system by crossing existing 
C57BL/6 “floxed” Myh9 mice (loxP sites flanking the ATG-containing exon 2) with 
C57BL/6 mice expressing Cre recombinase under control of the podocin promoter. 
Podocin is a glomerular slit-diaphragm protein with expression beginning during fetal 
development and limited to podocytes; thus Cre recombinase is only expressed in 
podocytes. Double heterozygous F1 offspring (Cre/wt; Myh9flox/wt) were crossed with 
Myh9 flox/wt resulting in Cre/wt;Myh9 flox/flox (podocyte-specific knockout mouse 
Cre+;Myh9flox/flox) and three other genotype combinations serving as controls for the 
study (Cre+;Myh9 wt/wt, Cre-;Myh9 flox/flox, Cre-;Myh9 wt/wt). Similar to previous 
studies, podocyte-specific Myh9 knockout mice were viable into adulthood and exhibited 
no gross or microscopic abnormalities in the kidney compared to their control littermates 
(data not shown).  Podocyte specific knockout was confirmed by immunohistochemistry 
on kidney sections and immunoblot analysis as shown in figure 5.3. Cre+;Myh9flox/flox 
mice showed absence of staining in podocytes.  
Elevated blood pressure in the kidney glomeruli (glomerular capillary 
hypertension (GCH)) is a distinctive feature of progressive chronic kidney disease. We 
hypothesized that podocyte NMIIA is essential for maintenance of podocyte function and 
glomerular intergrity when GCH develops. Therefore, loss of podocyte NMIIA will 
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increase susceptibilty to kidney damage in the presence of glomerular capillary 
hypertension (induced by systemic hypertension in this case). Hypertension was induced 
in mice using the deoxycorticosterone acetate (DOCA)-salt uninephrectomy hypertensive 
model. In this model, central hypertension potentiates the compensatory hyperfiltration 
response of nephrons in the remaining kidney to the loss of nephrons from 
uninephrectomy, thereby subjecting glomeruli in the remaining kidney to significantly 
elevated perfusion pressures. A previous study has shown a correlation between systolic 
blood pressure and GCH (Gabbai et al., 1996). Systolic blood pressure (SBP) was 
measured indirectly by tail-cuff measurements to observe if loss of podocyte Myh9 was 
enough to alter blood pressure measurements compared with control mice. Prior to 
DOCA-salt treatment, blood pressure was similar in both control and podocyte Myh9 
knockout mice. Blood pressure measurements did not change in sham treated mice 
(Figure 5.4A). As observed in Figure 5.4B, regardless of the genotype, in the 
uninephrectomized DOCA-salt treated mice, SBP was significantly elevated  one week 
post treatment. This result suggests that the presence or absence of podocyte Myh9 does 
not alter systemic blood pressure in C57BL/6 mice undergoing uninephrectomy and 
DOCA salt treatment. 
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Figure 5.1. Immunohistochemical staining reveals reduced expression levels of NMIIA 
in glomeruli of human FSGS biopsies: (A&B) The expression level of NMIIA is 
markedly decreased in glomeruli in FSGS biopsies (B) as compared to glomeruli in non-
diseased samples (A). (C) Intensity scores for NMIIA expression in normal and FSGS 
glomeruli in each patient determined by quantitative densitometric analysis of glomeruli 
shows a significant decrease in staining intensity in glomeruli of FSGS biopsies. 
(***:p<0.0001) 
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Figure 5.2. Timeline for mouse deoxycorticosterone acetate (DOCA) uninephrectomy 
treatment: Left uninephrectomy was performed on 10-12 week-old, C57BL/6, podocyte-
specific Myh9 knockout (KO) mice (Cre+; Myh9flox/flox) and controls (Cre+; 
Myh9wt/wt; Cre-; Myh9flox/flox).  The mice also received a timed-release DOCA pellet 
(150 mg/60 days) (Innovative Research of America, Sarasota, FL) implanted 
subcutaneously between the scapulae.  The mice were given 1% NaCl solution and fed 
standard chow for 6 weeks. Sham operated mice of the same genotype profile underwent 
left uninephrectomy on week 0 and received tap water for 6 weeks.  On a weekly basis 
during the experiment, systolic blood pressure (SBP) was obtained indirectly by tail-cuff 
measurements (BP-2000, Visitech Systems), and urine was collected for measurement of 
urine protein.  At week 6, all mice were anesthetized with isoflurane, and final blood and 
urine samples were collected, and the heart and kidney were harvested for experimental 
analysis.  
0 week 
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Figure 5.3. MYH9 expression is decreased in glomeruli from podocyte specific Myh9 
knockout mice: (A) Diagram illustrating algorithm used to generate podocyte-specific 
Myh9 knockout mice from double heterozygous Cre+ Myh9 floxed mice and Cre-Myh9 
floxed mice. (B) PCR analysis of genomic DNA extracted from tail clippings of 
Cre+;Myh9flox/flox (“fl/fl”, 1600 bp), Cre+;Myh9wt/wt (“wt/wt”, 1500 bp), and 
Cre+;Myh9flox/wt (“fl/wt”, both 1500bp and 1600bp product) mice. (C) Western blot 
analysis of glomerular cell lysates obtained from Cre+;Myh9flox/flox (KO) mice and 
Cre+;Myh9wt/wt (Ctrl) mouse immunoblotted with α-NMIIA and β-actin. (D) 
Representative images of glomeruli from Cre+;Myh9flox/flox (KO) and 
Cre+;Myh9wt/wt (Ctrl) mice, as seen in FFPE sections immunostained for NMIIA.  KO 
tissue shows a mesangial pattern of staining (arrowheads) and absence of staining in 
podocytes (arrows); whereas Ctrl tissue shows podocyte staining (arrows) as well as 
mesangial staining (arrowheads). 
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Figure 5.4. Systolic blood pressure is significantly increased in podocyte specific Myh9 
knockout mice and controls following uninephrectomy and deoxycorticosterone acetate 
(DOCA)-salt treatment, compared to sham operated mice: Podocyte-specific Myh9 
knockout (KO) mice (Cre+;Myh9flox/flox) and controls (Cre+;Myh9wt/wt, Cre-
;Myh9flox/flox, Cre-;Myh9wt/wt), all on a C57BL/6 background, underwent left 
uninephrectomy and timed-release DOCA pellet implantation. The mice were given 1% 
NaCl solution and fed standard chow for 6 weeks. Sham-treated mice of the same 
genotype profile underwent left uninephrectomy and received tap water. Systolic blood 
pressure (SBP) was measured weekly via tail cuff measurement. (A) Sham-treated mice 
do not show a significant increase in systolic blood pressure over time, irrespective of the 
mouse genotype (p=nonsignificant at 6weeks). (B) Uninephrectomy followed by DOCA-
salt treatment resulted in an increase in systolic blood pressure weeks after treatment in 
all mice groups (p<0.05 at 6weeks).  Bars are standard error of the mean; n=at least 3 
mice per genotype group at each time point. 
A 
B 
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5.2.3 Urine protein and nephrin levels increase in podocyte-specific Myh9 knockout 
mice subjected to DOCA-salt uninephrectomy.  
The above results suggest that the DOCA-salt uninephrectomy procedure 
produced GCH in all genotypes. A clinical feature of glomerular damage is albuminuria. 
We therefore examined if the loss of podocyte Myh9 and uninephrectomy DOCA-salt 
treatment correlated with proteinuria levels.  Urine samples were collected at various 
time points pre- and post-DOCA-salt uninephrectomy using custom cages. Urinary 
albumin-creatinine ratio (an estimator of urinary protein loss), and nephrin levels 
(nephrinuria), were obtained using enzyme-linked immunosorbent assay (ELISA) test 
kits. Urinary albumin-creatinine ratio in podocyte-targeted Myh9 knockout mice was 
significantly elevated compared with the control mice as early as one week post-
nephrectomy, relative to levels measured pre-procedure. In Cre+;Myh9flox/flox mice, 
albumin-creatinine ratio continued to increase over weeks 2, 5 and 6 (Figure 5.5A). 
Urinary nephrin excretion has been associated with glomerular disease pathogenesis. In 
this study, a peak in urine nephrin excretion was observed at week 3 and 4 and declined 
afterwards (Figure 5.5B). The initial increase in albunuria (proteinuria) at week one post-
nephrectomy could thus be attributed to loss of Myh9 in podocytes. The presence of 
nephrin in urine seen at week 3 and 4 could correspond to a significant loss of podocytes 
at those time points. These results suggest that loss of Myh9 in podocytes results in 
altered glomerular function (as measured by proteinuria levels) during GCH in mice 
lacking podocyte Myh9. 
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Figure 5.5. Proteinuria and nephrinuria develop in podocyte-specific Myh9 KO mice 
following DOCA-salt uninephrectomy treatment: Podocyte-specific Myh9 knockout 
(KO) mice (Cre+;Myh9flox/flox) and controls (Cre+;Myh9wt/wt, Cre-;Myh9flox/flox, 
Cre-;Myh9wt/wt) were subjected to DOCA-salt uninephrectomy, as described in Fig 5.4.  
Urine was collected weekly, and albumin, creatinine, and nephrin were quantified by 
ELISA. Urine albumin data are presented as albumin/creatinine ratio. (A) Podocyte-
specific Myh9 knockout mice developed significant albuminuria by week 1 post 
treatment (**p<0.005) compared with all control genotypes.  Urine albumin/creatinine 
levels continued to increase in Myh9 KO mice over the course of the study (*=p<0.05, 
***=p<0.0007; #p<0.05 compared to Cre-;Myh9flox/flox and Cre-;Myh9wt/wt; 
comparison with Cre+;Myh9wt/wt was not statistically significant at 6 weeks). (B) 
Urinary nephrin excretion (a marker of podocyte injury) was significantly increased in 
Myh9 KO mice at the 3
rd
 and 4
th
 week as compared to control mice as quantified by 
ELISA (**=p<0.005).  A decline in urinary nephrin to control levels was observed in 
Myh9 KO mice by the 5
th
 week.  Bars are standard error of the mean; n=at least 3 mice 
per genotype group at each time point. 
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5.2.4 Podocyte-specific Myh9 knockout mice subjected to DOCA-salt 
uninephrectomy model of glomerular hypertension develop severe glomerular 
disease.  
With the significant differences in kidney function as assessed by proteinuria 
levels, we determined if these findings correlated with histological changes. Six weeks 
after DOCA-salt uninephrectomy, the remaining kidneys were harvested and processed 
for light microscopic examination and examined. Podocyte Myh9 knock out (KO) mice 
showed evidence of significant glomerular injury as compared to the control groups by 
periodic acid schiff (PAS) staining (Figure 6A). These lesions include global (GS) and 
segmental (SS) glomerulosclerosis with or without evidence of epithelial proliferation. 
Other glomeruli showed global (GP) or segmental (SP) proliferation without evidence of 
sclerosis. Glomeruli within the juxtaglomerular region were predominantly injured. As 
shown in figure 6A the kidneys in these mice also showed numerous tubular microcysts 
and PAS positive casts, and focal tubular epithelial protein reabsorption, all of which are 
known secondary features of severe podocyte injury. Of note, the control mice belonging 
to the Cre+/wt; Myh9 wt/wt showed some minor histopathlogy compared to Cre negative 
controls. Significant renal fibrosis was also observed in Cre+;Myh9flox/flox unix 
DOCA-salt treated mice (Figure 6B and 6C) using Masson trichrome staining. 
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Figure 5.6. Podocyte-specific Myh9 knockout mice subjected to DOCA-salt 
uninephrectomy model of glomerular hypertension develop severe glomerular disease. 
(A) Microscopic images from periodic acid-Schiff (PAS)-stained kidney sections from 
podocyte-specific Myh9 knockout (KO) mice (Cre+;Myh9flox/flox) and controls 
(Cre+;Myh9wt/wt, Cre-;Myh9flox/flox, Cre-;Myh9wt/wt) 6 weeks after initiation of 
DOCA-salt uninephrectomy treatment, as described in Fig 5.4.  Left and right columns 
are 100x and 400x absolute magnification, respectively. The figure shows evidence of 
significant glomerular injury in Myh9 KO mice, compared to controls. Top row: Periodic 
A 
B 
C 
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acid-Schiff (PAS) kidney sections in Myh9 KO mice show heterogeneous 
tubulointerstitial and glomerular lesions. These lesions include numerous tubular 
microcysts with PAS-positive casts (left image, “*”), focal tubular epithelial protein 
reabsorption, focal tubular atrophy and interstitial fibrosis, and global (GS) and 
segmental (SS) glomerulosclerosis, with (right image, arrowhead) or without (right 
image, arrow) evidence of epithelial proliferation. These features are rarely seen in 
kidneys of control mice (bottom three rows). (B) Results of quantification of 
tubulointerstitial and glomerular lesions in Myh9 mice and controls.  PAS-stained kidney 
sections were evaluated blindly and scored as the percentage of affected glomeruli for 
glomerular lesions, including global sclerosis (GS) and segmental sclerosis (SS), and 
average percentage of cortical area affected for tubular injury (TI).  Bars are mean values 
of at least 3 mice, and error bars represent standard error of the mean. **p<0.001; 
***p<0.0001. (C) Representative images of Masson’s trichrome-stained sections of 
kidney tissues from Myh9 KO and representative control (Cre+;Myh9wt/wt) mice. KO 
mice show increased fibrosis (blue stain), in both glomerular and tubulointerstital 
compartments, as compared to control mice.  Images shown at 100x absolute 
magnification. 
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5.2.4 Loss of podocyte Myh9 causes alteration of loss of foot process architecture in 
DOCA-salt uninephrectomy treated mice 
Ultrastructural analysis of podocyte-specific Myh9 KO mice by transmission 
electron microscopy revealed segmental foot process effacement and mesangial 
expansion in podocyte-specific Myh9 KO mice, while control mice showed intact foot 
processes and less mesangial expansion (Figure 5.7). Intact foot processes were observed 
in the knockout mice as well, with surrounding foot processes showing significant loss of 
slit diaphragms. These results suggest that the absence of Myh9 expression in podocytes 
results in loss of podocyte structure, impacting podocyte function thereby making the 
podocyte and glomerulus vulnerable to injury in glomerular hypertensive states.  
5.2.5 Loss of podocyte Myh9 alters expression of slit diaphragm and cell adhesion 
proteins 
Because the slit diaphragm is considered an essential element of the filtration 
barrier, and with the observed loss of foot processes in tissues at the ultrastructural level, 
we assessed intrinsic damage to the slit diaphragm using podocyte specific markers. In 
comparing non-uninephrectomy DOCA-salt treated mice, podocin and nephrin 
expression and distribution levels were not different. On the other hand, podocin and 
nephrin expression levels were significantly downregulated within glomeruli of podocyte 
Myh9 mice subjected to uninephrectomy DOCA-salt treatment compared to control mice 
subjected to uninephrectomy DOCA-salt treatment (Figure 5.8A and 5.8B). Nephrin 
expression in the KO mice correlated with urine nephrin levels measured and was also 
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indicative of podocyte injury. In addition loss of nephrin and podocin was consistent with 
loss of podocyte and podocyte slit diaphragms as observed during ultrastructural analysis.  
Next, we tested the hypothesis that Myh9 deficient podocytes in the presence of 
podocyte stress was linked with altered expression of cellular alpha actinin 4 and integrin 
like kinase. Alpha actinin 4 is an actin bundling protein highly expressed in podocytes. 
Dandapani et al., 2007, showed that podocyte adhesion is dependent on α-actinin-4 and 
integrins under shear stress. Loss of α-actinin-4 was associated with decreased podocyte 
adhesion during shear stress. Podocyte depletion of integrin linked kinase (ILK), a 
protein responsible for regulating integrin, results in podocyte foot process effacement 
and loss of slit diaphragm followed with progression to unselective proteinuria (El-Aouni 
et al., 2006). Immunohistochemistry analysis of kidney tissues from 6 weeks post 
uninephrectomy DOCA-salt treated mice revealed significant loss of alpha actinin 4 and 
integrin linked kinase in KO mice in contrast with control mice exposed to 
uninephrectomy DOCA-salt induced hypertension (Figure 5.8A and 5.8C).  
These immunohistological and ultrastructural findings are consistent with the 
proteinuria and nephinuria findings observed. 
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Figure 5.7. Podocyte-specific Myh9 knockout mice subjected to DOCA-salt 
uninephrectomy show ultrastructural features of glomerular injury in viable (non-
sclerosed) glomeruli: Electron microscopic images from EM-processed kidney sections 
from podocyte-specific Myh9 knockout (KO) mice (Cre+;Myh9flox/flox: top row) and 
representative control (Cre+;Myh9wt/wt: bottom row), 6 weeks after initiation of DOCA-
salt uninephrectomy treatment, as described in Fig 5.4.  Left and right columns are 3000x 
and 12000x absolute magnification, respectively.  Analysis of Myh9 KO mice (top row) 
reveals segmental foot process effacement (inset) and mesangial expansion (arrows), 
while control mice (bottom row) show intact foot processes (inset) and less pronounced 
mesangial expansion. 
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Figure 5.8. Podocyte-specific Myh9 knockout mice subjected to DOCA-salt 
uninephrectomy show altered glomerular distribution of podocyte-associated proteins 
in viable (non-sclerosed) glomeruli: Paraffin sections of kidneys collected from Myh9 
KO and control mice treated with DOCA-salt uninephrectomy, as described in Fig 5.4, 
were stained with antibodies to alpha actinin-4, podocin, nephrin, and integrin-linked 
kinase 1.  In all cases staining was observed to be focally reduced, either globally or 
segmentally, in the viable (non-sclerosed) glomeruli of Myh9 KO mice, compared with 
control mice. (A) Epifluorescence images of alpha actinin-4 (left column) and podocin 
(right column) immunostained kidney sections taken from Myh9 KO (top row) and 
control (bottom row) mice.  Staining is globally (left arrow) or segmentally (right arrow) 
absent in viable glomeruli in Myh9 KO specimens, whereas staining is diffuse and global 
in control specimens. Images collected at 200x absolute magnification. (B) Quantification 
of the glomerular area showing positive staining of alpha actinin-4 and podocin in Myh9 
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and control mice.  Staining was graded semi quantitatively on a scale of 0 to 4 (0=no 
antibody staining; 1=25% or less; 2=25%-50%; 3=50%-75%; 4=>75% of glomerular area 
stained), and the total number of glomeruli for each score category was counted.  Data 
are presented as a percentage of the total number of glomeruli evaluated per sample 
section/s; data represents the mean±SEM for at least 3 samples for each group.  More 
than 50% of glomeruli from uninephrectomy DOCA salt treated podocyte specific Myh9 
KO mice show a loss of staining in alpha actinin-4 or podocin, whereas controls show 
global staining in at least 75% of glomeruli. *p<0.05; **p<0.005; ***p<0.0005; ns non 
significant 
 
 
 
 
 
 
 
 
(C) Brightfield images of nephrin-immunostained kidney sections taken from Myh9 KO 
(top row) and control (bottom row) mice.  Images show widespread loss of nephrin 
staining in viable glomeruli (arrow) in Myh9 KO specimen (left, top row), whereas 
control specimen (left, buttom row) shows strong, diffuse, global staining in peripheral 
capillary walls of glomeruli.  Images collected at 200x absolute magnification.  (D) 
Brightfield images of murine kidney sections taken from Myh9 KO (right, top row) and 
control (right, bottom row) mice, and immunostained for integrin-linked kinase-1 (ILK-1) 
showing loss of ILK-1 in viable glomeruli (arrow) in Myh9 KO specimen (right, top 
row), whereas control specimen (right, bottom row) shows strong, diffuse, global staining 
in peripheral capillary walls of glomeruli. Images collected at 200x (left column) and 
600x (right column) absolute magnification. 
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5.2.6 Podocytes lacking Myh9 exhibit increased cell motility 
After uninephrectomy DOCA-salt treatment, the increase in podocyte foot process 
effacement suggests that NMIIA might play an integral role in podocyte cell motility 
which has been suggested to correlate with foot process effacement. To address the role 
of NMIIA in podocyte motility, we performed a wound healing assay with primary 
control and KO podocytes. We harvested glomeruli from control mice and podocyte-
specific Myh9 KO mice using the sieving method to produce primary podocytes. We next 
performed a wound-healing assay on a monolayer of Cre+;Myh9wt/wt or 
Cre+;Myh9flox/flox primary podocyte cells. In comparison to Cre+;Myh9wt/wt primary 
podocytes, Cre+;Myh9flox/flox primary podocytes showed significant decrease in wound 
closure 12 hours after generation of wound (Figure 5.9). This suggests that NMIIA is 
involved in regulation of podocyte migration and its loss results in increased migration, 
favoring podocyte foot process effacement and the resultant proteinuria. 
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Figure 5.9. Primary podocytes isolated from podocyte-specific Myh9 knockout mice 
exhibit increased cell motility.  A wound healing assay was performed on a confluent 
monolayer of primary podocytes cultured from isolated glomeruli obtained from 
podocyte-specific Myh9 KO (Cre+;Myh9flox/flox) mice and control (Cre+;Myh9wt/wt) 
mice as described in detail in Methods. A uniform linear defect (“scratch”) was created in 
confluent cell monolayer on each plate and a reference mark was placed nearby to 
facilitate overlaying images for image processing.  Digital image processing was used to 
determine the proportion of the original defect covered by cells at 6 and 12 hrs.  (A) 
A 
B 
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Representative images of the scratched surface at 0, 6 and 12 hours after scratch. (B) 
Quantification of wound area coverage shows that primary podocytes from 
Cre+;Myh9flox/flox show the greatest wound area coverage at 6 and 12 hours, implying 
that Myh9 KO podocytes exhibit increased motility.  Data shown is the mean±SEM for 
each group. *p<0.05. 
5.3 Discussion 
MYH9 encodes for the protein non muscle myosin IIA. Multiple disease-
associated SNPs within the Myh9 gene have been linked to increased susceptibility to 
renal disease despite being predominant in the intronic regions of the genes (Kao et al., 
2008; Kopp et al., 2008). Recent findings identified potential causal variants within the 
adjacent APOL1 gene to be strongly associated with non-diabetic CKD than MYH9 in 
African Americans (Genovese et al., 2010). Regardless, autosomal dominant disorders 
have been linked to mutations within human MYH9 (Seri et al., 2000; Kelley et al., 
2000). These autosomal disorders include May-Hegglin, Fechtner, Sebastian and Epstein 
syndromes all characterized by macrothrombocyopenia and granulocyte inclusion bodies. 
Deafness, cataracts, and severe glomerulosclerosis progressing to end stage renal disease 
ensue in some patients later. Despite the controversies surrounding mutations in MYH9 
there is still a potential role for MYH9 in podocyte function especially since podocytes 
express high levels of MYH9 and MYH9 functions in cellular contractility, a function 
essential for podocyte biology and function. 
CKD involves the loss of renal functional mass. The remaining functioning 
kidney therefore has to compensate for the loss, eventually leading to elevated blood 
pressure in the renal glomeruli (glomerular capillary hypertension (GCH)). This 
compensatory effect could eventually lead to irreversible glomerular damage resulting in 
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progression of CKD (Hostetter et al., 2001). The DOCA-salt hypertensive model has 
been identified to result in glomerular hypertension, in the process leading to extreme 
expansion of many capillary loops reflecting increased expansile forces (Iverson and 
Ofstad, 1987; Dworkin et al., 1984). The podocytes have been identified to be the initial 
target of GCH (Kretzler et al., 1994). In addition to podocytes maintaining the filtration 
capacity of the glomeruli, they are also essential in bolstering the capillary walls against 
GCH (Kriz et al., 1994), a function which may require an efficient contractile apparatus 
in the podocytes. Normal looking interdigitating foot processes are observed under 
DOCA-salt treatment conditions in rats (Kriz et al., 2013). We therefore hypothesized that 
under normal glomerular capillary pressures, intact podocyte foot processes are able to 
resist wall tension; however under increased GCH, loss of podocyte contractility due to 
loss of Myh9 results in glomerulopathy. 
Initial studies have shown that podocyte specific deletion of MYH9 in C57BL/6 
mice does not lead to spontaneous glomerulosclerosis but in the presence of a secondary 
insult (Johnstone et al., 2011). The key finding in our study is that the absence of 
podocyte MYH9 in the presence of increased glomerular blood pressure results in 
glomerulopathy associated with tubular changes. Mice with ablated MYH9 within 
podocytes and exposed to high blood pressures showed focally sclerosed glomeruli 
similar to those observed in human hypertensive driven nephropathy and FSGS, which 
are both renal diseases initially linked to mutations in Myh9. In addition, significant 
glomerular ultrastructural changes were observed, particularly foot process effacement. 
We also observed a significant reduction in NMIIA protein expression in human FSGS 
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kidney biopsies compared to normal kidney sections. This finding is similar to findings 
by Miura et al., 2013, who showed decreased glomerular NMIIA expression in FSGS 
kidneys and Hays et al., 2012, who also show decreased glomerular NMIIA in HIV-
associated nephropathy (HIVAN) kidneys. With loss of podocyte MYH9, it could be 
suggested that reduction in MYH9 expression during kidney disease process might favor 
progression of CKD as a result of the loss of podocyte contractility needed to maintain 
glomerular capillary walls in remaining functional glomeruli experiencing higher work 
load. Although we have not proved podocyte contractility or its loss in vivo, we have 
showed in vitro that podocytes are contractile cells, and this contractility is reduced when 
MYH9 is ablated (Chapter 4).  
Of particular interest was the significant increase in primary cell motility in the 
absence of endogenous MYH9. In vitro, it has been observed that stimuli that cause 
podocyte foot process effacement also result in podocyte hypermotility using cell 
migration assays (Mundel and Reiser, 2010; Reiser et al., 2004). Podocyte cell motility in 
vitro has thus been linked to dynamic restructuring of podocyte foot process structure 
favoring foot process effacement in vivo (Mundel and Reiser, 2010). Our finding of 
increased cell motility in primary cells lacking Myh9 in vitro supports the hypothesis that 
Myh9 is important in regulating cellular migration, and its absence renders podocytes 
more motile in vivo resulting in foot process effacement. In several studies, NMIIA has 
been identified to influence cell migration, especially in polarized migration of different 
cells (Pecci et al., 2006; Jacobelli et al., 2004; Huang et al., 2009; Even-Ram et al., 2007; 
Sandquist et al., 2006; Wang et al., 2010; Kolega, 2006). 
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Off-note were histological changes observed in Cre+,Myh9wt/wt uninephrectomy 
DOCA-salt treated mice. There are a number of explanations for this, based on studies 
using the Cre lox system. The Cre transgene has been identified to exert deleterious 
effects especially in the absence of exogenous LoxP sites. Cre transgenes can act on 
cryptic or pseudo-LoxP like sites in the genome of the target cell in which it is expressed. 
Overexpression of the Cre transgene in post mitotic spermatids, for example, has been 
found to result in chromosomal abnormalities (Schmidt et al., 2000; Adams and van der 
Weyden, 2001). In this study, Cre alone without Myh9 Loxp sites did not create a 
phenotype; however, uninephrectomy DOCA-salt treatment resulted in a milder 
phenotype in the Cre positive control mice compared to KO mouse. To control for the 
expression of the Cre transgene, we generated podocyte Myh9 KO mice and control mice 
which harbored only one copy of the podocin Cre transgene.  We expect that this will 
rule out an overexpression of the Cre transgene and its side effects. Further studies are 
still needed to help explain the mild detrimental effects observed in Cre transgene 
expression in mice exposed to uninephrectomy DOCA-salt treatment.  
Alterations of components that make the slit diaphragm are known to play a role 
in the development of proteinuria. Localization of the slit diaphragm proteins most likely 
requires anchoring mechanisms which may need a well-structured actin cytoskeleton. 
Studies have shown an interaction of slit diaphragm proteins with the actin cytoskeleton 
in podocytes in vitro and in vivo (Yuan et al., 2002; Saleem et al., 2002; Welsch et al., 
2001). There were diminished staining levels of the slit diaphragm proteins nephrin and 
podocin in uninephrectomy DOCA-salt treated KO mice, supporting our hypothesis that 
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loss of podcoyte Myh9 in in the presence of stress alters actin bundling and subsequently 
slit diaphragm proteins. Of interest was the loss of alpha actinin 4, an actin bundling 
protein, in the KO hypertensive model supporting the hypothesis that the loss of Myh9 
impacts cytoskeletal structure and cytoskeletal proteins. The loss of these proteins may 
have been involved in CKD pathogenesis, but assessment of the proteins has to be made 
at an earlier time point in order to gain more insight, since at about 6 weeks we observe a 
lot of fibrosis. However, loss of nephrin, podocin and alpha actinin 4 have been 
associated with proteinuric diseases and similar observations were made in our study. 
NMIIA has been found to be involved in the regulation of adhesion through its 
actin bundling function. Podocyte loss has also been linked to glomerulopathy. In 
examining if loss of podocyte adhesion affects the disease process in podocyte Myh9 KO 
uninephrectomy DOCA-salt treated mice, we looked at the expression of integrin like 
kinase (ILK), a protein involved in the regulation of integrins Podocyte specific loss of 
ILK has previously been linked to proteinuria (El-Aouni et al., 2006). This suggests that 
in the absence of podocyte Myh9, cell to matrix adhesion may be altered be dysregulation 
of adhesion proteins. Once again, it must be emphasized that the expression of these 
proteins was examined in the latter stages of disease process, making it difficult to 
conclude whether the loss of these proteins is associated with mediating disease process 
or are just outcomes of the disease process. It must be mentioned that in the absence of 
hypertension however, expression of the slit diaphragm proteins, actin bundling proteins, 
and adhesion proteins examined was similar in both control and Myh9 KO groups. Loss 
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of podocyte Myh9 in the absence of stress was therefore not enough to impact the 
expression of these proteins.  
In conclusion, we have for the first time, examined the role of Myh9 deficient podocytes 
under glomerular capillary hypertension conditions. This study provides valuable insight 
into a pathogenic role of Myh9 loss under GCH conditions. The loss of a cellular 
cytoskeletal structure, slit diaphragm proteins, cell adhesion proteins and increased 
cellular migration may play a role in the pathogenesis of CKD in the absence of podocyte 
Myh9 and during increased glomerular pressure. 
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CHAPTER SIX 
6.1 Summary and Future Directions 
The overarching goal of this study is to increase our understanding of how the 
chromosome 22 haplotypes increase susceptibility to glomerular damage.  Despite 
significant findings associating sequence variants within the APOL1 and MYH9 genes 
with renal dysfunction, very little is known about the role of these genes in glomerular 
function, or the precise mechanism by which the genetic risk variants lead to kidney 
disease. An understanding of the contributions that these two genes play in renal 
dysfunction will lead to new approaches for the prevention of kidney disease, and 
potentially generate new or better therapeutic measures to treat kidney disease.  These 
new insights will be particularly important for the African American population and 
others of African ancestry, who are common carriers of these disease-associated 
haplotypes, and experience substantial disparity in kidney disease incidence in 
association with these haplotypes.  This study suggests several novel insights into the 
molecular and biological contribution of APOL1 and MYH9 to renal function and 
dysfunction. 
6.1.1 Role of APOL1 risk variants in kidney disease 
An important finding from this study is that APOL1 risk variant carriers do not 
show kidney morphological differences at the light microscopic level.  All compartments 
of the kidney were examined for this analysis, including the vasculature, 
tubulointerstitium, and glomeruli.  Specific features of glomerular alteration or damage 
associated with early adaptive FSGS, such as glomerular hypertrophy, were closely 
  
164 
examined, and no differences were found.  This result is important because it suggests 
that any functional differences associated with the APOL1 risk variants do not involve 
visible changes in cellular or tissue structure.   
Although morphologic differences are not evident, glomerular gene expression 
differences may explain why the population carrying 2 APOL1 kidney risk variants are at 
increased risk of renal failure compared to carriers of 0 or 1 APOL1 kidney disease risk 
variants.  From this study, carriers of 2 APOL1 kidney risk variants showed altered 
glomerular gene expression compared to carriers of 0 or 1 APOL1 kidney risk variants.  
Underscoring this, the risk group population showed a distinct gene expression pattern 
when unsupervised clustering analysis was performed with the gene expression data.  It 
therefore seems plausible that individuals carrying the APOL1 risk variant can be 
identified by their gene expression pattern.  In addition, exploratory analysis of the gene 
expression results showed potential in vivo pathways and individual genes that may be 
relevant in mediating renal dysfunction in this population.  
Some in vivo pathways identified in the study included the aldosterone signaling 
pathway, the Nrf2-mediated oxidative stress response pathway, and the IL-15 pathway, 
all of which have potential roles in mediating kidney disease. As discussed in Chapter 3, 
the aldosterone pathway plays an essential role in chronic kidney disease by influencing 
blood pressure.  Further, inhibitors against the aldosterone pathway are used to treat 
hypertension particularly among African Americans, who often do not to respond to 
RAAS inhibitors (Brewster et al., 2004; Flack et al., 2010).  The pathobiology of 
hypertension in African Americans has been linked to low plasma renin activity (PRA) 
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and low angiotensin-converting enzyme (ACE), which potentially tempers the use of 
therapeutics inhibiting these molecules in this population (Helmer and Judson, 1968; 
Opie and Seedat, 2005; Luft et al., 1991; Kaplan et al., 1976).   Therefore it will be 
essential to assess the response of patients harboring 2 APOL1 kidney risk variants to 
anti-hypertensives that target the renin-angiotensin aldosterone system (RAAS).   
The Nrf2 pathway is an essential cellular mechanism needed for combating 
oxidative and inflammatory stress. There is increasing evidence that the absence of 
molecules involved in the Nrf2 pathway play a role in kidney disease (Yoh et al., 2001; 
Liu et al., 2009; Yoh et al., 2008; Kim and Vaziri, 2010). Lack of Nrf2 activity may 
augment the oxidative and inflammatory response in the diseased kidney favoring disease 
progression (Kim and Vaziri, 2010). It is therefore possible that altered Nrf2 pathway in 
the kidney disease risk group may result in increased oxidative and inflammatory 
responses facilitating the disease process. Recent evidence suggests that targeting Nrf2 
could be a novel therapy in number of diseases (Zheng et al., 2011; Xue et al., 2008; 
Pergola et al., 2011; Jung and Kwak, 2010). These therapeutics could prove beneficial in 
treating kidney diseases. 
Future research directions which might be pursued based on our current findings 
include: 
6.1.1.1 Role of APOL1 kidney risk variants in modulating response to current 
kidney therapeutics 
Our current data shows an association between carrying 2 APOL1 kidney risk 
variants and gene expression patterns which affect both pathways targeted and not yet 
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targeted during treatment of kidney diseases, including the RAAS pathway and the Nrf2-
mediated oxidative stress response pathway. It is unclear whether carriers of 2 APOL1 
kidney risk variants respond differently to commonly used chronic kidney disease 
treatments.  Exploring this possibility will potentially be beneficial in improving 
prevention and treatment of renal dysfunction, particularly in African Americans. Studies 
examining the Nrf2 system as a potential therapeutic target in the risk population may 
prove beneficial. 
6.1.1.2 Gene expression changes in isolated podocytes from APOL1 kidney risk 
variant carriers 
Podocyte injury has been identified as a hallmark of FSGS and chronic kidney 
disease, thus identification of gene expression changes specific to this cell population will 
help identify novel genes and molecular pathways for further studies.  This will in turn 
help provide a better understanding of disease pathogenesis, and potentially lead to new 
treatment measures in the risk population. 
6.1.1.3 Gene expression changes in diseased kidneys from APOL1 kidney risk 
variant carriers 
This study focused on APOL1 haplotype-associated differences in glomerular 
gene expression in normal kidney tissues.  Characterization of APOL1 haplotype-
associated gene expression differences in diseased kidney tissue, particularly diseases 
involving podocyte injury, may lend additional insight into genes and pathways that are 
contributors to kidney disease pathogenesis in the risk population. 
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6.1.2 Role of Myh9 in podocyte biology 
The studies presented here show that Myh9 is required for maintenance of 
podocyte actin cytoskeletal and adhesion protein structure and organization, generation of 
podocyte traction, and restraint of podocyte motility in vitro.  Further, in vivo studies in 
mice lacking expression of nonmuscle myosin IIA and subjected to a remnant kidney 
model show that nonmuscle myosin IIA is not required in podocytes for maintenance of 
glomerular structure and function under normal conditions; but under conditions of 
hemodynamic stress, absence of nonmuscle myosin IIA from podocytes renders the 
glomeruli vulnerable to damage.  The juxtamedullary glomeruli are particularly 
vulnerable to damage in this model, which underscores the importance of pressure-
induced injury in this model, since these are the glomeruli that are subjected to the 
highest perfusion pressures.   Finally, immunohistochemical staining of FSGS-affected 
human kidneys showed evidence of decreased nonmuscle myosin IIA expression levels 
in structurally normal glomeruli. 
The results of the in vivo mouse studies suggest that nonmuscle myosin IIA is 
needed to protect the glomerulus from hemodynamic stress, and reduced quantities of 
nonmuscle myosin IIA render the podocyte vulnerable to injury.  Thus it may be 
speculated that anything that results in a reduction in nonmuscle myosin IIA in the 
podocyte could result in glomerular injury under conditions of hemodynamic stress.   
Hemodynamic stress in this case takes the form of increased glomerular perfusion 
pressure, which in turn results in increased wall tension in the glomerular capillary wall.  
Our working hypothesis is that nonmuscle myosin IIA is needed to generate cytoskeletal 
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tension and thereby maintain normal structural relationships in the complex foot process 
network, so that normal kidney ultrafiltration can continue, despite the increase in 
glomerular capillary pressure.  These studies appear to support this idea.    Another 
observation from these studies is that podocytes in Myh9-ablated mice subjected to the 
remnant kidney model appeared to become detached from the basement membrane, as 
evidenced by ultrastructural images showing frequent “bare areas” along the subepithelial 
surface of the glomerular basement membranes of glomeruli with developing lesions.  
Our in vitro studies indicate that Myh9 ablation results in altered focal adhesion 
and cytoskeletal structure in cultured podocytes.  Thus altered podocyte adhesion may 
also be a contributing factor to lesion development in this model.  These studies also 
showed an increase in cell motility associated with Myh9 ablation.  This is consistent 
with other in vitro studies where Myh9 expression was ablated and increased cell motility 
was observed (Vicente-Manzanares et al., 2007; Cai et al., 2006).   This is possibly 
because nonmuscle myosin IIA contraction along actin filament bundles inhibits 
polymerization of actin at the leading edge of cells thereby restraining cell spread and 
migration (Vicente-Manzanares et al., 2009).   Other studies have shown and association 
between dysregulated motility markers in podocytes and foot process effacement (Wei et 
al., 2008; Wei et al., 2011).  It could be that the observed increase in cell motility in this 
study may correlate with podocyte foot process effacement in mice lacking podocyte 
Myh9 under hypertensive conditions.  Thus there are several ways that changes in Myh9 
and nonmuscle myosin IIA expression could render the glomerulus more vulnerable to 
hemodynamic injury. 
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The findings of this study support the idea that altered Myh9/nonmuscle myosin 
IIA expression can lead to podocyte and glomerular injury.  However, the chromosome 
22 disease-associated haplotypes are not associated with DNA sequence variation in the 
coding regions of the Myh9 gene.  The studies presented here have focused on the 
contractile function of nonmuscle myosin IIA and how altered Myh9 expression affects 
these functions in the podocyte.  Nonmuscle myosin IIs also have a potential role in 
cytokinesis (Bao et al., 2005). There is school of thought that podocytes undergo mitotic 
catastrophe during kidney disease processes (Lasagni et al., 2013). Petermann et al., 
2003, have observed an in increase in mitotic cell cycle proteins in podocytes without a 
corresponding increase in proliferation. This finding was suggested to be due to altered 
cytokinesis (Petermann et al., 2003). Thus it could be that altered Myh9 expression also 
results in disrupted cytokinetic events which lead to podocyte injury. 
The mechanism by which nonmuscle myosin IIA expression may be reduced in 
FSGS is not known.  It could be that the initial events in FSGS lead to cell signaling 
changes which result in decreased Myh9 expression or increased NM IIA degradation.  
This, in turn, may render the glomerulus vulnerable to hemodynamic injury, and in this 
way the sequence of events leading to glomerulosclerosis is triggered.   
Future studies addressing the role of Myh9 in glomerular disease may take any of 
several approaches.  Such studies may target the following: 
6.1.2.1 Myh9 expression and function under conditions of podocyte stress 
As demonstrated in this study, nonmuscle myosin IIA glomerular expression 
levels are decreased during FSGS. It is however unknown how the regulation of Myh9 is 
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affected during the disease process. Further, it is not clearly understood how nonmuscle 
myosin IIA is distributed within in the podocyte in vivo, or when it is functionally active.  
It will therefore be interesting to assess Myh9 regulation at both the protein and mRNA 
level in mechanically or chemically stressed podocytes in vitro, and in the in vivo mouse 
remnant kidney model of glomerular hypertension.  These studies will help provide the 
molecular link between hypertension/stress and Myh9 in podocyte structure and function. 
6.1.2.2 Identification of the role of the loss of Myh9 in regulating podocyte proteins 
Several proteins in podocytes have been identified to be essential in playing a role 
in cell to cell adhesion (slit diaphragm proteins), cell to extracellular matrix adhesion, cell 
survival and also in maintenance of cellular structure.  However, the molecular 
association between nonmuscle myosin IIA protein expression and podocyte proteins 
involved in cell to cell interaction, cell adhesion and cell survival is not known.  It is 
therefore important to determine the impact of the loss of Myh9 on these proteins both in 
vitro and in vivo. This will provide insight into the mechanism leading to the loss of 
podocyte structure and function in the absence of Myh9.  
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APPENDIX 
Appendix A. siRNA oligonucleotide sequences 
 Oligonucleotide sequence 
(Myh9/2740/S) 5’-GATCCG-(GACAAAGGTTCGAGAGAAA)-(TTCAAGAGA)-
(TTTCTCTCGAACCTTTGTC)-TTTTTTGGAAG-3’ 
(Myh9/2740/AS) 5’-AATTCTTCCAAAAAA-(GACAAAGGTTCGAGAGAAA)-
(TCTCTTGAA)-(TTTCTCTCGAACCTTTGTC)-CG-3’ 
(Ctrl/2740/S) 5’-GATCCG-(GGAGAACGAGTAATCAGAA)-(TTCAAGAGA)-
(TTCTGATTACTCGTTCTCC)-TTTTTTGGAAG-3’ 
(Ctrl/2740/AS) 5’-AATTCTTCCAAAAAA-(GGAGAACGAGTAATCAGAA)-
(TCTCTTGAA)-(TTCTGATTACTCGTTCTCC)-CG-3’ 
(Myh10/2851/S) 5’-GATCCG-(AGGAAGAACTCCAGGCAAA)-(TTCAAGAGA)-
(TTTGCCTGGAGTTCTTCC)-TTTTTTTGGAAG-3’ 
(Myh10/2851/AS) 5’-AATTCTTCCAAAAAA-(AGGAAGAACTCCAGGCAAA)-
(TCTCTTGAATTTGCCTGGAGTTCTTCCT)-CG-3’ 
(Control/2851/S) 5’-GATCCG-(GGACTAACCGGCAAAGAAA)-(TTCAAGAGA)-
(TTTCTTTGCCGGTTAGTCC)-TTTTTTGGAAG-3’ 
(Control/2851/AS) 5’-AATTCTTCCAAAAAA-(GGACTAACCGGCAAAGAAA)-
(TCTCTTGAA)-(TTTCTTTGCCGGTTAGTCC)-CG-3’ 
S:   5’- GATCCG-(19bp target)-(TTCAAGAGA)-(19bp complm)-TTTTTTGGAAG 
AS:  GC-(19bp complm)-(AAGTTCTCT)-(19bp target)-AAAAAACCTTCTTAA -5’ 
In bold are BAMHI and EcoRI sites in either the sense (S) or antisense (AS) respectively 
to be inserted into VIRHD/E 
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Appendix B. Downregulated genes in risk group glomeruli versus control group 
glomeruli 
Symbol Entrez Gene Name Fold 
Change 
p-value False Discovery 
Rate (q-value) 
IGHA1 immunoglobulin heavy constant alpha 1 -4.800 6.07E-03 7.50E-01 
REN Renin -2.600 1.26E-02 8.40E-01 
IGHA2 immunoglobulin heavy constant alpha 2 (A2m marker) -2.300 3.57E-03 6.90E-01 
SNORA66 small nucleolar RNA, H/ACA box 66 -2.300 2.44E-03 6.20E-01 
PVRL3 poliovirus receptor-related 3 -2.100 4.30E-02 9.70E-01 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 -2.000 1.17E-02 8.30E-01 
HAVCR1 hepatitis A virus cellular receptor 1 -2.000 2.93E-02 9.20E-01 
IGHM immunoglobulin heavy constant mu -2.000 1.65E-03 5.90E-01 
PRUNE2 prune homolog 2 (Drosophila) -2.000 1.00E-02 8.20E-01 
GLYATL1 glycine-N-acyltransferase-like 1 -1.900 2.89E-03 6.20E-01 
OCLM Oculomedin -1.900 3.02E-02 9.20E-01 
SNORD116-14 small nucleolar RNA, C/D box 116-14 -1.900 4.04E-02 9.70E-01 
FAHD1 fumarylacetoacetate hydrolase domain containing 1 -1.800 2.64E-04 2.90E-01 
SNORA33 small nucleolar RNA, H/ACA box 33 -1.800 3.50E-04 3.20E-01 
UBQLN4 ubiquilin 4 -1.800 4.90E-04 3.60E-01 
HSPE1 heat shock 10kDa protein 1 (chaperonin 10) -1.700 1.75E-04 2.70E-01 
PSORS1C3 psoriasis susceptibility 1 candidate 3 (non-protein coding) -1.700 3.93E-03 6.90E-01 
SELE selectin E -1.700 1.52E-02 8.50E-01 
SNORA65 small nucleolar RNA, H/ACA box 65 -1.700 3.80E-02 9.60E-01 
SNORA68 small nucleolar RNA, H/ACA box 68 -1.700 2.72E-02 9.20E-01 
TTTY10 testis-specific transcript, Y-linked 10 (non-protein coding) -1.700 1.01E-02 8.20E-01 
ZNRD1-AS1 ZNRD1 antisense RNA 1 -1.700 2.19E-02 8.80E-01 
BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 
(gamma-butyrobetaine hydroxylase) 1 
-1.600 1.93E-02 8.70E-01 
CCL3 chemokine (C-C motif) ligand 3 -1.600 1.21E-03 5.20E-01 
FBLN5 fibulin 5 -1.600 2.11E-02 8.80E-01 
LOC100132356 uncharacterized LOC100132356 -1.600 1.10E-02 8.30E-01 
MEIS3P1 Meis homeobox 3 pseudogene 1 -1.600 2.91E-02 9.20E-01 
C10orf82 chromosome 10 open reading frame 82 -1.500 3.91E-03 6.90E-01 
CDC40 cell division cycle 40 -1.500 2.94E-02 9.20E-01 
CTSK cathepsin K -1.500 1.89E-03 6.20E-01 
FBXO36 F-box protein 36 -1.500 1.71E-02 8.50E-01 
G6PC glucose-6-phosphatase, catalytic subunit -1.500 8.50E-03 8.10E-01 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A -1.500 1.72E-02 8.50E-01 
PLIN2 perilipin 2 -1.500 1.88E-02 8.70E-01 
PTTG1 pituitary tumor-transforming 1 -1.500 7.60E-03 8.00E-01 
RAP1A RAP1A, member of RAS oncogene family -1.500 1.97E-02 8.70E-01 
RGS5 regulator of G-protein signaling 5 -1.500 3.05E-02 9.30E-01 
RNASE6 ribonuclease, RNase A family, k6 -1.500 2.76E-02 9.20E-01 
SNORA44 small nucleolar RNA, H/ACA box 44 -1.500 9.55E-03 8.20E-01 
AOC3 amine oxidase, copper containing 3 (vascular adhesion 
protein 1) 
-1.400 3.19E-05 1.30E-01 
BLOC1S6 biogenesis of lysosomal organelles complex-1, subunit 6, 
pallidin 
-1.400 6.42E-03 7.50E-01 
C5orf63 chromosome 5 open reading frame 63 -1.400 6.09E-03 7.50E-01 
CCDC12 coiled-coil domain containing 12 -1.400 4.55E-02 9.80E-01 
CD3D CD3d molecule, delta (CD3-TCR complex) -1.400 2.95E-02 9.20E-01 
CHST15 carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) 
sulfotransferase 15 
-1.400 4.15E-02 9.70E-01 
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CNTN4 contactin 4 -1.400 3.53E-02 9.60E-01 
CPNE4 copine IV -1.400 3.88E-02 9.60E-01 
GLUD1 glutamate dehydrogenase 1 -1.400 4.38E-02 9.70E-01 
HMOX1 heme oxygenase (decycling) 1 -1.400 6.92E-03 7.70E-01 
ITM2C integral membrane protein 2C -1.400 2.77E-03 6.20E-01 
KHK ketohexokinase (fructokinase) -1.400 2.62E-02 9.10E-01 
MRPL45 mitochondrial ribosomal protein L45 -1.400 3.54E-02 9.60E-01 
MTERFD3 MTERF domain containing 3 -1.400 2.56E-02 9.10E-01 
NOC2L nucleolar complex associated 2 homolog (S. cerevisiae) -1.400 4.08E-03 6.90E-01 
P4HA1 prolyl 4-hydroxylase, alpha polypeptide I -1.400 1.77E-03 6.10E-01 
PCDHA6 protocadherin alpha 6 -1.400 3.55E-03 6.90E-01 
PFDN4 prefoldin subunit 4 -1.400 3.27E-02 9.40E-01 
QPCT glutaminyl-peptide cyclotransferase -1.400 1.91E-02 8.70E-01 
RBM4B RNA binding motif protein 4B -1.400 2.48E-02 9.10E-01 
RHEB Ras homolog enriched in brain -1.400 4.62E-02 9.80E-01 
SHMT1 serine hydroxymethyltransferase 1 (soluble) -1.400 1.19E-02 8.30E-01 
SLC44A4 solute carrier family 44, member 4 -1.400 4.47E-02 9.70E-01 
SNX29P2 sorting nexin 29 pseudogene 2 -1.400 1.17E-02 8.30E-01 
TGFB3 transforming growth factor, beta 3 -1.400 3.88E-02 9.60E-01 
TGFBRAP1 transforming growth factor, beta receptor associated protein 
1 
-1.400 1.88E-02 8.70E-01 
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b -1.400 3.15E-02 9.40E-01 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8) 
-1.300 3.88E-02 9.60E-01 
ANKS6 ankyrin repeat and sterile alpha motif domain containing 6 -1.300 3.82E-03 6.90E-01 
B4GALT4 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 4 
-1.300 3.91E-02 9.60E-01 
C9orf47 chromosome 9 open reading frame 47 -1.300 3.70E-02 9.60E-01 
CDH11 cadherin 11, type 2, OB-cadherin (osteoblast) -1.300 8.92E-03 8.10E-01 
CERS4 ceramide synthase 4 -1.300 2.77E-04 2.90E-01 
CLCN1 chloride channel, voltage-sensitive 1 -1.300 2.95E-05 1.30E-01 
CLDN1 claudin 1 -1.300 1.61E-02 8.50E-01 
CPSF4L cleavage and polyadenylation specific factor 4-like -1.300 4.79E-03 7.10E-01 
CRYAB crystallin, alpha B -1.300 9.11E-03 8.10E-01 
DNAJC8 DnaJ (Hsp40) homolog, subfamily C, member 8 -1.300 3.61E-02 9.60E-01 
EVC Ellis van Creveld syndrome -1.300 6.14E-04 3.90E-01 
FCGBP Fc fragment of IgG binding protein -1.300 4.08E-04 3.50E-01 
FILIP1 filamin A interacting protein 1 -1.300 2.96E-02 9.20E-01 
FLJ42289 uncharacterized LOC388182 -1.300 3.98E-02 9.70E-01 
GCA grancalcin, EF-hand calcium binding protein -1.300 1.23E-02 8.30E-01 
GEMIN7 gem (nuclear organelle) associated protein 7 -1.300 3.55E-02 9.60E-01 
GPR126 G protein-coupled receptor 126 -1.300 5.16E-03 7.30E-01 
GSTP1 glutathione S-transferase pi 1 -1.300 2.27E-02 8.90E-01 
HYPK huntingtin interacting protein K -1.300 4.27E-02 9.70E-01 
JAK1 Janus kinase 1 -1.300 1.40E-02 8.50E-01 
KCTD1 potassium channel tetramerisation domain containing 1 -1.300 6.24E-03 7.50E-01 
KHDRBS3 KH domain containing, RNA binding, signal transduction 
associated 3 
-1.300 2.01E-02 8.70E-01 
KLHL2 kelch-like family member 2 -1.300 4.32E-02 9.70E-01 
KLHL23/PHOS
PHO2-KLHL23 
kelch-like family member 23 -1.300 2.51E-02 9.10E-01 
LCN2 lipocalin 2 -1.300 4.12E-02 9.70E-01 
LOC100128653 uncharacterized LOC100128653 -1.300 1.92E-02 8.70E-01 
LOC401010 nucleolar complex associated 2 homolog (S. cerevisiae) 
pseudogene 
-1.300 3.06E-02 9.30E-01 
LYPD6B LY6/PLAUR domain containing 6B -1.300 3.22E-02 9.40E-01 
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MAGOH mago-nashi homolog, proliferation-associated (Drosophila) -1.300 2.49E-02 9.10E-01 
MARS2 methionyl-tRNA synthetase 2, mitochondrial -1.300 9.95E-03 8.20E-01 
MED28 mediator complex subunit 28 -1.300 3.57E-02 9.60E-01 
MICU2 mitochondrial calcium uptake 2 -1.300 9.87E-03 8.20E-01 
mir-103 microRNA 107 -1.300 3.19E-02 9.40E-01 
MLX MLX, MAX dimerization protein -1.300 2.28E-05 1.30E-01 
MOXD1 monooxygenase, DBH-like 1 -1.300 2.96E-03 6.20E-01 
MPHOSPH6 M-phase phosphoprotein 6 -1.300 1.24E-02 8.30E-01 
MRPL50 mitochondrial ribosomal protein L50 -1.300 4.12E-02 9.70E-01 
MRPS22 mitochondrial ribosomal protein S22 -1.300 1.48E-02 8.50E-01 
MTA2 metastasis associated 1 family, member 2 -1.300 4.18E-03 6.90E-01 
MTHFS 5,10-methenyltetrahydrofolate synthetase (5-
formyltetrahydrofolate cyclo-ligase) 
-1.300 1.07E-02 8.30E-01 
NBPF3 neuroblastoma breakpoint family, member 3 -1.300 2.81E-04 2.90E-01 
NETO2 neuropilin (NRP) and tolloid (TLL)-like 2 -1.300 8.25E-03 8.10E-01 
ORAOV1 oral cancer overexpressed 1 -1.300 4.08E-03 6.90E-01 
OTUD3 OTU domain containing 3 -1.300 8.13E-03 8.00E-01 
PLEKHA8P1 pleckstrin homology domain containing, family A member 
8 pseudogene 1 
-1.300 4.16E-02 9.70E-01 
PPIC peptidylprolyl isomerase C (cyclophilin C) -1.300 8.18E-03 8.00E-01 
PRPF4 PRP4 pre-mRNA processing factor 4 homolog (yeast) -1.300 6.36E-03 7.50E-01 
PSMB2 proteasome (prosome, macropain) subunit, beta type, 2 -1.300 1.44E-02 8.50E-01 
PSMD14 proteasome (prosome, macropain) 26S subunit, non-
ATPase, 14 
-1.300 2.92E-03 6.20E-01 
PTCHD1 patched domain containing 1 -1.300 1.56E-02 8.50E-01 
RAB38 RAB38, member RAS oncogene family -1.300 1.21E-03 5.20E-01 
RGN regucalcin (senescence marker protein-30) -1.300 1.63E-02 8.50E-01 
RNF216P1 ring finger protein 216 pseudogene 1 -1.300 5.00E-02 9.80E-01 
SCARNA11 small Cajal body-specific RNA 11 -1.300 1.98E-02 8.70E-01 
SIAE sialic acid acetylesterase -1.300 1.94E-02 8.70E-01 
SIRPB1 signal-regulatory protein beta 1 -1.300 9.70E-03 8.20E-01 
SLC25A40 solute carrier family 25, member 40 -1.300 1.66E-02 8.50E-01 
SNORA16A small nucleolar RNA, H/ACA box 16A -1.300 3.17E-02 9.40E-01 
SNRPF small nuclear ribonucleoprotein polypeptide F -1.300 2.99E-02 9.20E-01 
SNX12 sorting nexin 12 -1.300 2.02E-02 8.70E-01 
TAF9 TAF9 RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 32kDa 
-1.300 1.60E-03 5.90E-01 
TATDN1 TatD DNase domain containing 1 -1.300 4.88E-02 9.80E-01 
TMEM132C transmembrane protein 132C -1.300 8.07E-04 4.30E-01 
TMEM185A transmembrane protein 185A -1.300 2.48E-03 6.20E-01 
TMEM86A transmembrane protein 86A -1.300 2.30E-02 9.00E-01 
TUBB2B tubulin, beta 2B class IIb -1.300 4.14E-02 9.70E-01 
UCHL3 ubiquitin carboxyl-terminal esterase L3 (ubiquitin 
thiolesterase) 
-1.300 3.27E-02 9.40E-01 
ZNF544 zinc finger protein 544 -1.300 5.33E-03 7.40E-01 
ZNF597 zinc finger protein 597 -1.300 2.12E-04 2.90E-01 
ABLIM3 actin binding LIM protein family, member 3 -1.200 2.94E-02 9.20E-01 
ACAP1 ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 -1.200 1.90E-02 8.70E-01 
ACP2 acid phosphatase 2, lysosomal -1.200 1.40E-02 8.50E-01 
AHCY Adenosylhomocysteinase -1.200 3.09E-02 9.30E-01 
AIP aryl hydrocarbon receptor interacting protein -1.200 1.73E-02 8.50E-01 
AKAP6 A kinase (PRKA) anchor protein 6 -1.200 1.71E-02 8.50E-01 
ALYREF Aly/REF export factor -1.200 3.34E-02 9.50E-01 
ANO9 anoctamin 9 -1.200 7.13E-03 7.80E-01 
ARL5A ADP-ribosylation factor-like 5A -1.200 2.00E-02 8.70E-01 
ARSI arylsulfatase family, member I -1.200 2.22E-02 8.80E-01 
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BAG1 BCL2-associated athanogene -1.200 1.59E-02 8.50E-01 
BAG5 BCL2-associated athanogene 5 -1.200 3.81E-02 9.60E-01 
BCL2L1 BCL2-like 1 -1.200 1.96E-02 8.70E-01 
C12orf66 chromosome 12 open reading frame 66 -1.200 3.50E-02 9.60E-01 
C12orf76 chromosome 12 open reading frame 76 -1.200 2.48E-02 9.10E-01 
C17orf53 chromosome 17 open reading frame 53 -1.200 2.63E-02 9.10E-01 
C19orf43 chromosome 19 open reading frame 43 -1.200 4.87E-02 9.80E-01 
C1orf186 chromosome 1 open reading frame 186 -1.200 1.49E-02 8.50E-01 
C20orf197 chromosome 20 open reading frame 197 -1.200 2.49E-02 9.10E-01 
C2orf78 chromosome 2 open reading frame 78 -1.200 4.42E-02 9.70E-01 
C6orf57 chromosome 6 open reading frame 57 -1.200 4.99E-02 9.80E-01 
C7orf55 chromosome 7 open reading frame 55 -1.200 3.27E-02 9.40E-01 
CCDC144NL coiled-coil domain containing 144 family, N-terminal like -1.200 1.65E-02 8.50E-01 
CCDC77 coiled-coil domain containing 77 -1.200 2.67E-03 6.20E-01 
CD109 CD109 molecule -1.200 2.73E-02 9.20E-01 
CD28 CD28 molecule -1.200 1.77E-02 8.60E-01 
CD2BP2 CD2 (cytoplasmic tail) binding protein 2 -1.200 4.31E-02 9.70E-01 
CEMP1 cementum protein 1 -1.200 2.76E-02 9.20E-01 
CERCAM cerebral endothelial cell adhesion molecule -1.200 4.99E-03 7.20E-01 
CHIT1 chitinase 1 (chitotriosidase) -1.200 1.59E-02 8.50E-01 
CHST7 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 -1.200 2.21E-02 8.80E-01 
CNPY4 canopy 4 homolog (zebrafish) -1.200 2.88E-02 9.20E-01 
COMMD4 COMM domain containing 4 -1.200 7.93E-03 8.00E-01 
COX4I2 cytochrome c oxidase subunit IV isoform 2 (lung) -1.200 4.18E-02 9.70E-01 
CRAT carnitine O-acetyltransferase -1.200 1.26E-02 8.40E-01 
CSGALNACT1 chondroitin sulfate N-acetylgalactosaminyltransferase 1 -1.200 2.96E-02 9.20E-01 
CTRB1 chymotrypsinogen B1 -1.200 2.07E-02 8.70E-01 
CTSL1 cathepsin L1 -1.200 3.89E-02 9.60E-01 
DDRGK1 DDRGK domain containing 1 -1.200 3.33E-02 9.50E-01 
DECR2 2,4-dienoyl CoA reductase 2, peroxisomal -1.200 1.84E-02 8.70E-01 
DIP2B DIP2 disco-interacting protein 2 homolog B (Drosophila) -1.200 4.18E-03 6.90E-01 
DNAJB5 DnaJ (Hsp40) homolog, subfamily B, member 5 -1.200 4.32E-02 9.70E-01 
DOK7 docking protein 7 -1.200 1.38E-02 8.50E-01 
DPEP1 dipeptidase 1 (renal) -1.200 3.73E-02 9.60E-01 
DUS1L dihydrouridine synthase 1-like (S. cerevisiae) -1.200 5.67E-03 7.40E-01 
DZIP1L DAZ interacting protein 1-like -1.200 3.75E-03 6.90E-01 
EBLN2 endogenous Bornavirus-like nucleoprotein 2 -1.200 3.46E-02 9.60E-01 
EID3 EP300 interacting inhibitor of differentiation 3 -1.200 4.86E-02 9.80E-01 
ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 -1.200 2.68E-02 9.10E-01 
ENTPD6 ectonucleoside triphosphate diphosphohydrolase 6 
(putative) 
-1.200 6.79E-03 7.70E-01 
ERCC1 excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes overlapping 
antisense sequence) 
-1.200 2.75E-03 6.20E-01 
EVC2 Ellis van Creveld syndrome 2 -1.200 1.42E-03 5.60E-01 
FAM102B family with sequence similarity 102, member B -1.200 3.68E-02 9.60E-01 
FAM196A family with sequence similarity 196, member A -1.200 2.03E-03 6.20E-01 
FAM216A family with sequence similarity 216, member A -1.200 2.52E-02 9.10E-01 
FAM78B family with sequence similarity 78, member B -1.200 3.32E-03 6.70E-01 
FCN1 ficolin (collagen/fibrinogen domain containing) 1 -1.200 6.37E-03 7.50E-01 
FGD1 FYVE, RhoGEF and PH domain containing 1 -1.200 3.73E-02 9.60E-01 
FGF13 fibroblast growth factor 13 -1.200 1.26E-02 8.40E-01 
GBA3 glucosidase, beta, acid 3 (cytosolic) -1.200 4.67E-02 9.80E-01 
GHDC GH3 domain containing -1.200 1.10E-02 8.30E-01 
GINS2 GINS complex subunit 2 (Psf2 homolog) -1.200 1.03E-03 5.10E-01 
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GPAA1 glycosylphosphatidylinositol anchor attachment 1 -1.200 1.98E-02 8.70E-01 
GRPEL1 GrpE-like 1, mitochondrial (E. coli) -1.200 4.73E-02 9.80E-01 
GRTP1 growth hormone regulated TBC protein 1 -1.200 1.34E-02 8.50E-01 
HCK hemopoietic cell kinase -1.200 6.83E-03 7.70E-01 
HCLS1 hematopoietic cell-specific Lyn substrate 1 -1.200 3.09E-02 9.30E-01 
HIRA HIR histone cell cycle regulation defective homolog A (S. 
cerevisiae) 
-1.200 1.86E-03 6.20E-01 
HNF4A hepatocyte nuclear factor 4, alpha -1.200 1.05E-02 8.30E-01 
HNRNPH2 heterogeneous nuclear ribonucleoprotein H2 (H') -1.200 4.39E-02 9.70E-01 
HPCAL1 hippocalcin-like 1 -1.200 4.06E-02 9.70E-01 
HSH2D hematopoietic SH2 domain containing -1.200 1.77E-02 8.60E-01 
IFNLR1 interferon, lambda receptor 1 -1.200 3.68E-03 6.90E-01 
ILDR1 immunoglobulin-like domain containing receptor 1 -1.200 4.03E-02 9.70E-01 
KHSRP KH-type splicing regulatory protein -1.200 7.72E-04 4.20E-01 
KIAA1191 KIAA1191 -1.200 3.58E-02 9.60E-01 
KLHL24 kelch-like family member 24 -1.200 1.95E-03 6.20E-01 
KLHL26 kelch-like family member 26 -1.200 9.79E-03 8.20E-01 
KLHL36 kelch-like family member 36 -1.200 2.59E-02 9.10E-01 
KLK11 kallikrein-related peptidase 11 -1.200 4.42E-03 6.90E-01 
KREMEN1 kringle containing transmembrane protein 1 -1.200 2.42E-02 9.10E-01 
KRT33B keratin 33B -1.200 2.21E-02 8.80E-01 
KRTAP10-4 keratin associated protein 10-4 -1.200 4.07E-02 9.70E-01 
LAIR2 leukocyte-associated immunoglobulin-like receptor 2 -1.200 9.23E-03 8.10E-01 
LGI2 leucine-rich repeat LGI family, member 2 -1.200 4.72E-03 7.10E-01 
LILRB1 leukocyte immunoglobulin-like receptor, subfamily B (with 
TM and ITIM domains), member 1 
-1.200 4.07E-02 9.70E-01 
LMO2 LIM domain only 2 (rhombotin-like 1) -1.200 3.32E-02 9.50E-01 
LOC389634 uncharacterized LOC389634 -1.200 3.62E-02 9.60E-01 
LRRC29 leucine rich repeat containing 29 -1.200 2.52E-03 6.20E-01 
LRRC40 leucine rich repeat containing 40 -1.200 6.31E-03 7.50E-01 
MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) -1.200 5.61E-03 7.40E-01 
MAP3K5 mitogen-activated protein kinase kinase kinase 5 -1.200 1.86E-02 8.70E-01 
MGLL monoglyceride lipase -1.200 1.50E-02 8.50E-01 
MITF microphthalmia-associated transcription factor -1.200 4.63E-02 9.80E-01 
MLLT4-AS1 MLLT4 antisense RNA 1 (head to head) -1.200 2.44E-02 9.10E-01 
MMP16 matrix metallopeptidase 16 (membrane-inserted) -1.200 4.88E-02 9.80E-01 
MRPL24 mitochondrial ribosomal protein L24 -1.200 5.62E-03 7.40E-01 
MRPL44 mitochondrial ribosomal protein L44 -1.200 3.68E-02 9.60E-01 
MST1R macrophage stimulating 1 receptor (c-met-related tyrosine 
kinase) 
-1.200 2.16E-03 6.20E-01 
MUC4 mucin 4, cell surface associated -1.200 2.45E-02 9.10E-01 
MYO5A myosin VA (heavy chain 12, myoxin) -1.200 1.51E-02 8.50E-01 
NEK6 NIMA-related kinase 6 -1.200 2.62E-02 9.10E-01 
NFYA nuclear transcription factor Y, alpha -1.200 4.09E-02 9.70E-01 
NKAP NFKB activating protein -1.200 2.90E-02 9.20E-01 
NRXN3 neurexin 3 -1.200 3.67E-02 9.60E-01 
NUP88 nucleoporin 88kDa -1.200 3.26E-02 9.40E-01 
NUPL2 nucleoporin like 2 -1.200 3.01E-02 9.20E-01 
OR2G6 olfactory receptor, family 2, subfamily G, member 6 -1.200 4.21E-02 9.70E-01 
OR5H6 olfactory receptor, family 5, subfamily H, member 6 -1.200 5.68E-03 7.40E-01 
PALM2 paralemmin 2 -1.200 2.11E-02 8.80E-01 
PDIA4 protein disulfide isomerase family A, member 4 -1.200 1.27E-02 8.40E-01 
PFDN2 prefoldin subunit 2 -1.200 3.67E-02 9.60E-01 
PHF6 PHD finger protein 6 -1.200 1.37E-02 8.50E-01 
PKP2 plakophilin 2 -1.200 3.66E-02 9.60E-01 
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PLEKHH1 pleckstrin homology domain containing, family H (with 
MyTH4 domain) member 1 
-1.200 3.69E-02 9.60E-01 
PLXNA1 plexin A1 -1.200 3.64E-02 9.60E-01 
PM20D1 peptidase M20 domain containing 1 -1.200 2.02E-03 6.20E-01 
PPP6R1 protein phosphatase 6, regulatory subunit 1 -1.200 1.87E-02 8.70E-01 
PRAME preferentially expressed antigen in melanoma -1.200 1.62E-02 8.50E-01 
PRKCZ protein kinase C, zeta -1.200 4.66E-02 9.80E-01 
PROC protein C (inactivator of coagulation factors Va and VIIIa) -1.200 4.82E-02 9.80E-01 
PTPN18 protein tyrosine phosphatase, non-receptor type 18 (brain-
derived) 
-1.200 1.20E-02 8.30E-01 
PXMP2 peroxisomal membrane protein 2, 22kDa -1.200 2.82E-04 2.90E-01 
RAE1 RAE1 RNA export 1 homolog (S. pombe) -1.200 4.23E-04 3.50E-01 
RANBP6 RAN binding protein 6 -1.200 3.95E-02 9.70E-01 
RBM15B RNA binding motif protein 15B -1.200 4.37E-02 9.70E-01 
RHBDF1 rhomboid 5 homolog 1 (Drosophila) -1.200 5.89E-03 7.50E-01 
RMI1 RMI1, RecQ mediated genome instability 1, homolog (S. 
cerevisiae) 
-1.200 8.19E-04 4.30E-01 
RNF112 ring finger protein 112 -1.200 3.46E-02 9.60E-01 
RNU105C RNA, U105C small nucleolar -1.200 1.04E-02 8.30E-01 
ROPN1L rhophilin associated tail protein 1-like -1.200 1.59E-02 8.50E-01 
RSL1D1 ribosomal L1 domain containing 1 -1.200 4.55E-02 9.80E-01 
SAMD5 sterile alpha motif domain containing 5 -1.200 1.89E-03 6.20E-01 
SCARB1 scavenger receptor class B, member 1 -1.200 3.37E-02 9.50E-01 
SELRC1 Sel1 repeat containing 1 -1.200 8.19E-03 8.00E-01 
SFN Stratifin -1.200 4.09E-02 9.70E-01 
SH2D7 SH2 domain containing 7 -1.200 4.85E-02 9.80E-01 
SH3BP5L SH3-binding domain protein 5-like -1.200 4.40E-02 9.70E-01 
SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin -1.200 4.94E-02 9.80E-01 
SLC23A1 solute carrier family 23 (nucleobase transporters), member 1 -1.200 3.56E-02 9.60E-01 
SLC2A11 solute carrier family 2 (facilitated glucose transporter), 
member 11 
-1.200 2.56E-02 9.10E-01 
SLC38A3 solute carrier family 38, member 3 -1.200 4.97E-02 9.80E-01 
SLC41A1 solute carrier family 41, member 1 -1.200 7.88E-03 8.00E-01 
SLC4A3 solute carrier family 4, anion exchanger, member 3 -1.200 2.88E-02 9.20E-01 
SLC6A17 solute carrier family 6, member 17 -1.200 1.03E-02 8.30E-01 
SNORA70C small nucleolar RNA, H/ACA box 70C -1.200 4.28E-02 9.70E-01 
SNORA70D small nucleolar RNA, H/ACA box 70D -1.200 1.05E-02 8.30E-01 
SNX20 sorting nexin 20 -1.200 3.97E-02 9.70E-01 
SPIN2A/SPIN2
B 
spindlin family, member 2B -1.200 3.99E-03 6.90E-01 
SPR sepiapterin reductase (7,8-dihydrobiopterin:NADP+ 
oxidoreductase) 
-1.200 4.80E-02 9.80E-01 
SPRYD7 SPRY domain containing 7 -1.200 2.87E-03 6.20E-01 
SRM spermidine synthase -1.200 3.04E-02 9.20E-01 
STARD10 StAR-related lipid transfer (START) domain containing 10 -1.200 4.40E-02 9.70E-01 
STBD1 starch binding domain 1 -1.200 2.02E-02 8.70E-01 
TIMD4 T-cell immunoglobulin and mucin domain containing 4 -1.200 4.60E-02 9.80E-01 
TIMM10 translocase of inner mitochondrial membrane 10 homolog 
(yeast) 
-1.200 1.65E-02 8.50E-01 
TMPRSS4 transmembrane protease, serine 4 -1.200 1.98E-02 8.70E-01 
TP53RK TP53 regulating kinase -1.200 3.74E-02 9.60E-01 
TPGS1 tubulin polyglutamylase complex subunit 1 -1.200 2.75E-02 9.20E-01 
TREX1 three prime repair exonuclease 1 -1.200 4.43E-03 6.90E-01 
UBAC2 UBA domain containing 2 -1.200 1.69E-02 8.50E-01 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 -1.200 2.44E-03 6.20E-01 
UBTF upstream binding transcription factor, RNA polymerase I -1.200 1.59E-02 8.50E-01 
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VIL1 villin 1 -1.200 1.63E-03 5.90E-01 
VPS72 vacuolar protein sorting 72 homolog (S. cerevisiae) -1.200 4.74E-02 9.80E-01 
WASF1 WAS protein family, member 1 -1.200 3.86E-02 9.60E-01 
WBP2NL WBP2 N-terminal like -1.200 3.75E-02 9.60E-01 
ZNF213 zinc finger protein 213 -1.200 6.46E-03 7.50E-01 
ZNF470 zinc finger protein 470 -1.200 1.61E-02 8.50E-01 
ZNF622 zinc finger protein 622 -1.200 2.02E-02 8.70E-01 
ZNF69 zinc finger protein 69 -1.200 4.24E-02 9.70E-01 
ZNF696 zinc finger protein 696 -1.200 1.12E-02 8.30E-01 
ZNRF1 zinc and ring finger 1, E3 ubiquitin protein ligase -1.200 2.20E-02 8.80E-01 
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Appendix C. Upregulated genes in risk group glomeruli versus control group 
glomeruli 
Symbol Entrez Gene Name 
Fold 
Change p-value 
False Discovery 
Rate (q-value) 
ACSL3 acyl-CoA synthetase long-chain family member 3 1.200 3.02E-02 9.20E-01 
ADARB1 adenosine deaminase, RNA-specific, B1 1.200 4.46E-02 9.70E-01 
AK3 adenylate kinase 3 1.200 3.57E-02 9.60E-01 
AKAP10 A kinase (PRKA) anchor protein 10 1.200 4.47E-03 6.90E-01 
AKIP1 A kinase (PRKA) interacting protein 1 1.200 1.19E-02 8.30E-01 
ALPK1 alpha-kinase 1 1.200 4.58E-03 7.00E-01 
ANAPC13 anaphase promoting complex subunit 13 1.200 4.53E-02 9.80E-01 
ANKDD1A ankyrin repeat and death domain containing 1A 1.200 2.81E-02 9.20E-01 
ARHGAP28 Rho GTPase activating protein 28 1.200 3.52E-02 9.60E-01 
ARPC5L actin related protein 2/3 complex, subunit 5-like 1.200 2.64E-02 9.10E-01 
ARRDC4 arrestin domain containing 4 1.200 2.74E-02 9.20E-01 
B3GNT1 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 1.200 9.81E-03 8.20E-01 
BAG4 BCL2-associated athanogene 4 1.200 2.49E-02 9.10E-01 
BEX1 brain expressed, X-linked 1 1.200 4.58E-02 9.80E-01 
BTBD9 BTB (POZ) domain containing 9 1.200 2.41E-02 9.10E-01 
C11orf58 chromosome 11 open reading frame 58 1.200 3.93E-03 6.90E-01 
C3orf70 chromosome 3 open reading frame 70 1.200 3.76E-02 9.60E-01 
C9orf156 chromosome 9 open reading frame 156 1.200 1.76E-03 6.10E-01 
CACNA2D1 
calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 1.200 3.38E-02 9.50E-01 
CAPN2 calpain 2, (m/II) large subunit 1.200 3.99E-02 9.70E-01 
CBR4 carbonyl reductase 4 1.200 4.36E-02 9.70E-01 
CCDC94 coiled-coil domain containing 94 1.200 1.60E-02 8.50E-01 
CD9 CD9 molecule 1.200 3.74E-02 9.60E-01 
CDC14A cell division cycle 14A 1.200 2.63E-02 9.10E-01 
CHD9 chromodomain helicase DNA binding protein 9 1.200 5.60E-03 7.40E-01 
CLUL1 clusterin-like 1 (retinal) 1.200 1.70E-02 8.50E-01 
COX16 
COX16 cytochrome c oxidase assembly homolog (S. 
cerevisiae) 1.200 2.29E-02 9.00E-01 
CPD carboxypeptidase D 1.200 1.88E-02 8.70E-01 
CPNE3 copine III 1.200 4.02E-03 6.90E-01 
CPNE8 copine VIII 1.200 4.18E-02 9.70E-01 
CPSF4 cleavage and polyadenylation specific factor 4, 30kDa 1.200 1.22E-02 8.30E-01 
DCN Decorin 1.200 2.13E-02 8.80E-01 
DHRS12 dehydrogenase/reductase (SDR family) member 12 1.200 7.14E-03 7.80E-01 
DHX8 DEAH (Asp-Glu-Ala-His) box polypeptide 8 1.200 2.13E-02 8.80E-01 
DNAJC18 DnaJ (Hsp40) homolog, subfamily C, member 18 1.200 3.80E-02 9.60E-01 
DNASE1L3 deoxyribonuclease I-like 3 1.200 2.69E-03 6.20E-01 
DNM3 dynamin 3 1.200 4.43E-02 9.70E-01 
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DPY19L1 dpy-19-like 1 (C. elegans) 1.200 6.67E-03 7.70E-01 
DST Dystonin 1.200 3.29E-02 9.40E-01 
FAM114A1 family with sequence similarity 114, member A1 1.200 1.41E-02 8.50E-01 
FAM127C family with sequence similarity 127, member C 1.200 3.83E-02 9.60E-01 
FAM219B family with sequence similarity 219, member B 1.200 3.07E-02 9.30E-01 
FAM98A family with sequence similarity 98, member A 1.200 2.16E-02 8.80E-01 
FCHSD2 FCH and double SH3 domains 2 1.200 2.78E-02 9.20E-01 
FDPS farnesyl diphosphate synthase 1.200 2.25E-03 6.20E-01 
FRY furry homolog (Drosophila) 1.200 3.10E-02 9.30E-01 
GFPT1 glutamine--fructose-6-phosphate transaminase 1 1.200 2.12E-02 8.80E-01 
GNG10 
guanine nucleotide binding protein (G protein), gamma 
10 1.200 2.69E-02 9.10E-01 
GORAB golgin, RAB6-interacting 1.200 1.60E-02 8.50E-01 
GPATCH11 G patch domain containing 11 1.200 7.79E-03 8.00E-01 
GPR116 G protein-coupled receptor 116 1.200 2.01E-02 8.70E-01 
GPRC5B 
G protein-coupled receptor, family C, group 5, member 
B 1.200 3.54E-02 9.60E-01 
HAPLN3 hyaluronan and proteoglycan link protein 3 1.200 2.05E-02 8.70E-01 
HARBI1 harbinger transposase derived 1 1.200 4.16E-05 1.40E-01 
HAUS1 HAUS augmin-like complex, subunit 1 1.200 2.70E-02 9.10E-01 
HINT2 histidine triad nucleotide binding protein 2 1.200 9.19E-03 8.10E-01 
HLA-L 
major histocompatibility complex, class I, L 
(pseudogene) 1.200 2.69E-04 2.90E-01 
HPRT1 hypoxanthine phosphoribosyltransferase 1 1.200 4.06E-02 9.70E-01 
IFNL2 interferon, lambda 2 1.200 1.01E-02 8.20E-01 
IL10RB interleukin 10 receptor, beta 1.200 3.63E-02 9.60E-01 
IL13 interleukin 13 1.200 2.38E-03 6.20E-01 
INPP5B inositol polyphosphate-5-phosphatase, 75kDa 1.200 2.41E-02 9.10E-01 
KANSL3 KAT8 regulatory NSL complex subunit 3 1.200 7.28E-03 7.80E-01 
KIAA1731 KIAA1731 1.200 4.58E-02 9.80E-01 
KLHL38 kelch-like family member 38 1.200 3.47E-02 9.60E-01 
KLHL5 kelch-like family member 5 1.200 4.18E-02 9.70E-01 
LOC100506
667 uncharacterized LOC100506667 1.200 1.42E-02 8.50E-01 
LRRC8C leucine rich repeat containing 8 family, member C 1.200 2.87E-02 9.20E-01 
LY6G5C lymphocyte antigen 6 complex, locus G5C 1.200 4.02E-02 9.70E-01 
LZIC leucine zipper and CTNNBIP1 domain containing 1.200 3.71E-02 9.60E-01 
MEGF9 multiple EGF-like-domains 9 1.200 4.24E-02 9.70E-01 
METTL10 methyltransferase like 10 1.200 8.30E-03 8.10E-01 
METTL21B methyltransferase like 21B 1.200 5.62E-04 3.70E-01 
MFAP1 microfibrillar-associated protein 1 1.200 2.67E-02 9.10E-01 
MFSD5 major facilitator superfamily domain containing 5 1.200 1.53E-02 8.50E-01 
MGAT5 
mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase 1.200 4.86E-02 9.80E-01 
MGC16121 uncharacterized protein MGC16121 1.200 8.66E-03 8.10E-01 
MGC72080 MGC72080 pseudogene 1.200 7.84E-03 8.00E-01 
MORF4L2 mortality factor 4 like 2 1.200 4.89E-02 9.80E-01 
MRPS7 mitochondrial ribosomal protein S7 1.200 7.46E-03 7.90E-01 
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MYLPF 
myosin light chain, phosphorylatable, fast skeletal 
muscle 1.200 1.12E-02 8.30E-01 
NADSYN1 NAD synthetase 1 1.200 4.58E-02 9.80E-01 
NCBP1 nuclear cap binding protein subunit 1, 80kDa 1.200 4.09E-02 9.70E-01 
NDRG2 NDRG family member 2 1.200 3.45E-02 9.60E-01 
NEK9 NIMA-related kinase 9 1.200 3.00E-02 9.20E-01 
NIPAL1 NIPA-like domain containing 1 1.200 4.99E-02 9.80E-01 
NLK nemo-like kinase 1.200 3.10E-02 9.30E-01 
NMNAT3 nicotinamide nucleotide adenylyltransferase 3 1.200 4.38E-02 9.70E-01 
NPNT Nephronectin 1.200 9.05E-03 8.10E-01 
OXR1 oxidation resistance 1 1.200 3.58E-02 9.60E-01 
PAQR7 progestin and adipoQ receptor family member VII 1.200 1.96E-02 8.70E-01 
PLAC9 placenta-specific 9 1.200 1.03E-02 8.30E-01 
PLBD2 phospholipase B domain containing 2 1.200 2.43E-02 9.10E-01 
PRKCI protein kinase C, iota 1.200 1.27E-02 8.40E-01 
PRR3 proline rich 3 1.200 4.95E-02 9.80E-01 
PTGER4 prostaglandin E receptor 4 (subtype EP4) 1.200 1.58E-02 8.50E-01 
PTK2 protein tyrosine kinase 2 1.200 1.10E-02 8.30E-01 
PTPN14 protein tyrosine phosphatase, non-receptor type 14 1.200 2.69E-02 9.10E-01 
PTPRO protein tyrosine phosphatase, receptor type, O 1.200 1.99E-02 8.70E-01 
RBM27 RNA binding motif protein 27 1.200 4.97E-02 9.80E-01 
RBMS1 RNA binding motif, single stranded interacting protein 1 1.200 1.46E-02 8.50E-01 
RMND1 
required for meiotic nuclear division 1 homolog (S. 
cerevisiae) 1.200 1.93E-02 8.70E-01 
RNF10 ring finger protein 10 1.200 5.97E-03 7.50E-01 
RPP38 ribonuclease P/MRP 38kDa subunit 1.200 4.73E-02 9.80E-01 
SDC2 syndecan 2 1.200 1.44E-02 8.50E-01 
SFTPD surfactant protein D 1.200 1.64E-02 8.50E-01 
SHISA5 shisa homolog 5 (Xenopus laevis) 1.200 4.10E-02 9.70E-01 
SIRT3 sirtuin 3 1.200 7.30E-03 7.80E-01 
SLC16A10 
solute carrier family 16, member 10 (aromatic amino 
acid transporter) 1.200 1.77E-02 8.60E-01 
SLC25A27 solute carrier family 25, member 27 1.200 4.41E-02 9.70E-01 
SLC35G1 solute carrier family 35, member G1 1.200 3.25E-02 9.40E-01 
SLC39A6 solute carrier family 39 (zinc transporter), member 6 1.200 4.34E-02 9.70E-01 
SLC44A2 solute carrier family 44, member 2 1.200 2.65E-02 9.10E-01 
SLC9A1 
solute carrier family 9, subfamily A (NHE1, cation 
proton antiporter 1), member 1 1.200 4.23E-02 9.70E-01 
SPATA13 spermatogenesis associated 13 1.200 2.78E-02 9.20E-01 
SPG11 spastic paraplegia 11 (autosomal recessive) 1.200 4.86E-02 9.80E-01 
SRSF2 serine/arginine-rich splicing factor 2 1.200 1.99E-02 8.70E-01 
STON1 stonin 1 1.200 4.49E-02 9.70E-01 
SURF1 surfeit 1 1.200 1.89E-02 8.70E-01 
TANK TRAF family member-associated NFKB activator 1.200 1.10E-02 8.30E-01 
TCF7L2 transcription factor 7-like 2 (T-cell specific, HMG-box) 1.200 1.17E-02 8.30E-01 
THEM4 thioesterase superfamily member 4 1.200 1.17E-02 8.30E-01 
THSD1 thrombospondin, type I, domain containing 1 1.200 9.98E-03 8.20E-01 
TIRAP toll-interleukin 1 receptor (TIR) domain containing 1.200 2.82E-02 9.20E-01 
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adaptor protein 
TM2D1 TM2 domain containing 1 1.200 2.14E-02 8.80E-01 
TMEM147 transmembrane protein 147 1.200 2.81E-02 9.20E-01 
TMEM30A transmembrane protein 30A 1.200 1.89E-02 8.70E-01 
TRAPPC11 trafficking protein particle complex 11 1.200 1.95E-02 8.70E-01 
TSC1 tuberous sclerosis 1 1.200 4.98E-03 7.20E-01 
TUBA3C/T
UBA3D tubulin, alpha 3c 1.200 4.34E-02 9.70E-01 
USP13 ubiquitin specific peptidase 13 (isopeptidase T-3) 1.200 1.69E-02 8.50E-01 
VKORC1L1 vitamin K epoxide reductase complex, subunit 1-like 1 1.200 1.11E-02 8.30E-01 
VWA5A von Willebrand factor A domain containing 5A 1.200 6.75E-04 4.10E-01 
WASH3P WAS protein family homolog 3 pseudogene 1.200 3.58E-02 9.60E-01 
WDR20 WD repeat domain 20 1.200 8.46E-03 8.10E-01 
WDR74 WD repeat domain 74 1.200 2.97E-03 6.20E-01 
YIPF2 Yip1 domain family, member 2 1.200 1.72E-04 2.70E-01 
YTHDF1 YTH domain family, member 1 1.200 1.31E-02 8.50E-01 
ZCCHC7 zinc finger, CCHC domain containing 7 1.200 8.61E-03 8.10E-01 
ZMYM2 zinc finger, MYM-type 2 1.200 6.81E-04 4.10E-01 
ZNF135 zinc finger protein 135 1.200 5.14E-03 7.30E-01 
ZNF181 zinc finger protein 181 1.200 2.17E-02 8.80E-01 
ZNF347 zinc finger protein 347 1.200 4.69E-02 9.80E-01 
ZNF706 zinc finger protein 706 1.200 3.21E-02 9.40E-01 
ZNRF3 zinc and ring finger 3 1.200 2.92E-02 9.20E-01 
ZRANB1 zinc finger, RAN-binding domain containing 1 1.200 2.63E-02 9.10E-01 
AAED1 AhpC/TSA antioxidant enzyme domain containing 1 1.300 2.89E-02 9.20E-01 
ALG9 ALG9, alpha-1,2-mannosyltransferase 1.300 1.61E-02 8.50E-01 
AP3B1 adaptor-related protein complex 3, beta 1 subunit 1.300 5.88E-05 1.50E-01 
ARF6 ADP-ribosylation factor 6 1.300 4.73E-02 9.80E-01 
ASCC1 activating signal cointegrator 1 complex subunit 1 1.300 1.12E-02 8.30E-01 
ATF7IP activating transcription factor 7 interacting protein 1.300 2.70E-02 9.10E-01 
C9orf85 chromosome 9 open reading frame 85 1.300 6.21E-03 7.50E-01 
CCDC82 coiled-coil domain containing 82 1.300 1.54E-02 8.50E-01 
CENPO centromere protein O 1.300 4.79E-02 9.80E-01 
CEP41 centrosomal protein 41kDa 1.300 2.29E-02 9.00E-01 
CEP78 centrosomal protein 78kDa 1.300 2.50E-02 9.10E-01 
CEP95 centrosomal protein 95kDa 1.300 3.46E-02 9.60E-01 
CHRM3 cholinergic receptor, muscarinic 3 1.300 3.67E-02 9.60E-01 
CLK2P CDC-like kinase 2, pseudogene 1.300 2.98E-02 9.20E-01 
CRYZL1 crystallin, zeta (quinone reductase)-like 1 1.300 9.45E-03 8.20E-01 
CTRB2 chymotrypsinogen B2 1.300 3.81E-02 9.60E-01 
DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 1.300 3.62E-02 9.60E-01 
DOC2B double C2-like domains, beta 1.300 1.50E-02 8.50E-01 
EIF5A2 eukaryotic translation initiation factor 5A2 1.300 2.37E-03 6.20E-01 
FAM120B family with sequence similarity 120B 1.300 1.97E-02 8.70E-01 
GBP4 guanylate binding protein 4 1.300 8.94E-03 8.10E-01 
GPRC5A 
G protein-coupled receptor, family C, group 5, member 
A 1.300 3.97E-02 9.70E-01 
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GSTA4 glutathione S-transferase alpha 4 1.300 4.29E-02 9.70E-01 
HAT1 histone acetyltransferase 1 1.300 3.42E-02 9.60E-01 
HAUS3 HAUS augmin-like complex, subunit 3 1.300 4.77E-02 9.80E-01 
HIGD1B HIG1 hypoxia inducible domain family, member 1B 1.300 2.97E-02 9.20E-01 
HPS5 Hermansky-Pudlak syndrome 5 1.300 2.70E-02 9.10E-01 
HSPB11 heat shock protein family B (small), member 11 1.300 1.19E-02 8.30E-01 
IFT27 intraflagellar transport 27 homolog (Chlamydomonas) 1.300 4.10E-03 6.90E-01 
INO80D INO80 complex subunit D 1.300 1.40E-02 8.50E-01 
KIAA0825 KIAA0825 1.300 1.07E-02 8.30E-01 
KIAA1328 KIAA1328 1.300 1.19E-03 5.20E-01 
LGALS8 lectin, galactoside-binding, soluble, 8 1.300 1.11E-03 5.20E-01 
MAL2 mal, T-cell differentiation protein 2 (gene/pseudogene) 1.300 1.38E-02 8.50E-01 
MIER1 
mesoderm induction early response 1 homolog (Xenopus 
laevis) 1.300 4.45E-02 9.70E-01 
NCOR1P1 nuclear receptor corepressor 1 pseudogene 1 1.300 1.40E-02 8.50E-01 
NDNF neuron-derived neurotrophic factor 1.300 3.95E-03 6.90E-01 
NHLRC3 NHL repeat containing 3 1.300 2.72E-03 6.20E-01 
NIPSNAP3
A nipsnap homolog 3A (C. elegans) 1.300 5.53E-03 7.40E-01 
NMRK1 nicotinamide riboside kinase 1 1.300 8.47E-03 8.10E-01 
PDHX pyruvate dehydrogenase complex, component X 1.300 1.68E-04 2.70E-01 
PDZD11 PDZ domain containing 11 1.300 1.33E-02 8.50E-01 
PEX5 peroxisomal biogenesis factor 5 1.300 2.15E-02 8.80E-01 
PHAX phosphorylated adaptor for RNA export 1.300 1.88E-02 8.70E-01 
PHF11 PHD finger protein 11 1.300 2.23E-02 8.80E-01 
PLTP phospholipid transfer protein 1.300 2.58E-02 9.10E-01 
POLR1C polymerase (RNA) I polypeptide C, 30kDa 1.300 1.68E-02 8.50E-01 
PSMG4 proteasome (prosome, macropain) assembly chaperone 4 1.300 3.49E-02 9.60E-01 
RALBP1 ralA binding protein 1 1.300 8.05E-03 8.00E-01 
RCN2 reticulocalbin 2, EF-hand calcium binding domain 1.300 3.17E-04 3.10E-01 
SDAD1 SDA1 domain containing 1 1.300 1.54E-02 8.50E-01 
SECISBP2 SECIS binding protein 2 1.300 1.59E-02 8.50E-01 
SLC29A1 
solute carrier family 29 (nucleoside transporters), 
member 1 1.300 4.82E-05 1.40E-01 
SPATA6 spermatogenesis associated 6 1.300 2.51E-02 9.10E-01 
SRGAP2 SLIT-ROBO Rho GTPase activating protein 2 1.300 3.81E-03 6.90E-01 
TRPC6 
transient receptor potential cation channel, subfamily C, 
member 6 1.300 1.01E-02 8.20E-01 
VEZT vezatin, adherens junctions transmembrane protein 1.300 1.58E-02 8.50E-01 
VRK2 vaccinia related kinase 2 1.300 3.24E-02 9.40E-01 
WDR92 WD repeat domain 92 1.300 4.53E-03 7.00E-01 
XPO4 exportin 4 1.300 2.84E-02 9.20E-01 
XRRA1 X-ray radiation resistance associated 1 1.300 7.91E-03 8.00E-01 
YY2 YY2 transcription factor 1.300 1.30E-03 5.50E-01 
ZBTB8A zinc finger and BTB domain containing 8A 1.300 9.02E-03 8.10E-01 
ZDHHC20 zinc finger, DHHC-type containing 20 1.300 2.82E-03 6.20E-01 
ZFAND1 zinc finger, AN1-type domain 1 1.300 2.69E-02 9.10E-01 
ZNF415 zinc finger protein 415 1.300 1.18E-02 8.30E-01 
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ZNF521 zinc finger protein 521 1.300 1.18E-02 8.30E-01 
ZNF623 zinc finger protein 623 1.300 5.33E-03 7.40E-01 
ZNHIT3 zinc finger, HIT-type containing 3 1.300 1.26E-02 8.40E-01 
ANKRD36C ankyrin repeat domain 36C 1.400 1.03E-02 8.30E-01 
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 1.400 1.64E-03 5.90E-01 
ASB16-AS1 ASB16 antisense RNA 1 1.400 8.72E-03 8.10E-01 
ERCC6L2 
excision repair cross-complementing rodent repair 
deficiency, complementation group 6-like 2 1.400 4.52E-04 3.60E-01 
F5 coagulation factor V (proaccelerin, labile factor) 1.400 2.86E-02 9.20E-01 
GLTP glycolipid transfer protein 1.400 4.39E-02 9.70E-01 
ILF3-AS1 ILF3 antisense RNA 1 (head to head) 1.400 1.38E-02 8.50E-01 
LINC00467 long intergenic non-protein coding RNA 467 1.400 2.99E-02 9.20E-01 
LOC441956 uncharacterized LOC441956 1.400 2.95E-02 9.20E-01 
LOX lysyl oxidase 1.400 4.84E-02 9.80E-01 
RAET1E retinoic acid early transcript 1E 1.400 1.13E-03 5.20E-01 
RPL23AP32 ribosomal protein L23a pseudogene 32 1.400 2.13E-03 6.20E-01 
SAMD9 sterile alpha motif domain containing 9 1.400 4.04E-03 6.90E-01 
TPST1 tyrosylprotein sulfotransferase 1 1.400 2.94E-02 9.20E-01 
ZNF138 zinc finger protein 138 1.400 8.62E-03 8.10E-01 
ZNF25 zinc finger protein 25 1.400 1.40E-02 8.50E-01 
ZNF254 zinc finger protein 254 1.400 4.90E-04 3.60E-01 
ZNF268 zinc finger protein 268 1.400 1.48E-02 8.50E-01 
ZNF442 zinc finger protein 442 1.400 1.16E-05 1.30E-01 
C5orf22 chromosome 5 open reading frame 22 1.500 3.56E-02 9.60E-01 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 1.500 1.70E-02 8.50E-01 
LRP2BP LRP2 binding protein 1.500 4.82E-03 7.10E-01 
MT1L metallothionein 1L (gene/pseudogene) 1.500 3.56E-02 9.60E-01 
SBSPON 
somatomedin B and thrombospondin, type 1 domain 
containing 1.500 7.00E-03 7.70E-01 
SLC2A13 
solute carrier family 2 (facilitated glucose transporter), 
member 13 1.500 9.11E-03 8.10E-01 
SNORD36C small nucleolar RNA, C/D box 36C 1.500 1.01E-03 5.10E-01 
BTN3A3 butyrophilin, subfamily 3, member A3 1.600 1.61E-02 8.50E-01 
GCNT4 glucosaminyl (N-acetyl) transferase 4, core 2 1.600 1.18E-02 8.30E-01 
ITIH5 
inter-alpha-trypsin inhibitor heavy chain family, member 
5 1.600 1.51E-05 1.30E-01 
LY6G5B lymphocyte antigen 6 complex, locus G5B 1.600 3.53E-04 3.20E-01 
PDIA3P 
protein disulfide isomerase family A, member 3 
pseudogene 1.600 1.86E-02 8.70E-01 
PMS2P4 postmeiotic segregation increased 2 pseudogene 4 1.600 2.48E-02 9.10E-01 
CLDN11 claudin 11 1.700 7.58E-04 4.20E-01 
ERAP2 endoplasmic reticulum aminopeptidase 2 1.800 1.95E-02 8.70E-01 
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